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Abstract 
The host restriction factor TRIM5α mediates a post-entry, pre-integration block to retroviral 
infection that depends upon recognition of the viral capsid by the TRIM5α PRYSPRY domain. 
The two predominant alleles of rhesus macaque TRIM5α (rhTRIM5α
Q and rhTRIM5α
TFP) restrict 
HIV-1, but cannot restrict the macaque-adapted virus SIVmac239. To investigate how TRIM5α 
recognizes retroviral capsids, we exploited the differential sensitivities of these two viruses to 
identify gain-of-sensitivity mutations in SIVmac239, and we solved the structure of the 
SIVmac239 capsid N-terminal domain. When mapped onto this structure, single amino acid 
substitutions affecting both alleles were in the β-hairpin. In contrast, mutations specifically 
affecting rhTRIM5α
TFP surround a highly conserved patch of amino acids that is unique to 
capsids of primate lentiviruses. This “patch” sits at the junction between the binding sites of 
multiple cellular cofactors (cyclophilin A, Nup-358 cyclophilin A-like domain, Nup-153 and ! iv!
CPSF6). Differential restriction of these alleles is due to a Q/TFP polymorphism in the first 
variable loop  (V1) within the PRYSPRY domain. Q reflects the ancestral state (present in the 
last common ancestor of Old World primates) and has remained unmodified in all but one 
lineage of African monkeys, the Cercopithecinae. While Q-alleles can be found among some 
Cercopithecinae primates, in others Q has been replaced by a G or overwritten by a two amino 
acid insertion (giving rise to TFP in macaques). In one lineage, the Q to G substitution was later 
followed by an adjacent 20 amino acid duplication. We found that these modifications in 
TRIM5α specifically impart the ability to restrict Cercopithecinae SIVs without altering β-hairpin 
recognition. At least twice Cercopithecinae TRIM5αs independently evolved to target the same 
conserved patch of amino acids in capsid. Based on these findings, we propose that the β-
hairpin is a retrovirus associated molecular pattern widely exploited by TRIM5α proteins, while 
recognition of the cofactor binding region was driven by the emergence of the ancestors of 
modern Cercopithecinae SIVs. Distribution on the Cercopithecinae phylogenetic tree indicates 
that selection for these changes in TRIM5α V1 began 11-16 million years ago, suggesting that 
primate lentiviruses are at least as ancient.  
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1. A. RETROVIRUSES AND PRIMATE LENTIVIRUSES  
 
The Retroviridae 
 
Primate lentiviruses and retroviruses. The Retroviridae can be subdivided into two 
subfamilies: the Spumaretrovirinae and the Orthoretrovirinae. The Spumaretrovirinae are 
comprised of a single extant lineage, the spumaviruses (foamy viruses). In contrast, the 
Orthoretrovirinae include six extant lineages: alpha-, beta-, gamma-, delta-, epsilon- and lenti– 
retroviruses [1,2]. Primate lentiviruses include the human immunodeficiency viruses types 1 and 
2 (HIV-1 and HIV-2 respectively) and the simian immunodeficiency viruses (SIVs). Primate 
lentiviruses are a member of the Lentivirus genus of the Retroviridae family of viruses [1,2]. 
Primate lentiviruses are a monophyletic lineage within the Lentivirus genus. All extant 
retroviruses express the same three proteins, the group specific antigen (Gag) polyprotein, the 
polymerase (Pol) and an envelope protein (Env) (Table 1-1). Among viruses of the 
Orthoretrovirinae Gag is a polyprotein that is cleaved to create the structural proteins of the 
virion, including the matrix, capsid and nucleocapsid proteins [2]. Among The Pol gene encodes 
for the viral enzymes whose activity are defining features of the Retroviridae, reverse 
transcriptase and integrase [1,2]. These proteins convert the RNA genome into DNA and ! 4!
facilitate its integration into the target cell’s DNA. The Env protein is the viral glycloprotein that 
facilities entry into the target cell [2].  
   ! 5!
Table 1-1. Primate lentiviruses have an expanded repertoire of accessory genes. 
Abbreviations. Viruses: Murine leukemia virus (MLV), human T cell lymphotropic virus type 1 
(HTLV-1), maedia-visna virus (MVV) human immunodeficiency virus type-1 (HIV-1), simian 
immunodeficiency virus of African green monkeys (SIVagm), simian immunodeficiency virus of 
rhesus macaques (SIVmac). 
 
 
 
   
glyco-gag (?)                         ! 6!
Retrovirus replication 
 
Replication cycle. Retroviral infection begins when the viral glycoprotein engages its 
receptor on the target cell. Primate lentiviruses require the sequential binding of a primary 
receptor, CD4, followed by binding of the co-receptor, such as the chemokine receptor CCR5 
[3-10]. Upon receptor (and co-receptor in this case) engagement, a series of conformational 
changes in the viral glycoprotein facilitates the fusion of the viral envelope with the target cell 
plasma membrane. This results in the deposition of the viral capsid, which contains the viral 
genomes, reverse transcriptase and integrase, into the cytoplasm (Figure 1-1A).   
   Upon deposition of the capsid into the cytoplasm of the target cell, the reverse 
transcriptase begins to convert the RNA genome into a double stranded DNA genome. Reverse 
transcription is thought to occur within the viral capsid [11-13]. At the completion of reverse 
transcription a complex consisting of the newly synthesized viral DNA genome, integrase and 
other viral components must access the cellular genomic DNA. Upon accessing the target cell’s 
nuclear DNA, integrase facilitates the integration of the viral DNA genome [2] (Figure 1-1 A). 
Unlike may other retroviruses that require the breakdown of the nuclear membrane during cell 
division to access the nuclear DNA, lentiviruses can access the DNA of non-dividing cells via 
the nuclear pore [2,14,15]. It should be noted that both the alpharetrovirus Rous Sarcoma Virus ! 7!
(RSV) and the betaretrovirus mouse mammary tumor virus (MMTV) have been reported to 
infect non-dividing cells to differing efficiencies [16,17].   
  For lentiviruses, the provirus (integrated viral genome) encodes transcriptional 
activators. These facilitate the production of spliced and unspliced messenger RNAs [2]. For 
primate lentiviruses the production of viral RNA species is enhanced by the trans-activator of 
transcription (Tat) protein. Nuclear export of unspliced or minimally spliced RNA transcripts is 
enhanced by the regulator of expression of virion (Rev) protein [2,18]. Some other retroviruses 
encode analogs of these proteins in their 3’ half to perform similar functions (e.g Tax and Rex in 
the human T-lymphotropic virus, HTLV-1). For primate lentiviruses unspliced RNA transcripts 
serve as viral genomes as well as mRNAs for the production of Gag and Gag-Pol. Subgenomic 
(Spliced) viral RNAs act as messenger RNAs encoding for the production of all other viral 
proteins aside from Gag and Gag-Pol [2,18]. Viral proteins and genomes co-assemble usually at 
the plasma membrane [19-22]. Finally, virions bud from the cell and go on to infect other cells 
(Figure 1-1A).     
   ! 8!
Figure 1-1. Primate lentivirus replication, host restriction factors and viral 
countermeasures. (A) A diagram of the lentiviral replication cycle. Steps in the replication cycle 
are numbered as follows: 1. The virion binds CD4 on the cell surface via its envelope protein. 2. 
Co-receptor binding following CD4 engagement by the viral envelope protein. 3. Fusion of the 
viral membrane with the cellular membrane. 4. Deposition of the viral capsid into the cytoplasm. 
5. Reverse transcription. 6. Nuclear import. 7. Integration. 8. Transcription of vrial RNAs 
(genomes and mRNA), nuclear export, and translation of viral proteins. 9. Virion assembly. 10. 
Virion budding. 11. Virion release and additional rounds of infection.  Green lines indicate host 
genomic DNA and red lines denote viral DNA/RNA (B) Host restriction factors antagonize 
lentivirus replication. Trim5α blocks the completion of reverse transcription by destabilizing the 
viral capsid. SAMHD1 prevents the completion of reverse transcription by starving the reverse 
transcription complex of dNTPs. BST2 acts a molecular tether that prevents viral release and 
traps virions on the cell surface. APOBEC3G acts in the next infected cell where it induces 
hypermutation of the viral genome during reverse transcription. (C) Lentiviruses have evolved 
viral countermeasures to antagonize restriction factors. Viral proteins are indicated in red. 
Primate lentivirus Vpx and Vpr proteins have evolved to degrade SAMHD1 to increase available 
dNTP pools. Viral Vpu/Nef/Env have independently evolved to remove BST2 from sites of 
budding through a combination of degradation, sequestration and mislocalization. The Vif 
protein degrades APOBEC3 proteins in the cytoplasm to prevent their incorporation into virions. 
Notably, there are no reported examples of a virally encoded antagonist of Trim5α. To replicate 
in Trim5α expressing cells viruses must adapt their capsid proteins to avoid recognition.  
 
   ! 9!
   
Figure 1-1. Primate lentivirus replication, host restriction factors and viral 
countermeasures: continued 
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Lentivirus accessory genes. Primate lentiviruses have had considerable evolutionary 
success, as evidenced by the fact that over 40 Old World primate species harbor at least one 
unique primate lentivirus [23-28]. The viral phylogeny is incongruent with that of the host 
phylogeny [23-25,27-29]. This indicates that primate lentiviruses have a longstanding 
evolutionary history of cross-species transmission. Replication in their native host species or a 
naïve species occurs despite the presence of rapidly evolving host restriction factors. This 
suggests that primate lentiviruses have evolved the required genetic plasticity to overcome 
restriction factors.  
In addition to the core set of genes, gag, pol and env (Table 1-1), lentiviruses encode a 
variable number of proteins that serve a variety of modulatory functions. Null mutations in these 
accessory genes often result in attenuation of replication in vivo, even when there is little or no 
effect on virus replication in cell culture [30]. The accessory genes are clustered in the 3’ half of 
the viral genome along with env, and separate from gag, pro and pol (Figure 1-2). It is tempting 
to speculate that physical separation of genes encoding conserved functions (structural proteins 
and enzymes) from variable functions (accessory proteins and surface glycoproteins) allows 
greater adaptive flexibility. 
The accessory proteins are the most divergent lentivirus proteins (only the Env protein 
displays similar levels of diversity) (Figure 1-2). The complement of accessory genes is not ! 11!
identical for all primate lentiviruses – for example, several do not have a vpx gene (e.g., HIV-1, 
SIVcpz) and many do not have vpu (e.g., SIVsmm, SIVmac) (Figure 1-2). If the comparison is 
expanded to include the “non-primate” lentiviruses (e.g., lentiviruses found in cats, cattle, horses 
and small ruminants), a distinct set of accessory genes is found, with only vif being common to 
both primate and non-primate lentiviruses (Table 1-1). Thus, lentivirus accessory genes vary in 
primary sequence and overall composition. The requirement for vif is not absolute among extant 
lentiviruses, it is notably absent from the equine infectious anemia virus (EIAV). Such 
evolutionary plasticity is consistent with the notion that accessory genes help determine 
species-tropism and may play a role in cross-species transmission and emergence of 
lentiviruses.! 12!
  
 
Figure 1-2. Accessory proteins are the most diverse of the primate lentivirus proteins. (A) 
Genomes of primate lentiviruses. Schematic representations of the three major types of genome 
organization found among primate lentiviruses. Genes encoding structural proteins (gag, pol, 
and env) are shown in gray. The regulatory genes, tat and rev, are in white. Accessory genes 
are color-coded to match the phylogenetic trees in the lower panel. (B) A comparison of genetic 
diversity among primate lentivirus proteins. Note that the accessory proteins are much more 
diverse than the structural proteins. Neighbor-Joining trees were generated using sequence 
alignments of primate lentiviruses available from Los Alamos National Labs 
(http://www.hiv.lanl.gov/). The Vpx and Vpr proteins are paralogs that arose by duplication 
during evolution of the primate lentiviruses and were therefore combined into a single tree. 
Scale bars below each gene indicate 20% diversity doi:10.1371/journal.ppat.1004017.g001 
 
 ! 13!
1. B.  THE CROSS-SPECIES TRANSMISSION OF PRIMATE LENTIVIRUSES  
 
Primates and the cross-species transmission of primate lentiviruses  
 
Primates and primate lentiviruses. Within the past century humans have been 
infected with SIVs from wild chimpanzees, gorillas and sooty mangabeys on no less than 13 
occasions [28]. Two independent cross-species transmissions of SIVs from captive macaques 
have also occurred as a result of laboratory accidents [31,32]. Of the 15 known SIV to human 
cross-species transmission events that have occurred in the past 100 years, only one has led to 
a global HIV-1 pandemic (HIV-1 Group M), while others have led to limited regional epidemics 
and in some cases have never spread beyond a single infected individual [25,28]. The factors 
that influence whether a virus infects a single individual or spreads to 60 million individuals have 
yet to be fully determined. However, through the study of primates and their lentiviruses a 
number of viral and host genetic determinants that influence this process have been identified. 
Primates and the primate lentiviruses have proven to be a powerful system to study the 
process of cross-species transmission, adaption to the novel host and the dissemination of a 
virus throughout a population. To date, evidence of current SIV infection has been found in at 
least 45 primate species [25,27,28]. In nature, these viruses have only been isolated from ! 14!
African primates. A majority of these reported SIVs have at least one reported full-length 
genome sequence. From these data it is clear that there are at least 40-50 genetically distinct 
primate lentiviruses circulating among African primates. SIVs are named for the species from 
which they are isolated, often by denoting the virus as  “SIV”, followed by three letters that are 
related to the species common name or genus and species. For example, an SIV isolated from 
a rhesus macaques is called SIVmac, while an SIV isolated from a pig-tailed macaque, macaca 
nemestrina, is SIVmne [33]. There is considerable genetic diversity among the primate 
lentiviruses or even within a single species’ HIV/SIV. To put this diversity in context, there is less 
antigenic diversity in the glycoproteins of all known hepatitis C (HCV) genotypes (1-7) than what 
is found within the env gene of the pandemic strain of HIV-1, group M (Figure 1-3).  
   ! 15!
 
 
 
 
Figure 1-3. Primate lentiviruses are genetically diverse. A comparison of the genetic 
diversity among the glycoproteins of viruses known to establish chronic infection in their hosts: 
Hepatitis C, HIV-1 and primate lentiviruses.  (A) Diversity of all Hepatitis C groups (groups 1-7) 
envelope proteins E1 and E2. The number of sequences included is 471 (n=471). (B) Envelope 
(GP160) diversity of HIV-1 group M. Top. Diversity of the envelope within the global HIV-1 
pandemic. This diversity exceeds that off all Hepatitis C groups. The number of sequences used 
to generate the tree is 3998 (n=3998). Bottom. The diversity of the 14 (n=14 ) group M  HIV-1 
isolates that are included in C. The diversity of these 14 isolates is less than all Hepatitis C 
groups together. (C) Envelope diversity across primate lentiviruses. The diversity among 
primate lentivirus envelopes exceeds the diversity found in A and B. Scale bars indicate 20% 
diversity.  Neighbor-Joining trees were generated using the curated protein sequence 
alignments of primate lentiviruses and Hepatitis C available from Los Alamos National Labs 
(http://www.hiv.lanl.gov/) and (http://www.hcv.lanl.gov).  
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An evolutionary history of cross-species transmission. The taxonomic order 
Primates includes prosimians, monkeys and apes/humans (Figure 1-4). Primate species have a 
well-defined phylogeny spanning at least 80 million years of evolution [34,35] and reviewed in 
[36]. Excluding humans (which originated in Africa), extant primate species naturally inhabit 
three continents, South America, Asia and Africa (including Madagascar), while evidence of 
extinct primates are found in Europe and North America [37]. Prosimians are only found in Asia 
and Africa [37]. Prosimians occupy two branches of the primate phylogeny that are basal to the 
monkeys and the apes/humans. New World monkeys are found in South America while Old 
World monkeys are found in Africa and Asia [37]. The separation of New World and Old World 
monkeys occurred approximately 40-45 million years ago [35]. The natural habitats of extant 
apes include Africa and Asia [37]. Apes/humans and Old World Monkeys last shared a common 
ancestor approximately 25-35 million years ago [34,35] and reviewed in [36]. The term Old 
World Monkey excludes apes/humans, while the term Old World primates includes 
apes/humans and monkeys. Due to their relation to humans and their medical importance, a 
number of primate genomes have been reported. For many more primate species there is a 
wealth of reported sequences for chromosomal regions or for targeted genes. Importantly, 
samples and cell lines remain accessible for targeted gene sequencing. Together, the well ! 17!
established phylogeny and the wealth of sequence information have been indispensable for 
studying the evolution of genes that have the capacity to block primate lentivirus infection.  
   ! 18!
  
Figure 1-4. Primate phylogeny. A phylogenetic tree illustrating primate phylogeny and 
classification. Common names of species occupying each branch are provided. Estimated dates 
of divergence are indicated with the time scale bar. Dates of divergence are based on [35], 
phylogenetic tree adapted from [34]. 
   ! 19!
Our collective knowledge of African primates and their primate lentiviruses has allowed 
for the construction of robust phylogenies. From these phylogenies it is apparent that the host 
(primate) phylogeny does not match that of the viral phylogeny [26,27,29] (Figure 1-5). This 
observation suggests that rather than diverging with their hosts, primate lentiviruses have a long 
evolutionary history of cross-species transmission. Each incongruence represents a separate 
viral cross-species transmission event between primates occupying different branches within 
the host or viral phylogeny. It is therefore likely that primate lentiviruses are particularly well 
suited to cross between species and rapidly adapt to a new host. It also implies that the cross-
species transmission events resulting in HIV infection in humans is the continuation of an 
ancient pattern.  
Counting the total number of cross-species transmission events based on the observed 
discordance between the host and virus phylogenies grossly underestimates the actual number 
of successful cross-species transmission events. From phylogenetic trees, it is impossible to 
determine whether related viruses infecting closely related species are the result of a cross-
species transmission or co-divergence. For example, humans and chimpanzees are closely 
related species and they harbor closely related primate lentiviruses. Based on the comparison 
of the viral and host phylogenies it is unclear whether HIV-1 in humans is the result of co-
divergence or cross-species transmission. It is only from other observations that we know that ! 20!
SIVcpz was transmitted to humans at some point in the early twentieth century, rather than co-
diverging from a last common ancestor 5-8 million years ago [28,38-40]. Similar conclusions 
have been reached for the 4 distinct SIVagm viruses which endemically infect the 4 subspecies 
of African green monkey [41]. Due to heavy surveillance we know that within the past century 
humans have been the recipients of at least 15 cross-species transmission events [26-28,31]. 
Though limited, these observations imply that cross-species transmission almost certainly 
occurs more often than the comparative virus-host phylogeny suggests.  
 
 
 
 ! 21!
 
 
 
 
Figure 1-5. A history of cross-species transmission. The primate phylogeny (left) is 
incongruent with that of their SIVs (right). Lines connect species and their SIVs. The following 
abbreviations were used: R-c mangabey for red-capped mangabey, AGM for African green 
monkey, W.r colobus for Western red colobus, GSN guenon for Greater spot-nosed guenon. 
The primate phylogenetic tree is adapted from [34]. The SIV Neighbor-Joining trees was 
generated using the curated primate lentiviruses Pol alignment available from Los Alamos 
National Labs (http://www.hiv.lanl.gov/).  
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  Primate lentiviruses are likely ancient. While the current distribution and genetic 
diversity found among primate lentiviruses suggests that they are ancient, no direct evidence 
supports their presence before the last Ice Age, 10,000 years ago [42,43]. Rising sea levels at 
the end of the last Ice Age isolated multiple SIVs and their host species on Bioko Island 10,000 
years ago. Phylogenetically, these SIVs are interleaved with the primate lentiviruses isolated on 
the African mainland [42]. This observation suggests that SIVs were already widespread and 
genetically diverse at this time. Despite a lack of direct evidence, a growing number of 
observations support the notion that the relationship between African primates and primate 
lentiviruses is far more ancient. However, these age estimates can vary wildly depending on the 
method used to date their existence. Molecular clock estimates based on viral sequences 
almost unanimously conclude that SIVs are between tens of thousands to hundreds of 
thousands of years old [41-43]. In contrast, through phylogenetic analysis of novel host gene 
variants with the capacity to antagonize lentivirus replication in Old World monkeys the 
emergence of primate lentiviruses has been dated to 5-10 million years ago [44-51]. These 
observations fit with the observations made from the detection of ancient endogenous lentiviral 
sequences in the genomes of European brown rabbits, Malagasey lemurs and weasels, which 
demonstrates that lentiviruses existed and formed independent lineages at least 8-12 million 
years ago [52-55].  ! 23!
Primates and their lentiviruses offer a unique temporal view into to the process of cross-
species transmission, adaptation, and dissemination of a virus throughout a population. The 
known histories of primate lentiviruses exceeds at least 5 orders of magnitude (1-10,000 years). 
The presence of primate lentiviruses on Bioko island suggests that some primate species like 
Drils, Guenons, and Colobus monkeys have harbored their SIVs for at least 10,000 years [42]. 
SIVcpz in chimpanzees arose through the cross-species transmission and recombination of two 
viruses related to those found in modern day guenons and mangabeys [29]. Molecular clock 
estimates date the emergence of SIVcpz to 300-1000 years ago [41]. The transmission of 
SIVcpz from chimpanzees to humans, which resulted in the emergence of epidemic HIV-1, 
occurred approximately 100 years ago [39,40]. The accidental infection of captive rhesus 
macaques with SIVsmm from sooty mangabeys resulted in SIVmac [56,57]. This virus freely 
circulated for 15-20 years before it was eradicated from United States primate colonies. This 
pathogenic SIVmac and the SIVmac239 molecular clone represent approximately 15-20 years 
of adaptation [23,56-58]. Experimental cross-species transmissions in laboratories involving 
sooty mangabeys, macaques, African green monkeys and their SIVs illustrate how viruses 
adapt to a new species on yearly or sub-yearly timescales [59-64].  
Time and pathogenesis. There is a correlation between the amount of time a species 
has harbored a particular SIV and the clinical outcome of SIV infection. Specifically, despite high ! 24!
viral loads, long-standing hosts tend to have apathogenic/asymptomatic SIV infections 
[24,25,28]. In captivity, SIV infection of African green monkeys with SIVagm or sooty 
mangabeys with SIVsmm is often accompanied by little to no pathogenesis [25]. This is in 
contrast to host species that have recently acquired a particular SIV. These species typically 
progress to an immunosuppressed sate [24,25]. Chimpanzees are believed to have acquired 
SIVcpz within the past 1000 years [41]. In nature, chimpanzees infected with SIVcpz have 
significantly shorter lifespans and lowered reproductive success than uninfected wild 
chimpanzees [65,66]. Humans acquired the pandemic lineage of HIV-1 group M approximately 
100 years ago and usually progress to AIDS in the absence of medical intervention [26,28,38-
40,43,67]. Infection of rhesus macaques with SIVmac results in simian AIDS, a condition similar 
in its symptomology to human AIDS [58,68]. While few in number, these examples suggest that 
successful cross-species transmission of primate lentiviruses can be coupled with pathogenic 
potential.  
 
1. C. GENETIC BARRIERS TO THE CROSS-SPECIES TRANSMISSION OF PRIMATE 
LENTIVIRUSES 
 
Adaptive immunity and passive genetic barriers  ! 25!
The evolution of barriers to cross-species transmission. Considering that primate 
lentiviruses have an evolutionary history that is laden with cross-species transmission events, 
together with the observation that successful cross-species transmission events can result in 
pathogenic infection, it is therefore very likely that the dynamic movement of primate lentiviruses 
between African primate hosts has driven the evolution of genes with anti-lentiviral activity. 
Accordingly, primate lentiviruses must have adapted (and must continue to adapt) to overcome 
barriers to replication in both their natural and acquired hosts following cross-species 
transmission events.   
Adaptive immunity. The genes responsible for antigen recognition for the adaptive 
immune system have rapidly evolved [69]. Diversity within loci such as the major 
histocompatibility complex (MHC) locus has been maintained through balancing selection [69-
75]. The MHC is responsible for the presentation of peptides from within the cell to the adaptive 
immune system. This includes peptides from pathogens that replicate intracellularly. Currently, it 
is impossible to determine whether lentivirus infection has contributed to the observed 
accelerated rates of evolution at this locus in Old World primates. Regardless, whether 
incidental or due directly to recurrent selection by primate lentiviruses, the adaptive immune 
system constitutes a significant barrier to the successful cross-species transmission of primate 
lentiviruses. Control of viral replication by cytotoxic CD8+ T-cells is observed in African green ! 26!
monkeys that are experimentally infected with SIVmac [63]. Cytotoxic CD8+ T-cells have been 
implicated as factors in controlling the replication of modified HIV-1 viruses in pig-tailed 
macaques [76,77], as well as chimeric SIV-HIV (SHIV) viruses in various macaque species [78-
83].  
  MHC influences the outcome of primate lentivirus infection when viruses are transmitted 
between closely related species or even between members of the same species. Rhesus 
macaques and crab-eating macaques shared a last common ancestor approximately 1 million 
years ago [34-36,84,85]. Experimental infection of crab-eating macaques with the rhesus 
macaque virus SIVmac239 can result in lower viral loads and slower disease progression than 
rhesus macaques inoculated with the same virus [86]. Differences between the MHC repertoire 
of rhesus and crab-eating macaques can lead to increased cytotoxic CD8+ cell responses and 
lowered viral loads [86-88]. Even within species with recently acquired primate lentiviruses the 
chance that a virus adapted to all possible MHC haplotypes is low due to balancing selection of 
diversity within the MHC locus. Indeed, both in humans and rhesus macaques the presence of 
specific HLA types is strongly associated with lower viral loads or even elite control, in addition 
to heterozygous advantage [87,89-91].  
  Passive barriers to viral entry. Primate lentiviruses utilize CD4 as their primary 
receptor [3,4,92]. Among primates, in particular Old World primates, the CD4 gene has evolved ! 27!
under positive selection [93,94]. Based on the co-crystal structure between the HIV-1 
glycoprotein soluble subunit GP120 and CD4, positively selected sites map to the D1 domain. 
The D1 domain makes extensive contacts with the CD4 binding pocket of the HIV-1 GP120 [95]. 
Furthermore, the specific amino acids substitutions that have been selected for alter the 
electrostatic surface of the GP120 binding interface in a primate lineage specific manner [94]. 
On this interface at least one site of difference between humans and macaques carries a 
functional consequence. The difference between the human N39 or macaque I39 largely 
accounts for the observed 20-50 fold reduction in the infectivity of primary transmitted founder 
HIV-1 viruses on macaque CD4 expressing cells [96].  Notably, HIV-1 envelopes have adapted 
in vivo to efficiency utilize the macaque receptor [96].  
  Upon CD4 engagement primate lentiviruses require a co-receptor to license the 
envelope for fusion [97]. While different proteins can serve as a co-receptor, the co-receptor is 
almost always a chemokine receptor. Among primate lentiviruses, including HIV-1, there is a 
very strong bias for the usage of CCR5 [98]. In at least three independent cases during Old 
World primate evolution, deletions in CCR5 have evolved that greatly reduce or entirely block 
cell surface expression. Both sooty and red-capped mangabey species share a 24 base pair in-
frame deletion (CCR5Δ24) that prevents surface expression [99,100]. An additional variant with 
a novel 2 amino acid deletion is also found in sooty mangabeys [101]. This deletion reduces cell ! 28!
surface expression. Similarly, approximately 10% of Caucasian humans have a CCR5 allele 
that is defective for cell surface expression due to a frame shift mutation that results in a 32 
amino acid truncation [102,103]. Both sooty and red-capped mangabeys are believed to have 
harbored their respective SIVs long enough to have coevolved to a state of apathogenesis. It is 
also likely that in nature they are exposed to other SIVs. Therefore, there exists the likelihood 
that these adaptations could have been selected by primate lentiviruses. For humans the 
identity of the agent that selected for the 32 amino acid deletion remains controversial 
[104,105]. Nonetheless, the presence of this polymorphism constitutes a significant barrier to 
HIV-1 infection and has been exploited to cure HIV-1 infection [102,103,106-108].    
For each of these examples, the reduction or lack of CCR5 expression has selected for 
viruses that utilize alternative co-receptors. Among red-capped mangabeys, the CCR5Δ24 
polymorphism exists at a very high frequency. As a result, the entire SIVrcm lineage has 
evolved to use another chemokine receptor (CCR2b) as a primary co-receptor [99]. In sooty 
mangabeys the presence of two independent CCR5 alleles with deletions that limit surface 
expression has selected for viruses that have gained the ability to use a number of alternative 
co-receptors. These alternative co-receptors are either chemokine receptors or orphan G 
protein-coupled receptors [98,101]. In humans, the significant reduction of CCR5 expressing ! 29!
cells during the late stages of AIDS progression is correlated with the emergence of viruses 
utilizing the chemokine receptor CXCR4 [109-113].  
  While the barriers to successful cross-species transmission imposed by the above 
examples are mechanistically different, they share a common quality. The evolution of these 
genes (MHC, CD4, CCR5) is subject to evolutionary constraints far beyond their interactions 
with primate lentiviruses. Evolutionary pressures on the MHC are exerted by a multitude of 
pathogens. While there can be enrichment for specific MHC alleles, positive selection and 
balancing selection of MHC alleles have clearly selected for diversity within the MHC locus 
[69,70,74,114]. Furthermore, since the MHC presents self-peptides in addition to pathogen 
peptides there is likely selection against promiscuous peptide presentation which can result in 
autoimmune disease or hypersensitivity reactions [115-117]. Interestingly, the MHC variants 
most associated with control of HIV-1 infection are also associated with autoimmunity [118]. 
While no apparent phenotype is associated with the loss of cell surface expression of CCR5, its 
presence across mammalian species argues that CCR5 must carry some selective advantage. 
Perhaps the clearest example of evolutionary constraints comes from CD4. The primary 
purpose of CD4 is to interact with MHC class II on antigen presenting cells. This interface is the 
same one exploited by primate lentivirus envelope proteins [95,114,119]. Therefore, despite 
selective pressures from primate lentiviruses there is likely a greater selective pressure to ! 30!
maintain the interaction with MHC class II [93,94]. Together, these observations predict that the 
most potent blocks to cross-species transmission events would be mediated by proteins whose 
evolution is not constrained by other cellular/organismal functions.  
 
Intrinsic immunity and restriction factors  
 
Intrinsic immunity. Intrinsic immunity is distinct from adaptive and innate immunity. In 
the context of this thesis, the name is used to encompass a number of complex phenotypes, all 
of which describe an observed cellular resistance to the replication of specific viruses. It does 
not rely on pre-exposure to viruses or specific classes of specialized effector cells and is thus 
distinct from adaptive immunity. Intrinsic immunity differs from innate immunity in that it does not 
describe a general anti-viral state but rather a specific cellular resistance to specific viruses. In 
addition, the mediators of intrinsic immunity actively antagonize viral replication while the innate 
immune system signals to stimulate the production of antiviral factors. This property, together 
with the observation that the mediators of intrinsic immunity are dominant acting, separates 
intrinsic immunity from virus-cell incompatibles or other passive blocks to viral infection. The 
mediators of intrinsic immunity are often referred to as host restriction factors.  ! 31!
Restriction factors. Restriction factors are cellular factors that block virus infection, 
either by direct interaction with viral factors or by rendering the cellular environment 
incompatible with viral replication. Well-characterized primate lentivirus restriction factors 
include SAMHD1 [120,121], BST-2/tetherin [122,123], APOBEC3G [124] and TRIM5α [125] 
(Figure 1-1B). In general, viruses evolve resistance to the restriction factors of their natural 
hosts, but may still be sensitive to homologs of the same restriction factors from other 
organisms. Thus, restriction factors are potentially major determinants of virus host-range in 
nature. Much of the evidence favoring this hypothesis comes from comparative studies of the 
primate lentiviruses. 
  The term “restriction factor” is not intended to reflect any additional relationships such as 
genetic relatedness or mechanism of action and in fact the mechanisms by which each 
restriction factor blocks viral replication is unique. These proteins are also genetically unrelated. 
The identified host restriction factors for primate lentiviruses have come from different gene 
families, for example the cytidine-deaminase family [124,126,127], tripartite motif family 
[128,129], or sterile alpha motif and HD-phosphohydrolase families of proteins [120,121,130].  
  While there is no formal definition for what constitutes a host restriction factor, generally 
well-studied restriction factors share many common attributes. In the context of primate 
lentivirus infection these factors generally: are dominant acting, actively antagonize viral ! 32!
processes (or proteins), have primarily evolved to meditate antiviral activity (thus, restriction 
factors most likely evolved without the evolutionary constraints of performing other cellular 
functions), and evolved under positive selection (or sites therein). Finally, it is usually found that 
viruses have evolved resistance to their host’s restriction factors or that other related viruses 
evolve resistance to a host’s restriction factors following a cross-species transmission event.  
 
SAMHD1: The myeloid block to reverse transcription  
 
SAMHD1. Despite the expression of the receptors that  HIV-1 does not efficiently infect 
resting CD4 T-cells or myeloid cells. In contrast, HIV-2 and some SIVs achieve significantly 
higher titers on these cells [131-137]. HIV-1 does not encode a Vpx protein, however the 
addition of Vpx-containing virus like particles to HIV-1 infections (or HIV-1 derived gene therapy 
vectors) can dramatically boost HIV-1 titers [138]. SAMHD1 was immunoprecipitated from 
human myeloid cells using the Vpx proteins of HIV-2/SIVs [120,121]. SAMHD1 is a 
deoxynucleoside triphosphate triphosphohydrolase [120,121,139,140].Its enzymatic activity 
depletes dNTP pools within terminally differentiated target cells, such as macrophages, thereby 
starving the reverse transcription complex of dNTPs [139,141] (Figure 1-1B). Supplementation 
of SAMHD1 expressing cells with exogenous dNTPs can partially restore HIV-1 titers [141-143].  ! 33!
Vpx, and some SIV Vpr proteins, have anti-SAMHD1 activity [120,121,144,145]. Both 
Vpx and Vpr are incorporated into virions during assembly and are delivered to the target cell 
during entry. These virion-delivered Vpx/Vpr proteins engage cellular ubiquitin ligase machinery, 
specifically the CUL4 complex, to degrade SAMHD1 in the target cell [120,121] (Figure 1-1C). 
Presumably, this tips the balance of dNTPs in the target cell such that the concentration is 
above the Km of the reverse transcriptase [141]. A few amino acid positions of SAMHD1 have 
been shown to have evolved under positive selection [144,145]. These sites occur at the N and 
C termini of the protein. This finding fits with the observation that different SIV Vpx/Vpr proteins 
engage different regions of SAMHD1 [144-146].  
Curiously, HIV-1 (and some other primate lentiviruses) does not encode Vpx or its 
functional equivalent [120,121,144-146]. Wild type HIV-1 is poorly infectious in cells that 
naturally express active SAMHD1 proteins [120,121,139-142,145,147-153]. Therefore, it does 
not overtly appear that HIV-1 has a mechanism to antagonize SAMHD1 restriction. In contrast, 
antagonism of SAMHD1 is a conserved property among primate lentiviruses that have a Vpx 
protein and among those with related Vpr proteins [144-146]. This argues that antagonism of 
SAMHD1 is biologically relevant, however its relevance in vivo is yet to be defined. Interestingly, 
SIVmac239 viruses modified to lack Vpx, Vpr or Vpx-Vpr, are pathogenic in rhesus macaques 
[154]. It should be noted that in nature SIVs with anti-SAMHD1 activity are found in hosts in ! 34!
which the virus has coevolved to a state of apathogenesis [24,25,144-146]. Correspondingly, 
these animals do not have the same patterns of chronic immune activation observed in humans 
infected with HIV-1 or macaque species infected with SIVmac [25]. Therefore, SAMHD1 
antagonism may be more important in situations where CD4+ T-cells are resting and there are 
less activated CD4+ monocytes to infect.  
 
BST2: The block to virion release   
 
BST2/tetherin. Production of HIV-1 molecular clones lacking a functional Vpu protein is 
blocked at a late stage of the budding process in some human cells [155-158]. Thus, under 
specific conditions Vpu is required for efficient virion release. Cells that are not permissive for 
efficient virion release have been shown to accumulate fully matured virions at the plasma 
membrane and in clathrin coated pits [155,156]. The factor inhibiting release was shown to be 
dominant acting as demonstrated by heterokaryons between permissive and non-permissive 
cells [159]. Virions can be released from the cells following protease treatment, indicating that 
the restricting factor was a protein and was present on the cell surface [158]. Finally, it was 
shown that treatment with interferon could render once permissive cells non-permissive [160]. 
The above observations led to the identification of BST2 (tetherin/CD317/HM1.24) as the ! 35!
mediator of these phenotypes [122,123]. BST2 has been shown to act as a molecular “tether” 
that traps fully budded virions on the surfaces of infected cells [122,123] (Figure 1-1B). The 
accessory gene Vpu efficiently removes BST2 from the plasma membrane, trapping it in 
intracellular compartments while also targeting it for degradation [161,162] (Figure 1-1C).  
Most primate lentiviruses do not encode a Vpu gene. This includes HIV-2, which like 
HIV-1 which infects humans. However, nearly all primate species encode functional BST2 
genes [122,123,163-166]. The Vpu independent mechanisms employed by primate lentiviruses 
to overcome the BST2 mediated block showcases the inherent plasticity of primate lentiviral 
proteins. Most other primate lentiviruses, including SIVmac, use Nef to overcome the BST2 
mediated block [163-165] (Figure 1-1C). Nef interacts with the cytoplasmic tail of BST2 to trap it 
in a perinuclear compartment. The amino acids in the cytoplasmic tail of BST2 that make up the 
Nef binding site were lost during Homo evolution [163,164,167]. This renders human BST2 
resistant to Nef antagonism.  
The HIV-1 virus is a recombinant between two other SIVs. The parental viruses of 
HIV/SIVcpz/SIVgor are most closely related to SIVs found in modern day red-capped 
mangabeys (SIVrcm) and those found in modern day greater-spot-nosed monkeys/mustached 
guenons (SIVmus/SIVgsn) [29]. The Vpu gene of HIV/SIVcpz/SIVgor is derived from the 
SIVmus-SIVgsn lineage while the HIV/SIVcpz/SIVgor Nef is related to those found in modern ! 36!
day SIVrcm isolates. In the SIVmus/SIVgsn lineage Vpu antagonizes mustached and greater 
spot-nosed guenon BST2s [165]. In the SIVrcm lineage Nef antagonizes red-capped mangabey 
BST2. The recombination event that generated the HIV/SIVcpz/SIVgor lineage probably 
occurred in an ape, most likely a chimpanzee [29]. Species-specific differences in the 
transmembrane domain of chimpanzee BST2 prevented the Vpu gene of the recombinant virus 
from counteracting ape BST2s. Instead, Nef evolved to acquire the ability to antagonize 
chimpanzee BST2 [165]. When this virus was transmitted to humans lacking the Nef binding 
motif, the recombinant virus re-adapted to utilize Vpu as a BST2 antagonist [165,168]. 
Interestingly, among the 4 HIV-1 groups (M, N, O, P) there is a correlation between the ability to 
antagonize BST2 and the success of the virus in humans [165,168,169].   
HIV-2 is the result of the cross-species transmission of SIVs from sooty mangabeys to 
humans. The HIV-2 Nef protein is also unable to counteract human BST2. Instead, a successful 
lineage of HIV-2 has acquired the ability to antagonize human BST2 mediated restriction via its 
Env protein [170] (Figure 1-1C). The interaction causes the entrapment of human BST2 in a 
perinuclear compartment similar to what is observed with Nef proteins [163,170]. SIVmac clones 
lacking a nef gene have been used as a live-attenuated vaccine model in macaques 
(SIVmac239ΔNef) [171]. At a low frequency these viruses can re-acquire virulence in adult 
macaques [172-175]. One viral lineage that re-acquired virulence adapted to overcome the ! 37!
rhesus macaque BST2 mediated block in the absence of Nef. In a case of convergent evolution, 
this virus also gained the ability to antagonize rhesus macaque BST2 via changes in its Env 
protein [174,176].  
From these in vivo examples it appears that there is a significant selective pressure to 
overcome the BST2 mediated block. This may be related to the direct inhibition of viral release 
from infected cells. However, animals vaccinated with SIVmac239ΔNef also have higher titers of 
antibodies that mediate antibody-dependent cell-mediated cytotoxicity, possibly due to the 
increased accumulation of virions on the cell surface [177]. In parallel, in vitro, HIV-1 viruses 
expressing mutant Vpu proteins that are incapable of antagonizing human BST2 have increased 
sensitivity to antibody-dependent cell-mediated cytotoxicity [178]. 
 
APOBEC3 Family: A block to infection upon a second round of replication   
 
APOBEC3G. Almost all lentiviruses have a vif gene. Vif is an acronym for viral infectivity 
factor, which came from the observation that viruses lacking Vif fail to establish spreading 
replication in human peripheral blood mononuclear cells (PBMC) and some human T-cell lines 
[179-183]. Perplexingly, the virions produced from these cells were apparently indistinguishable 
from wild type viruses but yielded dramatically lower titers. Heterokaryon fusions between ! 38!
permissive and non-permissive cells confirmed the presence of a dominant acting, producer cell 
mediated, block to infection [181,183]. Using the differential permissibility between two related 
cell lines, the RNA transcript encoding APOBEC3G (apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like G) was identified as the coding RNA responsible for the observed 
block to infection [124].  
In the absence of Vif, APOBEC3G has been shown to incorporate into assembling 
virions in the producer cell [124]. Reverse transcription in the cytoplasm of the next target cell 
produces a minus-strand DNA intermediate, which is attacked by APOBEC3G (Figure 1-1B). 
Deamination of cytosines to uracils in the viral minus-strand DNA produces C-to-U mutations, 
resulting in the accumulation of G-to-A substitutions in the coding strand, often referred to as 
hypermutation [127,184-186]. Additional deamination independent mechanisms have also been 
observed [187]. Other APOBEC3 family members have been shown to have anti-lentiviral 
activity, in particular APOBEC3D, APOBEC3H and APOBEC3F ([188,189] and reviewed in 
[190-192]). The presence of Vif prevents the incorporation of APOBEC3 into virions [124] 
(Figure 1-1C). This is accomplished via the depletion of APOBEC3 family members from the 
producer cell by ubiquitin mediated degradation, mediated by a Vif complex that includes CBFβ 
and CUL5 in complex with RBX2, ELOB and ELOC and the target APOBEC3 [193-196]. ! 39!
APOBEC3G was the first primate lentivirus host restriction factor to be identified. The 
observations made from the characterization of the Vif-APOBEC3G interaction have helped 
define primate lentivirus restriction factors. Importantly, it was demonstrated that APOBEC3G 
was a dominant acting factor that inhibited lentiviral infection [124,181,183]. Viruses, including 
HIV-1, have evolved to overcome their host’s APOBEC3G. The interaction between the Vif 
proteins and primate lentiviruses was shown to be species specific [197-200]. For example, 
HIV-1 Vif is incapable of degrading rhesus macaque or African green monkey APOBEC3G 
[198,201]. This phenotype is due to the accelerated rate of evolution of APOBEC3G, which has 
been shown to have evolved under strong positive selection [202,203]. Indeed at least some of 
the positively selected sites and insertions that have been selected for cluster to a single 
common Vif-APOBEC3G interaction face [44,199,200,204-206] 
 
TRIM5α: A capsid-dependent post entry block 
 
TRIM5α. TRIM5α is a broadly restrictive retrovirus-specific restriction factor. Both the 
nature of the interaction between retroviruses and TRIM5α and how retroviruses and TRIM5α 
have co-evolved are fundamentally different than the three other restriction factors discussed 
above. TRIM5α specifically targets the retroviral capsid shortly after it is deposited into the cell ! 40!
following membrane fusion [125,201,207]. TRIM5α binding usually results in the premature 
uncoating of the viral capsid and degradation of its contents [12,208,209]. How TRIM5α 
recognizes divergent retroviruses is unknown, but likely involves multimerization on the surface 
of incoming capsids through a series of high-avidity/low-affinity interactions [208,210-213]. 
Unlike the other restriction factors, TRIM5α has not been shown to directly restrict any non-
retrovirus viruses. Thus, it appears to target a highly conserved pattern that is unique to 
retroviruses. Among the Retroviridae, including the complex and accessory gene rich primate 
lentiviruses, no viral antagonists of TRIM5α have been reported. Instead, resistance (or 
sensitivity) to TRIM5α is determined directly by variation in the viral capsid.  
 
Viral strategies for evading restriction  
 
Common mechanisms to evade restriction factors. The Vif and Vpx/Vpr proteins use 
similar mechanisms to overcome restriction by APOBEC3 and SAMHD1, respectively. In both 
cases, the viral protein couples its target to ubiquitin ligase complexes, resulting in proteasome-
mediated degradation of the restriction factor [192,214]. Vpu also engages cellular ubiquitin 
ligase complexes, which may contribute, in part, to removal or sequestration of BST-2/tetherin 
from the cell surface [122,123,161,162]. Vpr is a paralog of Vpx, and like Vpx, it interacts with ! 41!
the cellular ubiquitin ligase machinery [120,121,215]. The cellular target of HIV-1 Vpr remains to 
be discovered, although in some SIV lineages Vpr has anti-SAMHD1 activity [145].  
Similar to some of the activities of Vpu, primate lentivirus Nef/Env proteins modulate cell-
surface expression of many cellular proteins, and for some SIV strains, Nef is the primary 
antagonist of BST-2 [163,164]. Interestingly, when SIVsmm jumped to humans and became 
HIV-2, the Nef protein could not interact with human BST-2 [28,163,164]. Consequently, the Env 
protein of HIV-2 evolved the capacity to counteract human BST-2 [170]. Similarly, when a 
SIVmac lacking a nef gene was passaged in macaques, BST2 imposed selection pressures that 
selected for changes in Env that impart anti-BST2 activity [174,176]. These envelopes induce 
the mislocalization and entrapment of BST2 in a perinuclear compartment [176].  
Restriction factors target general viral signatures. SAMHD1, BST-2 and APOBEC3G 
are evolutionarily and mechanistically distinct from one another, but share a common feature – 
the means by which they inhibit viruses are relatively non-specific. For example, SAMHD1 
inhibits viral replication indirectly by limiting the availability of precursors of DNA synthesis 
[120,121,139,141,214], potentially affecting any virus for which DNA synthesis is essential [147]. 
Likewise, BST-2 can, in theory, “capture” any membrane-enveloped structure (e.g., a virion) as 
it buds from the cell surface [192,214]. APOBEC3G acts on single-stranded DNA produced 
during reverse-transcription, but there is no evidence that the enzyme has a selective ! 42!
preference for viral DNA over other single-stranded DNAs. In other words, none of these factors 
targets a specific viral protein and consequently, viral resistance does not result from escape 
mutations in a binding site or epitope. Instead, all three factors are targeted by viral accessory 
proteins, and interactions with these viral antagonists are primary determinants of viral 
sensitivity to restriction.  
 
1. D. TRIM5α.  
 
Identification of TRIM5 
 
  The monkey block. Experiments to develop a non-human primate model for HIV-1 
infection began to define a post entry block to lentivirus infection that would later be attributed to 
TRIM5α. In contrast to chimpanzees, experimental cross-species transmissions of HIV-1 to 
captive monkeys demonstrated that they were resistant to HIV-1 infection [216-219]. Cultured 
monkey peripheral blood monocytes and monkey cell lines demonstrated that the observed 
resistance to HIV-1 was an intrinsic cellular property. The isolation of an SIV from captive 
macaques in the United States (SIVmac) demonstrated that monkeys were not generally ! 43!
resistant to lentiviruses [58]. Together, HIV-1, SIVmac and primate cells (including those of 
humans) were used to characterize the lentivirus susceptibility factor (LV1). 
  Before the gene responsible for the LV1 block was identified, the viral and cellular 
determinants were established. Viruses expressing heterologous envelopes demonstrated that 
the block was independent of receptor usage or entry pathway [201]. Consistent with this 
observation, the Gag protein was shown to govern sensitivity to the block [201]. The virally 
encoded determinant was serially mapped from Gag, to capsid-p2 and finally to the first 204 
amino acids of the capsid protein [201,220,221]. Additional evidence for a post entry block came 
from the study of reverse transcription intermediates. These indicated that in restrictive cells the 
accumulation of late reverse transcription products was inhibited [207,222,223]. All other 
downstream events in the viral replication cycle were also blocked. These observations 
suggested the block occurred in the cytoplasm of the target cell. Heterokaryons generated from 
non-permissive and permissive cells indicated that the block was dominant and not due to 
species dependent host factor incompatibilities [223-225]. Further support for an active 
dominant block came from the observation that infectivity of a restricted virus could at least in 
part be rescued using high-titered viruses or by saturating target cells with other restricted 
viruses [223,224,226].   ! 44!
  The differential infectivity of HIV-1 and SIVmac on primate cells was used to identify 
TRIM5 as the cellular mediator of the LV1 block [49,125]. The restriction factor TRIM5α was 
discovered by screening human cells transduced with a rhesus macaque cDNA library for cells 
that resisted HIV-1 replication [125]. A similar pattern of restriction was observed in cells derived 
from owl monkeys, a New World primate species. Most other New World monkey species are 
permissive for HIV-1 infection but not for SIVmac239 [227-229]. A unique property of the block 
to infection in owl monkey cells led to the independent identification of TRIM5. The addition of 
cyclosporine, an inhibitor of cyclophilin A, could render owl monkey cells permissive to HIV-1 
infection [230]. Cyclophilin A is an HIV-1 cofactor that binds to the HIV-1 capsid [231-233]. 
Furthermore, mutations in capsid that disrupt the interaction of HIV-1 with cyclophilin A also 
rescued HIV-1 infectivity in owl monkey cells [230]. These properties were used to identify a 
unique mRNA transcript in owl monkey cells that encoded a TRIM5α-cyclophilin A fusion 
protein. This fusion protein arose from a retrotransposition event that inserted a cyclophilin A 
mRNA into the owl monkey TRIM5α locus [49].  
TRIM5 is a member of the tripartite motif containing super family of genes. The tripartite 
motif is composed of an invariant sequence of domains, a RING, followed by at least one B-Box 
and then a coiled coil domain [128,129] (Figure 1-6). In contrast to the predictable pattern of 
domains within the tripartite motif, TRIM proteins encode a wide variety of C-terminal domains. ! 45!
The C-terminal domains are believed to give the TRIM proteins their substrate binding 
specificities. The alpha isoform of TRIM5, like a subset of TRIM proteins, encodes for a C-
terminal PRYSPRY/B30.2 domain [128] (Figure 1-6). This arrangement is shared among at 
least 14 known human TRIM proteins. TRIM5s modified to lack a C-terminal PRYSPRY or the 
delta isoform lack the capacity to restrict viruses [125].  
While initially discovered by its anti-lentiviral activity, TRIM5α is broadly active against 
many different retroviruses. Primate TRIM5αs have been shown to restrict retroviruses from at 
least four of the seven retroviral genera [125,229,234-236]. Remarkably, there are multiple 
examples of a single TRIM5α ortholog with the ability to restrict viruses from at least three 
retroviral genera [229,236,237]. These viruses may have last shared a common ancestor in 
excess of a hundred million years ago [238]. This observation supports the notion that TRIM5α 
must recognize a broadly conserved pattern common to retroviruses. Curiously, primate 
TRIM5αs often fail to restrict all viruses within a single retrovirus genus or may differentially 
restrict closely related virus [60,61,125,234,235,239,240]. Retroviral restriction by TRIM5α is not 
a property specific to primates. Endogenous expression of TRIM5α in many mammalian species 
has been demonstrated to have anti-retroviral activity [227,241,242].   
   ! 46!
 
 
 
 
 
 
 
Figure 1-6 Trim5α and the PRYSPRY domain. Top. A schematic representation of Trim5α. 
The variable loops within the PRYSPRY (V1-4) are highlighted for emphasis. Bottom. Structure 
of the rhesus macaque PRYSPRY domain (PDB:2LM3). Variable loops are labeled and colored 
according to the top schematic. Structural images created in PyMol ! 47!
Evolution of the TRIM5α PRYSPRY domain 
 
The variable loops have evolved to target retroviral capsids. Comparisons between 
the amino acid sequences of TRIM5α PRYSPRY domains have identified a pattern of 
alternating conserved and variable regions. Among TRIM5α PRYSPRY domains there are four 
stretches of amino acids that differ in their length and amino acid composition. For this reason, 
these variable stretches are referred to as variable loops and are designated V1 to V4 
[243,244]. Regions of conservation flank these variable stretches. This pattern is also observed 
among other closely related TRIM proteins. For example, TRIM5 is found on human 
chromosome 11 in a cluster of highly related but functionally distinct TRIMS: TRIM22, TRIM6 
and TRIM34. These genes are thought to have arisen via duplication of an ancestral gene. 
Among these four TRIMs, the constant regions are nearly identical while the variable regions 
differ in both length and sequence. It is therefore likely that different evolutionary constraints act 
upon the variable and conserved regions. Both TRIM5α and TRIM22 have reported antiviral 
activities and both have been shown to have evolved under strong positive selection [243,245]. 
All of the positively selected sites within the PRYSPRY domain can be mapped to the variable 
regions.  ! 48!
Reported structures of PRYSPRY domains put these observations in context. 
Representative structures of this domain, including that of rhesus macaque TRIM5α, indicate 
that they share a conserved architecture [211,246-250]. The conserved regions of the 
PRYSPRY domain map to a structurally conserved β-barrel core. The variable regions map to a 
series of loops that extend off of the β-barrel core. The structure of TRIM21 bound to its natural 
ligand, IgG-Fc, serves as a conceptual framework for how the PRYSPRY domain of TRIM5α 
may engage retroviral capsids. In this structure the variable loops are the critical mediators of 
substrate binding [248].  
The evolution of the TRIM5α PRYSPRY domain across primates is consistent with the 
notion that TRIM5α has evolved to restrict retroviruses. Retroviruses are a diverse viral family, 
and as evidenced by HIV-1, they have the capacity to rapidly evolve.  Fittingly, the variable 
loops within the PRYSPRY domain of TRIM5α have been shown to have rapidly evolved under 
positive selection [243]. Few amino acid differences are present within the conserved β-barrel 
core, while the sequences of the variable loops differ in both length and amino acid composition 
[243,244,251]. While the variable loops harbor the majority of positively selected sites, it should 
be noted that insertions and deletions are typically excluded from standard measures of positive 
selection. However, the maintenance and further evolution of insertions in TRIM5α indicate that 
they have been selected for, likely by retroviruses. Based on the primate phylogeny it is likely ! 49!
that the diversity seen among primate TRIM5α orthologs is the result of different selective 
events. These selective events were probably the result of different retroviruses.  
Multiple lines of evidence have converged to implicate the involvement of the TRIM5α 
variable loops in capsid targeting. Molecular approaches have involved mutagenesis or the 
production of chimeric TRIM5α proteins by swapping select regions or entire variable loops 
between TRIM5αs [211,243,252-267]. All of these approaches have demonstrated that 
modulation of the variable loop sequences can dramatically impact restriction. For example, a 
single amino acid substitution in human TRIM5α can confer the ability to restrict SIVmac239, a 
virus that is normally resistant to human TRIM5α [252,268]. Similarly, TRIM5αs with chimeric 
variable loops (exchanged between two TRIM5α) have been shown to restrict viruses in a 
pattern more similar to the loop donor than the parental loop recipient [243,252-254,257,266]. 
Scanning mutagenesis has identified patches of amino acids within the variable loops that are 
required for capsid binding and restriction [259,265]. Biochemically, NMR titration experiments 
with a soluble rhesus TRIM5α PRYSPRY domain and HIV-1 capsids have found chemical 
perturbations in V1 and V2 consistent with conformational changes induced by capsid binding 
[211].  
 
Capsid encoded determinants of restriction ! 50!
Difficulties in studying the TRIM5α-capsid interaction. While the TRIM5α variable 
loops are clearly involved in capsid recognition, it is unclear how they recognize retroviral 
capsids. Efforts to elucidate the interaction between capsid(s) and the PRYSPRY domain have 
been impeded by the very nature of the interaction. For example, TRIM5α destabilizes capsid 
complexes [208,213,269-271], making the pre-restriction complex difficult to isolate. The 
interaction between TRIM5α and retroviral capsids is thought to be made up of a network of 
high-avidity low-affinity interactions [210,211,246,271]. The binding site of the PRYSPRY 
domain may include multiple capsid monomers spanning multiple hexamers/pentamers 
[208,210,246,269,272]. Retroviral capsids have variable morphology and composition and the 
binding of TRIM5α is likely templated by the capsid lattice [20,210,273,274]. Finally, there is 
considerable genetic diversity found among the TRIM5αs and retroviral capsids used to study 
the interaction. For example, it is currently unclear how results obtained using human TRIM5α 
and the gammaretrovirus murine leukemia virus relate to data obtained with rhesus TRIM5α and 
the lentivirus HIV-1.  
The interaction between TRIM5α and retroviral capsids is thought to be a high-avidity 
low-affinity interaction. Sedimentation assays demonstrated that that TRIM5α does not co-
sediment with monomeric capsid (or does so very weakly) but does co-sediment with virions 
[208,213]. This argues that the interaction may span multiple capsid monomers in the context of ! 51!
the higher ordered capsid lattice. TRIM5α has also been reported to exist in dimeric and other 
higher order states [210,235,255,267,269,271,275-281] .Mutations that disrupt the dimerization 
or oligomerization of TRIM5α have established a correlation between the ability to appropriately 
multimerize and the ability to restrict retroviruses [271,277-279].  Two observations make the 
most compelling argument for the high avidity-low affinity interaction model. First, in vitro TRIM5 
(modified to be soluble) has been demonstrated to have an inherent property to self assemble 
into a hexameric array [210]. The presence of a planar hexameric capsid array can serve as a 
guide for TRIM5α lattice formation [210]. Second, NMR titration experiments involving soluble 
rhesus PRYSPRY domains and HIV-1 capsid N-terminal domains have measured a weak 
dissociation constant (in excess of 400 µM) [211,212].  
  Capsid features that modulate restriction. The interaction between TRIM5α and 
capsid has been largely defined through mutagenesis. Mutations in capsid have been shown to 
modulate TRIM5α sensitivity [61,234,235,240,256,258,282-299]. While these efforts to map the 
interaction between capsid and TRIM5α have used different viruses and different TRIM5αs, 
some general trends are apparent. A majority of the mutations that modulate TRIM5α sensitivity 
can be mapped to the N-terminal domain of capsid for both primate lentiviruses 
(HIV-1/HIV-2/SIVmac/SIVsmm/SIVagm) and gammaretroviruses (N-MLV/B-MLV/MoMLV). 
Specifically, sites that modulate TRIM5α sensitivity are enriched on surfaces that would make ! 52!
up the exterior of the capsid. On the surface of a single capsid monomer, the sites that 
modulate TRIM5α sensitivity can be over 25 Å apart, yet have the same restricted phenotype. 
These observations imply that for some viruses there may be multiple determinants of restriction 
spread over the capsid surface. Recent NMR studies have confirmed that the PRYSPRY 
domain of rhesus TRIM5α can weakly interact with the N-terminal domain of the HIV-1 capsid 
[211]. In these NMR experiments the sites in the capsid most perturbed by the presence of 
TRIM5α were on the capsid surface [212].  
  TRIM5CypA. The naturally occurring TRIM5α-cyclophilin A gene fusion demonstrates 
that TRIM5α can act as a surface recognition molecule. The productive interaction of cyclophilin 
A with a loop on the lentivirus capsid surface has been exploited in the form of TRIM5-
Cyclophilin A fusion proteins multiple times over the course of primate evolution [45-50,231-
233,300]. Owl monkeys in the New World and macaques in the Old World express TRIM5Cyp 
proteins [45-50]. Evidence exists that suggests two additional TRIM5-cyclophilin A gene fusions 
may have existed millions of years ago, but have been lost in modern day primates [45]. All four 
of these fusion proteins are the result of independent retrotransposition events that have 
inserted cyclophilin A mRNAs into the TRIM5 locus. In the modern day TRIM5Cyp fusion 
proteins, splicing replaces the C-terminal PRYSPRY domain with a C-terminal cyclophilin A 
domain, effectively exchanging one viral recognition domain for another [46-51,251] ! 53!
  The probable targets of TRIM5α. Taken together, the fact that TRIM5Cyp can restrict 
viruses solely through capsid surface interactions, the prevalence and density of mutations 
modulating TRIM5α sensitivity on the capsid surface, and recent findings using NMR, it is likely 
that TRIM5α recognizes a unique retrovirus specific pattern on the capsid surface (reviewed 
above). These studies support a series of major conclusions. First,it appears to generally take 
less mutagenic steps to confer the restricted phenotype upon a resistant virus than it does to 
confer the resistant phenotype upon a restricted (a virus can be made sensitive by a single 
amino acid substitution, but there are fewer examples of a single amino acid substitution 
rendering a virus resistant). For many naturally restricted viruses, multiple, possibly 
independent, determinants of restriction are spread across the capsid surface. If the surface of 
the capsid N-terminal domain is a major determinant of restriction, then the pattern created by 
the higher ordered arrangement of capsid surface features must in some way explain the 
discrepancy between the observed breadth of restriction and the specificity of restriction. Put 
simply, the capsid must be both a rapidly evolving and conserved target.  
 
1. E. CAPSID AS A RETROVIRAL TARGET FOR TRIM5α 
The unique interaction between TRIM5α and capsid  
 ! 54!
The capsid is a retrovirus specific target. It can be argued that the viral signatures 
that are targeted by the aforementioned restriction factors can be divided into two categories; 
those that target general viral processes and those that directly target a retroviral-specific 
signature. The restriction factors SAMHD1, APOBEC3-family members, and BST2 exert their 
restrictive potential by acting on general processes. SAMHD1 prevents DNA synthesis by 
lowering cellular dNTP pools, APOBEC3 proteins target single stranded DNA, and BST2 tethers 
enveloped viruses [122-124,127]. Due to the generality of the viral signatures they target, these 
proteins have also been shown to act directly upon representative viruses outside of the 
Retroviridae. SAMHD1 has been shown to restrict DNA viruses like poxviruses and 
herpesviruses in myeloid cells [147,301]. While the in vivo consequences of APOBEC3 family 
members against non-retroviruses has yet to be realized, they have been shown to have activity 
against a variety of DNA viruses including human papillomaviruses [302,303], hepadnaviruses 
(HBV) [304], herpesviruses [305] and parvoviruses [306,307] under some conditions. BST2 has 
been shown to have a broad range of restriction for enveloped viruses, and the broadest range 
of restriction for any of the discussed factors. Viruses restricted by BST2 include RNA viruses 
such as filoviruses [308,309], New and Old World arena viruses [310,311], and DNA viruses 
such as herpesviruses [312,313], ! 55!
Among the discussed lentiviral restriction factors, TRIM5α is unique in that it directly 
targets a pattern created by the higher-ordered arrangement, or lattice, of capsid monomers 
within the core. Therefore, the pattern created by the retroviral capsid lattice must have at least 
four important properties. First, the pattern created by the higher ordered capsid structure must 
be unlike any other higher ordered protein arrangement naturally found in cells. Second, the 
pattern created by the capsid lattice must reflect a general pattern that is unique to the 
Retroviridae. This is evidenced by the ability of TRIM5αs to restrict viruses from multiple 
retroviral genera while simultaneously lacking direct restriction activity against any other known 
viral family. Third, for a factor like TRIM5α to have evolved, its target must be stable through 
deep evolutionary timescales. Finally, for a restriction factor like TRIM5α to have been 
continuously selected for and upon, escape from restriction must involve multiple simultaneous 
mutations or escape mutations must be accompanied with a high fitness cost. Fittingly, its 
target, the retroviral capsid, fulfills all of these criteria.  
 
The involvement of capsid at most steps of retroviral infection 
Assembly. The structural components of retroviral virions are encoded by the gag gene. 
While all retroviruses encode for a Gag protein, the Gag proteins of the orthoretrovirinae are 
cleaved into three major proteins. These proteins form three distinct layers within the virion. The ! 56!
matrix protein, which is myristoylated, forms a structured, yet incomplete lattice, along the inner 
leaflet of the inner viral membrane [20-22,273,314]. The capsid protein condenses to form a 
higher-ordered protein shell around the inner components of the virion. The inner components 
include two viral genomes (normally identical or near-identical to each other) , which are coated 
in the final major Gag derived protein, the nucleocapsid protein. Also within the higher-ordered 
capsid shell are the reverse transcriptase and integrase enzymes. While the composition of 
cleavage products varies between retroviral genera the order and timing of each cleavage event 
are critical for the production of infectious virions [20,22,273].  
Estimates for the number of gag proteins within the virion range from 2500-5000 [315-
318]. The number of capsid monomers within the virion is identical due to the one to one ratio of 
capsid proteins to gag proteins. Of these 2500-5000 capsid monomers within the virion, atomic 
resolution models of the HIV-1 capsid core suggest that it is comprised of approximately 1,056-
1,356 capsid monomers [319,320]. These models predict there to be 166-216 capsid hexamers 
and exactly 12 pentamers within the capsid. The 12 pentamers create the necessary curvature 
to close the otherwise hexameric lattice [274]. The asymmetric distribution of these 12 
pentamers give lentiviral capsid cores their distinctive morphology that can be described as a 
fullerene cone [274]. Multiple functional surfaces of the capsid protein contribute to a carefully 
orchestrated series of cleavage events and conformational changes that liberate capsid proteins ! 57!
from their gag precursor and facilitate the condensation into a fully assembled fullerene cone 
[19,20,273,274,320,321].  
Reverse transcription. Following fusion, the core is deposited into the cytoplasm of the 
target of the cell [97]. The diffusion of dNTPs through the core is thought to trigger reverse 
transcription [13]. Reverse transcription is believed to occur to completion, or near completion 
within the capsid shell [11]. This likely serves two purposes. The first is that the capsid core 
traps the two viral genomes, reverse transcription intermediates, reverse transcriptase and 
integrase within a protein shell. This keeps their local concentration high and prevents their 
diffusion and the dissociation of the reverse transcription complex into the cytoplasm. Evidence 
from TRIM5α restriction demonstrates that the capsid becomes permeabilized resulting in the 
release of the capsid core’s internal components [11,12,208,322]. This is correlated with the 
block to late reverse transcription products. Second, the capsid core prevents reverse 
transcription intermediates from being sensed by pattern recognition receptors of the innate 
immune system [323]. Importantly, the capsid is not an inert protein shell; rather it is a mediator 
of critical interactions with cellular cofactors.   
   The capsid co-factor cyclophilin A. Primate lentivirus capsids have been shown to 
efficiently bind to a number of cellular cyclophilins [231-233,291,324,325]. Cyclophilins make up 
a superfamily of proteins that are present among all known cellular organisms [326]. ! 58!
Functionally, they catalyze trans to cis isomerization of prolines relative to the peptide backbone 
(peptidyl-prolyl isomerase activity), thus facilitating protein folding [326]. Of the reported 
cyclophilin-capsid interaction partners two have been shown to positively influence primate 
lentivirus infection in human cells [231,233,327]. The first is cyclophilin A (PPIA) which was 
identified as the first capsid interacting protein [231] (the second is a cyclophilin A-like domain in 
Nup358, discussed below). It has been shown to bind an elongated loop between α-helix 4 and 
α-helix 5 that extends off of the capsid protein of lentiviral capsid proteins [232,233,300]. Due to 
its interaction with cyclophilin A, this loop is colloquially referred to as the cyclophilin A binding 
loop [300]. This loop is structurally unique to the capsid retroviruses of lentivirus genus 
[300,324,328-333]. Fittingly, the capsid-cyclophilin A interaction is also unique to this genus. 
Importantly among most lentiviruses, including endogenous lentiviruses dated to be at least 5-8 
million years old, this loop has a proline rich sequence capable of binding cyclophilin A 
[232,300,324,327,333,334]. The high affinity interaction between capsid and cyclophilin A leads 
to efficient incorporation into virions in the producer cell [232,233]. While reports exist for the 
requirement for cyclophilin A in both the producer cell and the target cell, it appears that the 
stronger phenotype occurs in the target cell [335-346]. In human cells the presence of 
cyclophilin A in the target cell is generally associated with an increase of infectivity for HIV-1. 
One explanation for this interaction may be that it helps to shield it from human TRIM5α ! 59!
[292,339,347-350]. However, the requirement for cyclophilin A to enhance the infectivity of 
HIV-1 is not absolute among human cell lines [282,287,335,339,340,344,349,351-357]. The 
pattern of cell lines requiring cyclophilin A at least in part matches cell lines which express 
cytosolic DNA innate sensors. Therefore the phenotype may at least in part be explained by the 
observation that cyclophilin A binding helps to shield the reverse transcription complex from 
innate sensors [323].  
Capsid facilitates nuclear import. Lentiviruses can efficiently infect non-dividing cells 
[2,14,15,18]. While numerous viral proteins have been implicated in this phenotype, the capsid 
protein has been shown to be the major determinant [358]. Some details of the mechanisms 
underlying this phenotype have come from a number of RNA interference screens [359-362]. 
Collectively, these screens have implicated the requirement of a number of nuclear pore 
proteins, karyopherins, and karyopherin cargos for the efficient infection of cells by HIV-1.  
The coordinated interactions of host proteins with lentiviral capsids shuttle primate 
lentivirus capsids through a preferred nuclear import pathway. This pathway not only results in 
efficient trafficking through the nuclear pore, but also influences the selection of integration 
sites. Sampling of thousands of independent integration sites has shown that HIV-1 (and 
presumably primate lentiviruses) are biased towards transcriptionally active regions of DNA and 
transcriptionally active gene clusters [204]. Perturbation of the preferred nuclear import pathway ! 60!
either through depletion of the above cellular factors or through capsid mutations that disrupt the 
interaction with the above factors can bias HIV-1 integration target site selection away from its 
wild type pattern [204,327,363,364]. The transcriptional environment into which a lentiviral 
provirus inserts can influence viral gene expression [204]. Fittingly, deviations from the preferred 
pattern of integration are correlated with reduced replication [327,365].  
   Nup358/RANBP2.  Two independent RNA interference screens implicated the 
involvement of nuclear pore protein Nup-358/RANBP2 in efficient HIV-1 infection [359,360]. This 
protein has a cyclopilin A-like domain that extends from the nuclear pore into the cytoplasm 
[327]. The HIV-1 capsid protein, and the capsid proteins of other lentiviruses can bind to this 
cyclophilin A-like domain via the 4-5 loop (cyclophilin A binding) [327]. The capsid-Nup-358 
interaction has been implicated in the efficient nuclear trafficking of the pre-integration complex 
as well as the appropriate integration target site biases that exist for the lentivirus genus of the 
Orthoretrovirinae [327]. The relevance of the interaction between lentivirus capsids and the 
cyclopilin A-like domain of Nup358 has recently been called into question [366]. While the 
cyclopilin A-like domain of Nup358 may not be strictly required for nuclear import, it does indeed 
interact with the 4-5 loop of the HIV-1 capsid and the capsids of other (but not all) lentiviruses 
[327,366].  It is currently unclear which (if any) additional specific contacts between Nup358 and 
capsids contribute to lentivirus infection.  ! 61!
  CPSF6. Cleavage and polyadenylation specific factor 6 (CPSF6), is a proven capsid 
interacting protein [367]. The interaction of capsid with CPSF6 was fortuitously identified in a 
cDNA screen to identify restriction factors. A prematurely truncated and mis-spliced CPSF6 
mRNA gave rise to a cDNA that potently restricted HIV-1 [367]. This cDNA encoded an mRNA 
that was lacking an arginine-serine rich domain that is required for nuclear localization [368]. 
Cytosolic localization is associated with primate lentivirus restriction [367,369,370]. CPSF6 
directly binds lentiviral capsids. This interaction is mediated by a putative capsid interacting 
domain. This domain contains a capsid binding peptide that is required for efficient HIV-1 
nuclear import [363,370]. The structure of the CPSF6 capsid binding peptide in complex with the 
HIV-1 capsid N-terminal domain has been determined and shown to bind in a groove along one 
side of the monomeric capsid protein [363]. Both the structure and amino acid composition of 
this pocket are highly conserved across primate lentiviruses [363].  
  Nup-153. Two of the four RNA interference screens have implicated the involvement of 
Nup-153 as a mediator of HIV-1 infectivity [359,360]. The requirement for Nup-153 has been 
confirmed for HIV-1 and extended to include additional primate lentiviruses [371]. Specific 
capsid mutations in addition to chimeric HIV/MLV viruses established that the capsid protein 
governs sensitivity to Nup-153 depletion [371]. The FG repeats at the C-terminus of Nup-153 
have been demonstrated to directly bind to lentivirus capsids. This interaction has been mapped ! 62!
to the same binding pocket within the N-terminal domain of capsid that binds the CPSF6 capsid 
binding peptide [372].  
  Host factor shield. While interactions with the above factors shuttle the preintegration 
complex through the nuclear pore, some of these co-factor interactions also shield it from innate 
sensors [323]. The interactions with cyclophilin A (and possibly the cyclophilin A-like domain of 
Nup358) have been shown to reduce the detection of reverse transcription intermediates in the 
cytoplasm [323]. The interaction of human CPSF6 with HIV-1 can pause reverse transcription 
[323]. This is thought to delay reverse transcription until is within proximity of the nuclear pore, 
reducing the potential exposure of the reverse transcription intermediates from innate sensors 
[323]. These coordinated interactions with cellular co-factors prevent innate signaling and the 
establishment of an antiviral state by the production of interferon stimulated gene products 
(including restriction factors like BST2 [122,123]). Interferon signaling also establishes a local 
anti-viral environment. Since primate lentiviruses more efficiently spread through cell-to-cell 
transmission, interferon signaling in one cell may render adjacent cells more resistant to 
infection.  
 
The retroviral capsid is a conserved target 
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Evolutionary constraints. As highlighted by the above examples, the capsid protein of 
primate lentiviruses either actively participates or at minimum influences almost every step of 
the replication cycle. As reviewed above multiple functional surfaces on the capsid protein are 
dynamically required to orchestrate a number of conformational rearrangements and inter- and 
intra- molecular interactions not limited to its role in Gag-dimerization, maturation, regulated 
uncoating, and its interactions with various cellular cofactors that ultimately lead to proper 
nuclear import and integration target site selection. Likely due to its relatively small size of 
approximately 230 amino acids, these functional surfaces are often used for multiple purposes. 
For example, the 4-5 loop productively interacts with cycolyphin A [231,232,300,327] and the 
cyclophilin A-like domain of Nup-358. At least for the assembly of the betaretrovirus Mason-
Pfizer Monkey Virus, the capsid surfaces also mediate critical contacts prior to the condensation 
of the capsid [321]. These interactions are also believed to exist for other retroviruses including 
the primate lentiviruses [321]. The same binding groove mediates interactions with CPSF6 and 
Nup-153 [363,372]. The first three alpha helices in the capsid C-terminal domain participate in 
contacts required for Gag-Gag dimerization prior to assembly. In the context of the 
hexamer/pentamer they participate in intra-hexamer contacts that effectively cradle the N-
terminal domain of an adjacent capsid monomer and between capsid hexamers/pentamers they 
are the major mediators of the inter-hexamer contacts that provide both the stability and ! 64!
flexibility needed to form the core [19,20,22,319,320,373,374]. Therefore, the capsid would be 
predicted to have a multitude of evolutionary constraints.  
   Structural conservation. The amino acid sequences of the capsid proteins of 
orthoretroviruses bear little sequence identity. The notable exception to this observation is an 
approximately 22 amino acid stretch within the C-terminal domain that participates in Gag-Gag 
and multiple capsid-capsid interactions. The high degree of conservation between retroviruses 
and some retrotransposons has led to this stretch of amino acids being termed “the major 
homology region” or MHR. Despite the clear lack of sequence identity, the wealth of reported 
orthoretroviruses capsid structures demonstrate that the overall capsid structure is highly 
conserved [300,328,329,331,338,375]. To put this observation in context, conservative 
estimates postulate that the last common ancestor of all extant members of the 
Orthoretrovirinae existed between 70-100 million years ago. Despite the fact that among the 
orthoretroviruses the amino acid sequence of the N-terminal domain is far more variable than 
that of the C-terminal domain, reported structures of viruses from 5 of the 6 Orthoretrovirinae 
genera illustrates that the N-terminal domains share a common fold [300,328,329,331,338,375]. 
This conservation makes the structures of these capsids superimposable (Figure 1-7B-D). In 
particular, the presence of a β-hairpin at the extreme N-terminus and a core composed of 5 α-
helices are invariant features of Orthoretrovirinae capsids (Figure 1-7B). Hexameric capsid ! 65!
structures have been reported for both B and N tropic MLV in addition to HIV-1. Together they 
demonstrate that the higher ordered capsid species are also highly conserved. 
[319,330,373,375] (Figure 1-8). Perhaps this conservation is fitting considering the difference 
between the fullerene cone of lentiviruses and the sphere of gammaretroviruses is the 
distribution of pentamers in the capsid [20,274,330].  
   ! 66!
Figure 1-7. Structural conservation across Orthoretrovirinae capsid N-terminal domains.  
(A) The HIV-1 capsid N-terminal domain (PDB: 1GWP). Notable features are labeled: The β-
hairpin (BHP), α-helices 1-7 (αH), the 4-5 loop (4-5L) and 6-7 loop (6-7L). A structurally 
conserved core of 5 α-helices is shown with a black line. (B) Conserved features of 
Orthoretrovirinae capsid N-terminal domains. Structures of divergent Orthoretrovirinae capsids 
aligned to HIV-1 (red). The variable surface features have been removed to display the 
conserved 5 α-helix core and β-hairpin (boxed). (C) Structural heterogeneity is segregated from 
structural conservation. Structures of divergent Orthoretrovirinae capsids aligned to HIV-1. 
Variable surface structures are boxed. (D) Structures of Orthoretrovirinae capsids aligned to 
HIV-1 (red) and separated by retrovirus genus. (PDB: Lenti-HIV-1-1GWP, Lenti-HIV-2-2WLV, 
Lenti-PSIV-2XGU gamma-N-MLV-1U7K, gamma-B-MLV-3BP9, alpha-RSV-1D1D, delta-1QRJ, 
beta-M-PMV-2KGF beta-JSRV-2V4X).  Images created in PyMol. 
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Figure 1-7. Structural conservation across Orthoretrovirinae capsid N-terminal domains. 
Continued.   
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Figure 1-8. Conservation of higher ordered capsid structures. Hexameric capsid structures 
from the lentivirus HIV-1 and gammaretrovirus N-tropic MLV are superimposable. Top.  A top 
view of the superimposed structures. Bottom. A side view of the superimposed structures. PDB: 
1U7K and 3GV2. Red: HIV. Cyan: MLV. Images created in PyMol 
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The sites of major structural deviation found among the capsids of orthoretroviruses are 
on the capsid surface. Variation among structural features is found on the opposite side of the 
capsid surface from the highly conserved β-hairpin [300,328,329,331,338,375]. (Figure 1-7B-C). 
Therefore the capsid surface has segregated regions of structural conservation and structural 
heterogeneity. While variable between Orthoretrovirinae genera, these regions tend to be 
structurally conserved within any single retrovirus genus. Reported Orthoretrovirinae capsid 
structures differ in the presence of one or two surface α-helices. These surface α-helices also 
differ in their orientation relative to the conserved 5-α-helix core. Variation is found in the length 
of the linker between the final surface helix and the last α-helix of the N-terminal domain 
(between helix 6 and 7 of primate lentivirus capsids). Finally, there is considerable 
heterogeneity in the length and the conformation of an extended loop bridging α-helix 4 and the 
first surface α-helix. This corresponds to the 4-5 loop for primate lentiviruses 
[300,328,329,331,338,375].  
These variances in structure are not without biological consequence. The corresponding 
variable structures of lentiviruses are the same structures that facilitate the infection of non-
dividing cells (nuclear import), a phenotype that is a defining property of lentiviruses. 
Specifically, the elongated 4-5 loop which extends off of the capsid surface into the cytoplasm 
binds cellular cyclophilin A as well as the cyclophilin A-like domain of the nuclear pore protein ! 70!
Nup-358 [232,300,327]. Similarly, the primate lentivirus surface α-helices 5 and 6 create a 
binding pocket and coordinate waters that facilitate the binding of the capsid binding loop of 
CPSF6 [363,370]. Importantly, the orientation and sequence of the HIV-1 α-helices 5 and 6 are 
predicted to be critical for this interaction. This same binding pocket also binds the FG-repeats 
of the nuclear pore protein Nup-153 [372]. Considering that the lentivirus-specific structural 
features are involved in efficient nuclear import it is possible that the corresponding structural 
features of other retrovirus capsids mediate contacts with cellular cofactors. Perhaps the 
structural similarities between the HIV-1 and Rous sarcoma virus capsid N-terminal domains 
account for the observation that Rous sarcoma virus can weakly infect non-dividing cells [16]. 
Interestingly, the betaretrovirus MMTV has recently been reported to infect non-dividing cells 
[17]. The mechanism by which MMTV infects non-dividing cells appears to be different from the 
canonical HIV-1 nuclear import pathway [17].   
Fragility of capsid. As outlined above, the capsid participates in a number of dynamic 
interactions that are required for optimal viral infectivity. Selection to maintain these interactions 
would therefore impart a great number of evolutionary constraints upon the capsid protein. 
Indeed, the capsid protein is the most conserved Gag protein within any one Orthoretrovirinae 
genus. The capsid of the gammaretrovirus Moloney murine leukemia virus (MoMLV) has been 
shown to be the least tolerant gag protein to insertional mutations [376]. Further characterization ! 71!
of insertion and point mutants within the MoMLV capsid demonstrated that most mutations 
interfere with assembly [376,377]. Similarly, in the context of mutation, the HIV-1 capsid has 
been reported to be extremely fragile. Specifically, the HIV-1 capsid is the least tolerant viral 
protein ever analyzed by random single amino acid mutagenesis [378]. An overwhelming 
majority of these mutations were shown to disrupt one or more steps in the assembly and 
condensation of fullerene cone shaped core. These results are largely consistent with earlier 
observations made from alanine-scanning mutagenesis for the HIV-1 capsid protein [379].  
 
1. F.  CONCLUDING REMARKS   
 
Summary and findings 
 
Summary. TRIM5α has evolved to restrict retroviruses through its interaction with the 
viral capsid. The qualities of orthoretrovirus capsids match the qualities that one would predict to 
be necessary to drive the evolution of an antiretroviral factor such as TRIM5α. Orthoretrovirus 
capsids are an evolutionarily stable target that are generally intolerant to random mutations. The 
evolution of Orthoretrovirinae capsids is constrained by the capsid protein’s direct involvement 
or influence upon most steps of viral replication cycle. Conservation is seen at both the ! 72!
structural level across the Orthoretrovirinae and the sequence level within any one 
Orthoretrovirinae genus. In the absence of obvious sequences common amongst TRIM5α 
resistant or TRIM5α restricted viruses from across the Orthoretrovirinae, conserved structures 
may account for the observed breadth of restriction. In parallel, sequence conservation among 
Orthoretrovirinae genera, or subgroups within, such as primate lentiviruses, may account for the 
specificity of restriction or resistance to TRIM5α orthologs observed for some viruses. Finally, 
based on the relationship between TRIM5α and retroviruses, it is likely that retrovirus infection 
has driven the evolution of TRIM5α while the presence of TRIM5α has likely driven the 
evolution of retroviral capsids.  
Findings. Similar to a great body of previous work, I set out to define a binding site for 
rhesus TRIM5α on the HIV-1 capsid protein. As an ultimate test of our understanding of this 
interaction I sought to engineer a rhesus TRIM5α-resistant HIV-1 capsid. Unlike previous 
approaches, I took a gain-of-sensitivity approach rather than assaying for a gain of resistance. 
Specifically, I generated a series of mutations in the rhesus macaque adapted SIVmac239 virus. 
These mutant SIVmac239 viruses were modified to express chimeric capsids proteins in which 
whole regions or single amino acids were replaced with the corresponding sequences of the 
HIV-1 molecular clone, HIV-1nl4.3. This allowed us to separate multiple determinants of 
restriction across three major capsid surface features (β-hairpin, 4-5 loop and α-helix-6). This ! 73!
led to the generation of the first reported HIV-1 capsid resistant to rhesus macaque TRIM5α. 
Furthermore, we identified two targets for rhesus TRIM5α: one in the structurally conserved β-
hairpin and another in a patch of amino acids on the capsid surface that are both highly 
conserved in sequence and structurally unique to lentiviruses [380]. Conservation of this site 
may be due to its position at the junction of the Cyclophilin A/Nup-358 cyclophilin A-like 
domainand the CPSF6/Nup-153 binding sites [300,327,363,372].  
Rhesus macaques have two TRIM5α variants, one reflective of an ancestral and ancient 
state, while the other was more recently acquired during macaque evolution [251]. We observed 
that only the more recently evolved variant gained the ability to restrict viruses with mutations in 
lentivirus specific features (conserved surface patch). However, both alleles were capable of 
restricting viruses with mutations in the highly conserved β-hairpin. This led us to propose an 
evolutionary model in which all Old World monkey TRIM5αs have an intrinsic ability to target the 
pan-Orthoretrovirinae feature, the β-hairpin. We proposed that this accounts for the observed 
breadth of TRIM5α restriction that can encompass multiple retroviral genera. Furthermore, we 
suggest that this association allows other regions of TRIM5α to evolve virus-specific contacts, 
such as the primate lentivirus specific conserved surface patch. 
We and others noted that the site that functionally differentiates the two rhesus macaque 
alleles has been heavily modified across members of a single clade of African primates, the  ! 74!
Cercopithecinae [61,208,228,243,251,257]. To test our proposed evolutionary model and to 
understand the viral factors driving the evolution of primate TRIM5α we studied this rapidly 
evolving site within TRIM5α. We reconstructed an ancestral TRIM5α as it may have existed 11-
16 million years ago, before the selective events took place. Into this isogenic and ancient 
backbone we introduced these evolutionarily acquired changes. These modifications led to the 
specific gain of ability to restrict Cercopithecinae SIVs. The restriction of non-SIV viruses was 
largely unaffected. Our observations imply that specific Old World monkey TRIM5αs evolved to 
restrict viruses from a specific primate lentivirus lineage. Using the known primate phylogeny we 
have concluded that selection by a specific lineage of primate lentiviruses occurred 11-16 
million years ago. Thus, we speculate that Cercopithecine SIVs and primate lentiviruses are at 
least as ancient.    ! 75!
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2. A. ABSTRACT 
Retroviral capsid recognition by TRIM5 blocks productive infection. Rhesus macaques 
harbor three functionally distinct TRIM5 alleles: TRIM5α
Q, TRIM5α
TFP and TRIM5
CypA. Despite 
the high degree of amino acid identity between TRIM5α
Q and TRIM5α
TFP alleles, the Q/TFP 
polymorphism results in the differential restriction of some primate lentiviruses, suggesting these 
alleles differ in how they engage these capsids. Simian immunodeficiency virus of rhesus 
macaques (SIVmac) evolved to resist all three alleles. Thus, SIVmac provides a unique 
opportunity to study a virus in the context of the TRIM5 repertoire that drove its evolution in vivo. 
We exploited the evolved rhesus TRIM5α resistance of this capsid to identify gain-of-sensitivity 
mutations that distinguish targets between the TRIM5α
Q and TRIM5α
TFP alleles.  While both 
alleles recognize the capsid surface, TRIM5α
Q and TRIM5α
TFP alleles differed in their ability to 
restrict a panel of capsid chimeras and single amino acid substitutions. When mapped onto the 
structure of the SIVmac239 capsid N-terminal domain, single amino acid substitutions affecting 
both alleles mapped to the β-hairpin. Given that none of the substitutions affected TRIM5α
Q 
alone, and the fact that the β-hairpin is conserved among retroviral capsids, we propose that the 
β-hairpin is a molecular pattern widely exploited by TRIM5α proteins. Mutations specifically 
affecting rhesus TRIM5α
TFP  (without affecting TRIM5α
Q) surround a site of conservation unique 
to primate lentiviruses, overlapping the CPSF6 binding site. We believe targeting this site is an ! 78!
evolutionary innovation driven specifically by the emergence of primate lentiviruses in Africa 
during the last 12 million years. This modularity in targeting may be a general feature of TRIM5 
evolution, permitting different regions of the PRYSPRY domain to evolve independent 
interactions with capsid 
 
2. B. INTRODUCTION 
The anti-retroviral activity of TRIM5α was discovered in a screen to identify rhesus 
macaque cDNAs conferring resistance to HIV-1 replication [125]. Antiretroviral activity has since 
been demonstrated for a large number of primate TRIM5 orthologs, including prosimians, as 
well as homologs from cow and rabbit [241,242,264,381]. While no single ortholog of TRIM5 
universally restricts all retroviruses, the collective breadth of restriction, coupled with the 
observation that some orthologs can restrict viruses from two or more genera, suggests that 
TRIM5 recognizes a conserved, pathogen-associated molecular pattern common to members of 
the Retroviridae [229,236,381].  
TRIM5α is composed of four domains: the RING, the B-Box and the Coiled-coil domains, 
which make up the tripartite RBCC of TRIM proteins, and a C-terminal PRYSPRY domain 
[128,129]. The PRYSPRY domain is thought to recognize the viral capsid [125,208,213]. In the 
case of lentiviruses, the cone-shaped capsid is composed of 12 pentamers and approximately ! 79!
200 hexamers, each in turn comprised of identical copies of monomeric capsid (CA) protein 
[274,319]. An HIV-1 CA monomer has two α-helical domains connected by a flexible linker 
[382]. The N-terminal domain makes up the outer surface of the capsid and mediates 
interactions with cellular cofactors [231,232,327,363,367,371,383].   
Comparisons between reported CA structures from viruses representing five 
Orthoretrovirinae genera show that the overall architecture of the N-terminal domain is 
conserved, despite little conservation of protein sequence. All reported retroviral N-terminal 
domain structures contain a conserved five α-helix core, from which a conserved surface 
feature, the β-hairpin, protrudes into the cytoplasm. Structural variation can be found among 
additional features on the CA surface. These differences include the presence and arrangement 
of 1-2 additional α-helices and/or the presence of an extended loop connecting helices 4 and 5 
(4-5 loop) [328-331,338,384].  
Reports suggest that multiple sites within retroviral CAs modulate TRIM5α sensitivity 
[61,234,235,240,256,258,282-299]. The majority of these sites map to the N-terminal domain 
and are enriched within the CA surface features. Perplexingly, engineered CA mutations, 
naturally occurring variants, and escape mutations can have similar phenotypes even when 
separated by distances in excess of 25 Å. Understanding how these sites relate to one another ! 80!
is critically important for defining how TRIM5α recognizes retroviral capsids, and how viruses 
evolve to evade TRIM5α restriction.  
We previously reported that the TRIM5 locus of rhesus macaques (Macaca mulatta) is 
highly polymorphic, and that the different allelic lineages of rhesus TRIM5 (rhTRIM5) have been 
maintained by long-term balancing selection [46,251]. Based on functional assays and gene 
association studies, rhTRIM5 alleles can be grouped into 3 classes, rhTRIM5α
TFP, rhTRIM5α
Q 
and rhTRIM5
CypA [47,48,50,51,61,257,385]. When tested against a panel of primate lentiviruses, 
the 3 alleles give differing patterns of restriction [61,251,257] – an indication that rhTRIM5 has 
at least 3 distinct (or incompletely overlapping) targets on the lentiviral CA protein.  
SIVmac emerged in captive macaque colonies in the 1970s, most likely the result of an 
unintentional interspecies transmission of SIV from sooty mangabeys (SIVsm) [23,58,386,387]. 
We previously reported that SIVsm isolates are resistant to rhTRIM5α
Q, but sensitive to 
rhTRIM5α
TFP and rhTRIM5
CypA alleles [61]. Because rhTRIM5α
TFP, rhTRIM5α
Q and rhTRIM5
CypA 
likely have deferring targets within CA and because all are present at moderate-to-high 
frequency, emergence of SIVmac in rhesus macaque colonies required adaptations permitting 
simultaneous resistance to all three. Thus, comparisons between SIVmac and other restricted 
isolates provide a unique opportunity to understand the basis of recognition by TRIM5α proteins ! 81!
and to identify specific features of CA that determine sensitivity and resistance to rhTRIM5α-
mediated restriction. 
The structural basis for CA recognition by rhTRIM5
Cyp is clear: the cyclophilin A domain 
(CypA) specifically binds the 4-5 loop [300,333]. In contrast, rhTRIM5α
TFP and rhTRIM5α
Q 
interact with capsids via a C-terminal PRYSPRY domain, but the basis for capsid recognition by 
TRIM5 PRYSPRY domains remains poorly understood. There are several factors that 
complicate studies of the interaction. For example, TRIM5α destabilizes capsid complexes 
[208,213,269-271], the nature of the interaction is believed to be high avidity and low affinity 
[210,211,246,271], the interaction site may extend beyond a single CA monomer or hexamer 
[208,210,246,269,272], retroviral capsids and presumably the TRIM5α lattice surrounding them 
have variable morphology and composition [20,210], and there is considerable diversity among 
TRIM5α orthologs and retroviral CA sequences.  
To investigate how TRIM5α recognizes retroviral CAs, we combined genetic, phylogenic 
and structural investigations with an alternative mutational strategy to separate and map the 
determinants for the differential restriction of HIV-1 and SIVmac by rhTRIM5α alleles. The 
resolution of our mapping, together with the structural determination of the SIVmac239 CA N-
terminal domain and consideration of primate lentivirus diversity, allowed us to identify two 
conserved CA surface elements that appear to be targets of rhTRIM5α recognition. The first, the ! 82!
β-hairpin, is a structural feature that is present in all reported retroviral CA structures. Mutations 
in the β-hairpin affected targeting by both rhTRIM5α
Q and rhTRIM5α
TFP alleles. The second 
element, a patch of highly conserved amino acids among primate lentivirus CAs, may be a 
unique target of the more recently evolved rhTRIM5α
TFP allele. Strikingly, this patch is a surface-
exposed extension of the recently identified CPSF6 binding site [363]. Therefore, similar to the 
exploitation of the interaction between cyclophilin A and Nup358 by TRIM5
CypA, it appears that 
rhTRIM5α
TFP has evolved to target the binding site of a required cellular cofactor. Taken 
together, the observations made from investigating the differential breadth and specificities of 
rhTRIM5α alleles have revealed a complex evolutionary relationship between retroviruses and 
TRIM5α orthologs.  
 
2. C. RESULTS 
Differential restriction by the rhesus TRIM5α
Q and TRIM5α
TFP alleles.  
Differential restriction by rhTRIM5α
Q and rhTRIM5α
TFP has been mapped to a length 
polymorphism in the PRYSPRY domain (TFP339-341Q) [257]. Despite the fact that the protein 
sequences are >98% identical, the rhTRIM5α
Q and rhTRIM5α
TFP alleles yield different patterns 
of restriction when tested in parallel against divergent retroviruses [61,251,257,385]. We tested 
both alleles against multiple primate lentiviruses and found that even among these related viral ! 83!
strains, the rhTRIM5α
Q and rhTRIM5α
TFP alleles give different patterns of restriction (Figure 2-
1). Specifically, rhTRIM5α
Q restricted a human viral isolate, HIV-1nl4.3, but failed to restrict any 
of the lentiviruses isolated from Cercopithecine primates (SIVmac239 from rhesus macaques, 
SIVsmE041 and SIVsmE543-3 from sooty mangabeys, and SIVagmTAN-1 from African green 
monkeys) or HIV-2ROD (which originated by cross-species transmission of SIVsm [26]). In 
contrast, rhTRIM5α
TFP restricted HIV-1nl4.3, SIVsmE041, SIVsmE543-3, SIVagmTAN-1 and to 
a lesser extent, HIV-2ROD. Only the rhesus macaque isolate, SIVmac239, was resistant to both 
alleles. Thus, while both alleles are functional, the differing patterns of restriction are consistent 
with the hypothesis that rhTRIM5α
Q and rhTRIM5α
TFP proteins differ in the way they recognize 
primate lentivirus CAs.  
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Figure 2-1. Differential restriction of primate lentiviruses by rhesus TRIM5α
TFP and 
TRIM5α
Q alleles. GFP reporter viruses were used to infect CRFK cells expressing the rhesus 
TRIM5α
TFP allele mamu3 (TFP) and the rhesus TRIM5α
Q allele mamu4 (Q). Infectivity on empty 
vector control cells is shown (Ctrl). (A) HIV-1nl4.3. (B) SIVmac239. (C) SIVsmE041. (D) 
SIVsmE543-3. (E) SIVagmTan-1. (F) HIV-2Rod. Infections were done in triplicate. Error bars 
indicate SEM. These results are representative of at least 3 independent experiments.  
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Individual surface elements of capsid determine restriction by TRIM5α.  
HIV-1 and SIVmac239 had opposite restriction profiles when tested for restriction on 
rhTRIM5α expressing cells. HIV-1nl4.3 was restricted by both rhTRIM5α
TFP and rhTRIM5α
Q 
alleles, whereas SIVmac239 was resistant to both alleles. At least three lines of evidence 
support the existence of multiple sites of rhTRIM5α recognition within the HIV-1 CA. First, HIV-1 
is restricted by both rhTRIM5α
TFP and rhTRIM5α
Q alleles while other tested primate lentiviruses 
are resistant to the rhTRIM5α
Q allele. Second, attempts to evolve an HIV-1 with resistance to 
rhTRIM5α have not yielded fully resistant viruses [294], while other viruses have successfully 
evolved resistance to rhTRIM5α-mediated restriction with genuine escape mutations both in 
vitro and in vivo [61,240]. Third, mutagenesis approaches in which elements of the SIVmac239 
CA were inserted into the HIV-1 CA resulted in rhTRIM5α restricted viruses [282,283,289,290]. 
With 79 amino acid differences between the two viruses (Figure 2-2A), we hypothesized that 
isolating each determinant would allow us to resolve the specific amino acids involved in 
rhTRIM5α recognition at each target site. We therefore chose to take an alternative approach, 
based on identifying gain of sensitivity mutations of the inherently rhTRIM5α-resistant 
SIVmac239 CA. We inserted individual features of the HIV-1nl4.3 CA into the SIVmac239 CA 
and measured the impact on restriction.! 86!
                                                                                      
 
Figure 2-2. Distribution of amino acid differences between HIV-1nl4.3 and SIVmac239.   
(A) Sequence alignment of HIV-1nl4.3 and SIVmac239 CAs. Surface features are indicated on 
the top, internal α-helices on the bottom. Amino acid differences between the two viruses are in 
bold type. (B) Structure of the HIV-1nl4.3 N-terminal domain (PDB: 3GV2). The β-hairpin (BHP), 
the linker connecting the β-hairpin to helix 1 (linker), helix 6 (h6) and 4-5 loop (4-5L) are 
indicated. Additional α-helices are numbered αH1-αH7. Residues that are identical in HIV-
1nl4.3 and SIvamc239 are in red, residues that differ are in blue.  ! 87!
The ability of TRIM5α orthologs to restrict highly divergent retroviruses with little to no 
sequence identity suggests TRIM5α may target conserved, structural elements of CA. All 
reported retroviral N-terminal domain structures have a conserved five α-helix core.  To 
determine whether differences within the five α-helix core impact rhTRIM5α recognition, we 
generated SIV-HIVinterior, by replacing most of the five α-helix core of SIVmac239 with that of 
HIV-1nl4.3. This virus retained the SIVmac239 residues at the first and last amino acid of each 
α-helix (Figure 2-3). We then tested this virus for restriction by all verified rhTRIM5α
TFP (n=3) 
and rhTRIM5α
Q  (n=2) alleles. This mutant was 2.3-fold more sensitive to rhTRIM5α
TFP than the 
SIVmac239 parent (Figures 2-4A-C and Figure 2-5). This differed markedly from SIV-HIVsurface, 
in which three surface elements, the β-hairpin, 4-5 loop and helix 6, were derived from 
HIV-1nl4.3. This virus was restricted by all rhTRIM5α alleles tested, at levels similar to 
HIV-1nl4.3 (Figures 2-4A-D). 
  Because SIV-HIVsurface was phenotypically similar to HIV-1nl4.3, we asked whether a 
reciprocal chimera was sufficient to render HIV-1nl4.3 restriction resistant. Therefore, we 
replaced the HIV-1nl4.3 CA surface features with the three SIVmac239 surface features (the 
β-hairpin, 4-5 loop and helix 6) to create HIV-SIVsurface (Figure 2-3). This HIV-1 variant differed 
from HIV-1nl4.3 by 28 amino acids and was highly resistant to restriction by rhTRIM5α
TFP and 
rhTRIM5α
Q alleles (Figure 2-4E). Within the linker that connects the β-hairpin to helix 1, ! 88!
HIV-1nl4.3 and SIVmac239 differ at three positions (amino acids 13-15) (Figure 2-2 and Figure 
2-3). Using a second HIV-1-SIV chimera, HIV-SIVsurface25, we determined that these three 
differences do not influence restriction (Figure 2-4F). To our knowledge, HIV-SIVsurface and 
HIV-SIVsurface25 represent the first description of an HIV-1 strain resistant to all allelic classes of 
rhTRIM5. Titration of these viruses and abrogation assays confirm that resistance was not due 
to saturation of rhTRIM5α in the target cell lines (Figures 2-5 and 2-6). ! 89!
Figure 2-3. Amino acid alignment of chimeric viruses.   
Amino acid sequences of chimeric viruses used in this manuscript aligned to SIVmac239. Black 
lettering indicates unique SIVmac239 amino acids. Red lettering indicates unique HIV-1nl4.3 
amino acids. Gray dots indicate conserved positions between SIVmac239 and HIV-1nl4.3. 
Hyphens were inserted to preserve the alignment in cases of insertions/deletions. Numbered 
rows correspond to the following viruses: 1. SIV-HIVInterior 2. SIV-HIVsurface 3. SIV-HIVbhp 4. SIV-
HIVbhpQ7∆,  5. SIV-HIV4-5L 6. SIV-HIVh6 7. HIV-SIVsurface 8. HIV-SIVsurface25 9. SIVV2I10. SIVQ3V 11. 
SIVI5N 12. SIVG6L 13. SIV∆7Q 14. SIVN9Q 15. SIVY10M 16. SIVQ86V 17. SIVP87H 18. SIV∆88A 19. 
SIVA89G 20. SIV∆91I 21. SIVQ92A 22. SIVQ93P 23. SIVL96M 24. SIVS100R 25. SIVS110T 26. SIVV111L 27. 
SIVD112Q 28. SIVQ116G 29. SIVY119T 30. SIVR120H 31. SIVR120N 32. SIVQ121∆ 33. SIVQ122N 34. SIVN123P 
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Figure 2-4. Rhesus TRIM5αs recognize the capsid surface.  
The indicated GFP reporter viruses were used to infect CRFK cells expressing rhesus 
TRIM5α
TFP alleles mamu1, mamu2 and mamu3 (TFP) and the TRIM5α
Q alleles mamu4 and 
mamu5 (Q). Infectivity on empty vector control cells is shown (Ctrl). (A) HIV-1nl4.3. (B) 
SIVmac239. (C) SIV-HIVinterior . (D) SIV-HIVsurface. (E) HIV-SIVsurface. (F) HIV-SIVsurface25. (G) SIV-
HIVbhp. (H) SIV-HIVbhpQΔ7.(I) SIV-HIV4-5L. (J) SIV-HIVh6. Infections were done in triplicate. Error 
bars indicate SEM. These results are representative of at least 3 independent experiments. ! 92!
 
Figure 2-5. Characterization of viruses. The infectivity and capsid antigen content of viruses 
presented in this manuscript are provided. Capsid antigen concentration was determined by p24 
and p27 antigen capture ELISA (Advanced Bioscience Laboratories, Rockville MD.). All viruses 
in which the C-terminal domain was derived from HIV-1 were used with p24 antigen capture kit, 
while all viruses in which the C-terminal domain was derived from SIVmac239 were tested using 
a p27 antigen capture kit.   ! 93!
Figure 2-6. Surface feature chimeras do not abrogate TRIM5α activity. Two independent 
saturation controls were done to insure that attenuated viruses did not abrogate TRIM5α 
activity. (A) Titration curves on CRFK-Neo control cells (Black lines I-IV) and mamu1 
(rhTRIM5α
TFP) expression cells (red lines I-IV) were carried out. Data points are the average of 
3 infections. Error bars indicate the S.E.M. 50,000 cells were seeded in a 24 well plate in 0.5 ml 
of media. Infections were carried out in 0.2 ml media and harvested for FACS 40 hours post 
infection. (I) SIVmac239. (II) HIV-1nl4.3. (III) HIV-SIVsurface. (IV) HIV-SIVsurface25. Notably there is 
little or no deviation between the apparent infectivities of SIVmac239, HIV-SIVsurface and HIV-
SIVsurface25 on control cells and on mamu1 expressing cells at every concentration of virus 
tested. There is a very large difference between the apparent infectivity of HIV-1nl4.3 on control 
cells and mamu1 (rhTRIM5α
TFP) cells.  (V) Graphs I-IV graphed together. Importantly, despite 
the attenuation of HIV-SIVsurface and HIV-SIVsurface25 their curves fall inside the saturating curve 
for HIV-1nl4.3 on mamu1 cells. (B) Two color abrogation assays were conducted under identical 
conditions to those in Table 2-1 and Figures 2-1 and 2-4. Cells were harvested at 30 hours post 
infection. Identical amounts of HIV-1, SIVmac239-S100R, HIV-SIVsurface and HIV-SIVsurface25  to 
those used in Figure 2-4 and Table 2-1 were used. Additionally, the same concentration (ng of 
capsid) as the most attenuated mutant, HIV-SIVsurface, was used for the two rhTRIM5α restricted 
viruses HIV-1nl4.3 and SIVmac239 S100R. Cells were co-infected with a fixed concentration of 
a HIV-1 CFP reporter virus. Values for GFP and CFP positive cells are separated into two 
columns (“GFP” and “CFP”) for ease of viewing, but the values are from the same co-infection. 
Under all conditions an enhancement of infectivity for the CFP reporter virus on restrictive cells 
mamu1 and mamu4 (rhTRIM5α
TFP and rhTRIM5α
Q) was not observed. Therefore, despite high 
concentrations of virus, our experimental conditions did not saturate TRIM5α. Bar graphs 
represent the average of 3 independent infections. Error bars indicate the S.E.M ! 94!
Figure 2-6. Surface feature chimeras do not abrogate TRIM5α activity: continued ! 95!
To examine the individual contributions of each of the three surface features to 
restriction, we produced a series of SIVmac239 CAs each grafted with a single HIV-1nl4.3 
surface feature. To take into account the fact that the β-hairpin is one amino acid shorter in 
SIVmac239, we generated two SIV variants: SIV-HIVbhp, with a full length HIV-1nl4.3 β-hairpin, 
and SIV-HIVbhpQ7∆, with a single amino acid deletion in the HIV-1nl4.3 β-hairpin. We also 
generated SIVmac239 variants with the HIV-1nl4.3 4-5 loop or helix 6 (SIV-HIV4-5L and 
SIV-HIVh6, respectively). Rhesus TRIM5α
TFP alleles restricted all four of these viruses 
(SIV-HIVbhp, SIV-HIVbhpQ7∆ , SIV-HIV4-5L, and SIV-HIVh6). With the exception of SIV-HIVh6, the 
chimeras had little effect on restriction by rhTRIM5α
Q (Figure 2-4G-J). Together, these mutants 
suggest that the HIV-1 restriction-sensitive and SIVmac239 restriction-resistant phenotypes 
involve contributions from all three capsid surface features.     
 
Capsid mutagenesis reveals differences in restriction by TRIM5α
TFP and TRIM5α
Q.  
Based on results obtained from the HIV-SIVsurface25 chimera, we generated a series of 
SIVmac239 CA mutations in which the amino acid at each of the 25 positions of interest was 
substituted with the amino acid found at the homologous position in HIV-1nl4.3 (Figures 2-2A, 2-
4F, 2-3, 2-5 and Table 2-1).  The length of the SIVmac239 and the HIV-1nl4.3 CAs sequences 
are different. Relative to the other there are insertions and deletions that are distributed across ! 96!
the capsid surface features. Therefore all mutant viruses are named according to the sequence 
alignment in Figure 2-2A. Table 2-1 details the relationship between the mutant SIVmac239 
virus numbering and the numbering for the HIV-1nl4.3 and SIVmac239 CAs. Two of the 25 
mutations in the SIVmac239 CA, R117H and N123P, resulted in loss of infectivity. Although a 
His is found at position 117 in HIV-1nl4.3, an Asp is more common among HIV-1 isolates. We 
found that an SIVmac239 in which R117 was substituted with Asp instead of His retained 
infectivity (Figure 2-5).  
The 24 infectious SIVmac239 variants with single amino acid substitutions in CA were 
tested for sensitivity to restriction by rhTRIM5α
TFP and rhTRIM5α
Q. Restriction was quantified by 
determining the level of infectivity relative to SIVmac239 (Table 2-1). Only two mutant viruses 
single amino acid substitutions (SIVmac239Q3V and SIVmac239G6L), both in the β-hairpin, 
resulted in gain-of-sensitivity to both rhTRIM5α
TFP and rhTRIM5α
Q. There were 12 additional 
mutations that caused gain-of-sensitivity to rhTRIM5α
TFP, but not to rhTRIM5α
Q. These 
mutations were spread among all three CA surface features. Together these results indicate 
that the targets of the two alleles partially overlap, and that the overlap involves elements within 
the β-hairpin. The observation that a large number of residues outside of the β-hairpin 
exclusively affect rhTRIM5α
TFP without altering rhTRIM5α
Q sensitivity raises the possibility that 
rhTRIM5α
TFP either has a larger footprint on the CA surface than rhTRIM5α
Q, or that it has the ! 97!
capacity to target more than one determinant in CA. Most notably, there were no mutations that 
affected only the rhTRIM5α
Q allele (that is, none of the mutations tested caused gain-of-
sensitivity to rhTRIM5α
Q but not to rhTRIM5α
TFP). This trend was mirrored among the 14 other 
viruses tested, including both naturally occurring viruses and chimeric viruses generated for this 
study (Figures 2-1 and 2-4).  
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Table 2-1. Single amino acid mutants reveal differences in restriction by TRIM5
TFP and 
TRIM5
Q. The amino acid numbering of mutant viruses corresponds to the alignment in Figure 2-
2A. Numbering of mutated residues corresponding to the SIVmac239 capsid (Accession 
number M33262) and HIV-1nl4.3 (Accession number M19921.2) are also provided. All values 
are shown as fold-restriction relative to parental SIVmac239. The values are the result of 3 
independent experiments, each done in triplicate. The error represents the standard deviation 
between these 9 infections.  N.D - mutant was not infectious and was not analyzed.   
 
Mutant&virus& SIVmac239&Residue& HIV71nl4.3&Residue& TFP& Q&
V2I& V2& I2& 1.21&±0.08& 1.02&±0.14&
Q3V& Q3& 3V& 5.58&±&0.92& 5.42&±0.05&
I5N& I5& N5& 0.70&±0.05& 0.86&±0.08&
G6L& G6& L6& 8.37&±1.46& 6.59&±2.28&
Δ7Q& Δ& Q7& 7.73&±1.35& 0.96&±0.15&
N9Q& N8& Q9& 1.82&±0.21& 1.09&±0.20&
Y10M& Y9& M10& 3.41&±0.07& 0.94&±0.11&
Q86V& Q85& V86& 3.14&±0.31& 0.99&±0.05&
P87H& P86& H87& 5.73&±1.06& 0.95&±0.17&
Δ88A& Δ& A88& 1.12&±0.10& 0.95&±0.04&
A89G& A87& G89& 4.08&±0.50& 0.94&±0.14&
Δ91I& Δ& I91& 4.53&±0.56& 0.91&±0.22&
Q92A& Q89& A92& 0.95&±0.20& 1.00&±0.21&
Q93P& Q90& P93& 2.53&±0.28& 1.01&±0.24&
L96M& L93& M96& 7.12&±0.58& 1.03&±0.08&
S100R& S97& R100& 10.80&±2.46& 0.95&±0.20&
S110T& S107& T110& 1.6&±0.23& 1.01&±0.18&
V111L& V108& L111& 6.01&±0.09& 2.11&±0.37&
D112Q& D109& Q112& 7.15&±0.76& 1.39&±0.25&
Q116G& Q113& G116& 2.83&±0.16& 1.05&±0.15&
Y119T& Y116& T119& 0.73&±0.03& 0.94&±0.07&
R120H& R117& H120& N.D.& N.D.&
R120N& R117& H120& 0.71&±0.08& 1.04&±0.14&
Q121Δ& Q118& Δ& 1.79&±0.13& 0.91&±&0.13&
Q122N& Q119& N121& 0.75&±0.07& 1.01&±0.09&
N123P& N120& P122& N.D.& N.D.&! 99!
Structure of the SIVmac239 CA N-terminal domain. 
To provide a relevant structural context for evaluating the mutagenesis results, we 
determined the structure of the SIVmac239 CA N-terminal domain (Figures 2-7A, 2-8, 2-9 and 
Table 2-2).  The SIVmac239 CA N-terminal domain was very similar to reported structures of 
HIV-1 (PDB: 2X2D) (RMSD at Cα positions: 2.29Å) and HIV-2 (PDB: 2WLV) (RMSD at Cα 
positions: 1.42Å) (calculations used SuperPose [388]) . In particular, the five α-helices of the 
SIVmac239 N-terminal domain core did not deviate from those of HIV-1 or HIV-2, consistent 
with the observation that the SIV-HIVinterior chimera remained largely resistant to restriction 
(Figure 2-4C). 
   ! 100!
Table 2-2.  Crystallography refinement statistics.  
Table generated by Aaron G. Schmidt 
 
 
Table S1: Data collection and Refinement Statistics
SIVmac239 CA NTD
Data Collection APS ID-24-E
Resolution, Å 50-2.9 (2.95-2.90)
Wavelength (Å) 0.9792
Space Group P212121
Unit cell dimensions (a, b, c), Å 24.61, 56.66, 102.57
Unit cell angles (α, β, γ) ° 90,90,90
mean I/σ  17.17 (3.0)
Rsym 0.063 (0.365)
Completeness, % 99.46 (95.10)
Number of reflections 15,453
Redundancy 4.4
Refinement
Resolution, Å 2.9
Number of reflections:
Working 3,345
Free 152
Rwork, % 25.4
Rfree, % 29.2
Ramachandran plot,
% favored 89.1 (123/138)
% disallowed 0.72 (1/138)
Rmsd bond lengths, Å 0.0111
Rmsd bond angles, ° 1.37
Average B-factor 109.3
Note: values in parentheses denotes highest resolution shell! 101!
Figure 2-7. Structure of the SIVmac239 capsid N-terminal domain:  
(A) Structure of the SIVmac239 CA N-terminal domain at 2.9 Å resolution. There was no clear 
density for Pro88, and thus, it was omitted from the structure. A dashed line is used to indicate 
its place. (B) Comparison of the SIVmac239 β-hairpin and 4-5 loop to all other wild type HIV-1 
and HIV-2 X-ray structures deposited in the PDB. HIV-1 structures are colored dark gray, except 
PDB: 2X2D, which is colored red (and used in all subsequent comparisons). HIV-2 structures 
are colored light gray, and the SIVmac239 N-terminal domain is colored blue. (C and D) 
Locations of amino acids mutations associated with rhesus TRIM5α
Q (C) and rhesus TRIM5α
TFP 
(D) restriction from Table 2-1. Blue spheres indicate amino acid differences that do not impact 
TRIM5α restriction. Orange spheres show the location of mutations associated with 2.5-5 fold 
gains in sensitivity to rhesus TRIM5α relative to SIVmac239. Red spheres indicate positions 
associated with >5 fold gains in sensitivity to rhesus TRIM5α. Images created in PyMol. 
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Figure 2-7. Structure of the SIVmac239 Capsid N-terminal domain: continued.  
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Figure 2-8. B-factor analysis of SIVmac239 structure. Average B-factor plot of each residue 
included in the final model. The β-hairpin and 4-5 loop are delineated as reference points. (B) 
Visual “heat-map” of average B-factors.  Dark blue’s indicate lowest B-factors dark red indicates 
the highest B-factors. Residue 88 was removed from the structure due to lack of clear density 
and is indicated by the dashed red line. Images created in PyMol. Figure and legend generated 
by Aaron G. Schmidt   ! 104!
 
 
Figure 2-9. Electron density maps of key regions in the SIVmac239 structure. (A) the β-
hairpin, residues 1–14. (B) the 4-5 loop, residues 83–100—residue 88 has been removed from 
the structure as there was no clear electron density (C) the “conserved patch” residues 95–116 
(D) isolated residues 94–106 and (E) 106–116. All images are 2Fo-Fc maps and are contoured 
at 1.5σ throughout for consistency. Structure factors and the final model have been deposited in 
the Protein Data Bank accession 4HTW. All images created in PyMol Figure and legend 
generated by Aaron G. Schmidt. 
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Since the amino acids governing rhTRIM5α restriction mapped to the CA surface, we 
were particularly interested in structural differences between SIVmac239 and HIV-1 in the β-
hairpin, 4-5 loop and helix 6. We compared the SIVmac239 CA N-terminal domain structure to 
all of the previously reported wild type HIV-1 and HIV-2 CA N-terminal domain structures in 
which the surface features were properly folded (Figure 2-7B and Figure 2-9). This dataset 
includes structures of CA monomers, CA monomers from cyclophilin A bound HIV-1 CAs, HIV-1 
hexamers and HIV-1 pentamers. From this analysis, we found a clear distinction between the 
HIV-1 structures and those of the more closely related HIV-2 and SIVmac239. Specifically, the 
4-5 loops and β-hairpins formed two clusters; one composed of HIV-1 structures, and the other 
composed of SIVmac239 and HIV-2 structures. Measurements between the HIV-1 Cα of Gly94 
or Gln95 and the corresponding Gly91 and Gln92 of SIVmac239 indicate that these two groups 
are separated by 3.3-11 Å in the structural alignment. Similarly, measurements between the Cα 
of HIV-1 Gly8 and the homologous SIVmac239/HIV-2 Gly7 show the two groups are separated 
by 4-8.5 Å in the structural alignment (Figure 2-7B). These CA structural differences may help to 
explain the observed changes in restriction between the reciprocal SIV-HIVsurface and 
HIV-SIVsurface chimeras (Figures 2-4D and 2-4E) 
To determine the spatial arrangement of the single amino acid substitutions associated 
with rhTRIM5α restriction, we mapped the restriction data for rhTRIM5α
Q and rhTRIM5α
TFP onto ! 106!
the structure of the SIVmac239 N-terminal domain (Figures 2-7C and 2-7D respectively) as well 
as the structure of the HIV-1 CA hexamer (Figure 2-10). The two individual point mutations 
associated with rhTRIM5α
Q restriction were confined to the β-hairpin and were within 10 Å of 
each other. This differed from rhTRIM5α
TFP, which in addition to being affected by the same two 
sites in the β-hairpin, also recognized amino acid substitutions outside the β-hairpin, spanning 
approximately 30 Å of the CA surface.! 107!
                                   
 
                              
Figure 2-10. Mutations modulating TRIM5α sensitivity mapped to the HIV-1 hexamer. 
Mutations from Table 2-1 mapped to the HIV-1 hexamer structure 3GV2. Restriction data for 
mutant viruses tested against the rhesus TRIM5α
TFP allele mamu1 (A) and the rhesus TRIM5α
Q 
allele mamu4 (B). Positions that were mutated on the capsid surface and were <2.5 fold more 
sensitive to TRIM5α restriction than SIVmac239 are shown in gray spheres Orange spheres 
show the location of mutations associated with 2.5-5 fold gains in sensitivity to rhesus TRIM5α. 
Red spheres indicate positions associated with >5 fold gains in sensitivity to rhesus TRIM5α. 
Images created in PyMol. 
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Residues influencing rhesus TRIM5α
TFP sensitivity surround a conserved capsid patch.  
In contrast to rhTRIM5α
Q, we found that rhTRIM5α
TFP restricts at least three 
phylogenetically distinct primate lentiviruses: HIV-1, SIVagmTan, and SIVsm (Figure 2-1).  
While single amino acid substitutions affecting rhTRIM5α
Q were confined to the β-hairpin, 
substitutions that increased sensitivity to rhTRIM5α
TFP were spread across the N-terminal 
domain surface (Figures 2-7C and 2-7D). Based on these two observations, we hypothesized 
that rhTRIM5α
TFP may have evolved to target a conserved element(s) unique to the primate 
lentivirus CA N-terminal domain. To identify uncharacterized sites of primate lentivirus 
conservation, we generated an alignment of CA N-terminal domains using one representative 
virus from eleven different primate lentivirus lineages (Figure 2-11). We then scored the number 
of unique amino acids found at each position, and mapped the results onto the SIVmac239 
structure (Figure 2-12A).  
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Figure 2-11. Amino acid alignment of divergent primate lentiviruses.   
Primate lentiviruses from eleven different lineages are aligned corresponding to the published 
alignment found in the Los Alamos Sequence database. The majority sequence is depicted at 
top. An “X” indicates that there is no amino acid majority at that position.  Accession numbers: 
SIVmac239-M33262, HIV-1-K03455, SIVcol-AF301156, SIVlho-AF075269, SIVagm-U58991, 
SIVgsn-AF468658, SIVwrc-AM745105, SIVdrl-AY159321, SIVmand2-AY159322, SIVdeb-
AY523865, SIVtal-AM182197 ! 110!
Figure 2-12. Mutations modulating rhesus TRIM5α
TFP restriction ring a conserved surface 
patch: (A) Top row: Orientations of the SIVmac239 capsid used for Figure 2-12A. Middle row: 
Surface representation of the SIVmac239 capsid N-terminal domain colored to reflect amino 
acid conservation across divergent primate lentiviruses. The number of unique amino acids 
found at each position in an amino acid alignment of eleven divergent primate lentiviruses 
(Figure 2-11) was scored and colored according to the legend: Orange ≥4 unique amino acids 
at the specified position, yellow 3 unique amino acids at the specified position, light gray 2 
unique residues at the specified position and dark gray 1 amino acid (100% conservation) at the 
specified position. The location of the conserved surface patch is indicated by dashed lines. 
Bottom panel: Locations of mutations that are associated with a >2.5 fold gain in sensitivity to 
rhTRIM5α
TFP are shown in dark red. (B) Atomic view of the conserved surface patch. For 
reference the SIVmac239 and HIV-1 (2X2D) ribbon diagrams are shown in light blue and pink, 
respectively. The amino acids that make up the conserved surface patch are shown in sticks 
that are colored according to the capsid ribbon diagram, SIVmac239 in light blue and HIV-1 in 
light red. Variable positions shown to modulate rhesus TRIM5α
TFP sensitivity are colored in dark 
blue (SIVmac239) and dark red sticks (HIV-1) for emphasis. Images created in PyMol. 
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Figure 2-12. Mutations modulating rhesus TRIM5α
TFP restriction ring a conserved surface 
patch: continued.  
 ! 112!
Despite significant sequence diversity among primate lentiviruses, we found a cluster of 
conserved residues on the CA surface. This site overlapped with the structurally conserved C-
terminus of the 4-5 loop, and helices 5 and 6. In SIVmac239, this patch is composed of residues 
Lue93, Arg94, Pro96, Gly98, Asp100, Ile101, Ala102, Gly103, Thr105, Ser106, Ser107, Glu110, 
Gln112 and Trp114 (Figures 2-12, 2-8, 2-9, and 2-11). This patch of conservation extends into a 
larger site of conservation formed by α-helices 3, 4 and 5. This site of conservation has recently 
been identified as the binding site for nuclear import factor CPSF6 [363]. Mutation SIVmac239 
viruses that were restricted rhTRIM5α
TFP greater than 2.5-fold include  SIVmac239S100R, 
SIVmac239V111L, SIVmac239D112Q and SIVmac239Q116G, which positionally ring the boundaries of 
this patch, and SIVmac239Q86V, SIVmac239P87H, SIVmac239A89G, SIVmac239Δ91I, SIVmac239Q93P 
and SIVmac239L96M which correspond to amino acids in the 4-5 loop just above the patch (Table 
2-1, Figure 2-12 and Figure 2-9). In the immediate vicinity of the surface exposed conserved 
patch there were three observed trends for amino acid substitutions that influenced 
rhTRIM5α
TFP restriction: 1) mutations in the variable regions of the 4-5 loop, 2) amino acid 
differences at the periphery of the surface patch, and 3) amino acid differences extending into 
the surface patch.    
There were five amino acid substitutions within the highly variable regions of the 4-5 loop 
that had an impact on rhTRIM5α
TFP restriction. The SIVmac239 4-5 loop, like that of HIV-2, is ! 113!
positioned further over the conserved surface patch than that of most HIV-1 loops. (Figures 2-
7B and 2-12B). It has been documented that amino acid substitutions can alter the conformation 
or the dynamics of the 4-5 loop [334,389]. It is therefore possible that the mutations in 
SIVmac239Q86V, SIVmac239P87H, SIVmac239A89G, SIVmac239Δ91I and SIVmac239Q93P may alter 
the conformation or dynamics of the 4-5 loop in such a way as to enhance rhTRIM5α 
recognition of the conserved surface patch.   
Structurally, the surface patch was conserved across SIVmac239, HIV-1 and HIV-2. The 
C-terminus or the 4-5 loop, helix 5 and helix 6 were in very close agreement with the structures 
of HIV-1 and HIV-2, indicative of strong selection to preserve the overall architecture and amino 
acid composition of this site.  Rather than changes to the structure or sequence of the patch, a 
majority of substitutions that altered rhTRIM5α
TFP sensitivity were found at its periphery. For 
example, we found that altering Ser97 in SIVmac239 to the corresponding HIV-1 Arg had the 
largest effect of any single substitution tested. An Arg at this position is found in an 
overwhelming majority of reported SIVsm sequences, and importantly, the Arg to Ser mutation 
was found to be a critical adaptive change acquired by SIVsm to evade rhTRIM5α
TFP-mediated 
restriction in vivo [61]. In HIV-1 and HIV-2 an Arg at this position contributes to a hydrogen bond 
bridging the base of the 4-5 loop. In SIVmac239 the corresponding Ser97 does not participate in 
a similar contact, but rather, it appears to engage in additional contacts within helix 5 which are ! 114!
not observed in HIV-1 or HIV-2. SIVmac239 Asp109 and HIV-1 Gln112 are oriented similarly, 
however the presence of an acidic group would alter the chemical environment at the periphery 
of the patch (Figure 2-12B). There was no obvious difference to explain why the V111L mutant 
in helix-6 was six-fold more sensitive to restriction than parental SIVmac239. Perhaps slight 
differences between the side-chains of these residues can impact rhTRIM5α
TFP restriction.  
Two substitutions that were associated with increased rhTRIM5α
TFP sensitivity extend 
into the conserved surface patch itself. We found that substituting the Leu at position 93  (which 
sits over the surface patch) for the less-bulky Met residue resulted in a 7-fold gain in sensitivity 
to rhTRIM5α
TFP (Figure 2-12B and Table 2-1). Notably, Leu93/Met96 cover Trp114 and Arg94, 
both of which are absolutely conserved among primate lentiviruses. Finally, SIVmac239 residue 
Gln113 reaches deeper into the patch than the corresponding Gly116 in HIV-1nl4.3 (Figure 2-
12B).  
  Together, mutagenesis and structural data suggests that rhTRIM5α
TFP targets a 
surface-exposed patch of CA that is conserved in both structure and sequence across primate 
lentiviruses. Furthermore, differences between SIVmac239 and HIV-1 at the periphery of this 
patch account for their differential sensitivity to rhTRIM5α
TFP.  At the same time, TRIM5α
TFP and 
TRIM5α
Q are both affected by changes in the β-hairpin, suggesting that restriction by both 
alleles involves recognition of this conserved feature of retroviral CAs ! 115!
Evolution of TRIM5α
TFP. 
To reconstruct the evolutionary origins of the Q/TFP polymorphism, we analyzed 
multiple primate TRIM5α sequences. We found that Gln341 in rhTRIM5α is present at the 
homologous location in TRIM5α of hominoids (Homo sapiens and Pan troglodytes), colobines 
(C. guereza and P. nemaeus) and macaques (M. mulatta and M. fasicularis) (Figure 2-13). In 
contrast, the insertion is found only in Papionins, including sooty mangabeys (Cercocebus atys), 
baboons (P. anubis), geladas (T.  gelada), mandrills (M. sphinx), Barbary macaques (M. 
sylvanus), rhesus macaques (M. mulatta) and crab-eating macaques (M. fasicularis). Therefore, 
the insertion most likely originated in a common ancestor of the Papionini. Strikingly, a 60-
nucleotide insertion/duplication at an identical position is found in TRIM5 of Cercopithecini (E. 
patas and other Cercopithecus species.). We therefore cannot rule out an earlier origin of the 
insertion in a common ancestor of the Cercopithecini and Papionini. Together, these 
observations give a range of insertion times between 9.8 and 11.6 million years ago (Figure 2-
13) [84]. Thus, Gln341 is the ancestral state at this position, and TFP is the evolutionarily 
derived state – consistent with our hypothesis that rhTRIM5α
TFP alleles may be the result of 
selection to recognize the CA of primate lentiviruses. 
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Figure 2-13. Evolutionary origins of the TRIM5α
TFP allele. A Cladogram depicting the 
evolutionary relationships among TRIM5 coding sequences from 16 extant primate species. 
Major divergence times are in bold, approximate dates of events discussed in the text are 
indicated with arrows. For each species/allele, the amino acid sequence corresponding to 
residues 335-346 (relative to rhesus TRIM5) is shown; species names followed by numbers 
indicate multiple alleles. Residues with dN/dS >1 and a high posterior probability of positive 
selection are indicated by † (posterior probability >99%) or * (posterior probability >95%). 
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  We also noted considerable variation in the first codon of the inserted element itself, 
finding (in addition to TFP) orthologs encoding SFP, MFP and LFP among extant species 
(Figure 2-13). To ask whether this variation is consistent with continued positive selection since 
the time of insertion, we calculated dN/dS for each codon in the PRYSPRY domain using an 
alignment representing sixteen species of old world primate, including 4 species for which 
multiple haplotypes are available (M. mulatta, M. sylvanus, P. anubis and C. atys). We identified 
five codons in the PRYSPRY (332, 334, 337, 339 and 341) with high posterior probabilities of 
positive selection, including two in the 6 b.p. insertion itself (339 and 341), a pattern consistent 
with sequences evolving under continuous or repeated cycles of positive selection.   
 
2. D. DISCUSSION 
Rhesus macaques have three functionally distinct TRIM5 alleles, rhTRIM5α
TFP, 
rhTRIM5α
Q, and rhTRIM5
CypA [46-48,50,51,251]. Of these, the structural basis for recognition of 
CA by rhTRIM5
Cyp is best understood, and is attributed to interactions between the CypA 
domain and the 4-5 loop [300,333]. In contrast, CA recognition by C-terminal PRYSPRY 
domains, such as those found in rhTRIM5α
TFP and rhTRIM5α
Q, is not well understood. Using 
genetic, mutagenic, and structural approaches we found evidence that restriction by rhTRIM5α ! 118!
proteins involves at least two structurally conserved elements of the primate lentivirus CA N-
terminal domain.  
There are four possible phenotypes for viruses that encounter rhTRIM5α
TFP and 
rhTRIM5α
Q alleles: resistance to both, sensitivity to both, and sensitivity to one or the other but 
not both. We observed only three of the four possibilities: resistance to both (SIVmac239), 
sensitivity to both (HIV-1nl4.3), and sensitivity to rhTRIM5α
TFP but resistance to rhTRIM5α
Q 
(SIVagmTAN, SIVsmE04, SIVsmE543 and HIV-2Rod) (Figure 2-1). We did not observe the 
converse, resistance to rhTRIM5α
TFP combined with sensitivity to rhTRIM5α
Q. Moreover, none of 
the 34 chimeric viruses assayed displayed a rhTRIM5α
TFP-res/rhTRIM5α
Q-sens phenotype, and 
there are no reports of other retroviruses displaying a rhTRIM5α
TFP-res/rhTRIM5α
Q-sens 
phenotype. In fact, the only mutations in SIVmac239 that resulted in sensitivity to rhTRIM5α
Q 
also resulted in sensitivity to rhTRIM5α
TFP (Figures 2-4, 2-5 and Table 2-1).  
The substitutions that increased sensitivity to both alleles map to the β-hairpin of CA. 
Structurally, the β-hairpin is the most conserved retroviral surface feature and is present in 
structures from five different genera [328-331,338,384]. Thus, it appears that the β-hairpin is a 
retrovirus-associated molecular pattern by which TRIM5α evolved to “recognize” retroviruses. In 
support of these hypotheses, we note that experimental evolution of a rhTRIM5α
TFP-resistant 
N-MLV in cell-culture selected for a single change in the β-hairpin of the MLV capsid [240]. ! 119!
When we superimposed the MLV and lentiviral CA structures, the identified resistance mutation 
in MLV overlaps with Y9, a residue we identified in the SIVmac239 β-hairpin that modulates 
recognition by rhTRIM5α
TFP (Figure 2-14).! 120!
                    
 
Figure 2-14. Structural comparison between SIVmac239 and MLVs with differential 
restriction by rhesus TRIM5α. (A) β-hairpin of N-Tropic MLV (PDB: 1U7K) with residue L10 
shown in sticks and spheres (B) β-hairpin of the N-MLV L10W mutant (PDB:2Y4Z) that is 
rhesus TRIM5α
TFP resistant, 10W shown in sticks and spheres. (C) β-hairpin of HIV-1 
(PDB:2X2D) with M10 shown in sticks and spheres. (D) SIVmac239 β-hairpin Y9 shown in 
sticks and spheres. (E) Structural alignment of rhesus TRIM5α sensitive N-MLV with HIV-1. (F) 
Structural alignment of the rhesus TRIM5α resistant N-MLV L10W with SIVmac239. Images 
created in PyMol. ! 121!
In addition to substitutions in the β-hairpin that increased sensitivity to both rhTRIM5α
Q 
and rhTRIM5α
TFP, there were twelve additional mutations specifically associated with 
rhTRIM5α
TFP restriction (Table 2-1). We interpret this to mean that the rhTRIM5α
TFP allele has 
retained the CA-recognition capacity of rhTRIM5α
Q, but has evolved to interact with an 
additional target or targets in the lentiviral CA.  These mutations map to surface features that 
distinguish primate lentivirus CAs from other retroviral CAs. Specifically, these substitutions ring 
a spatially clustered group of amino acids that are conserved across primate lentiviruses, 
altering this site at its periphery.  
  Interestingly, these mutations also overlap the binding sites of lentivirus-specific cellular 
cofactors, including CypA, NUP358 and CPSF6; notably, when these factors are fused to a 
TRIM5 RBCC, the resulting fusion proteins function as restriction factors [300,333,363,370,390]. 
Primate lentiviruses have extended 4-5 loops that productively interact with at least two cellular 
cyclophilins, CypA and the CypA-like domain of a nuclear import factor, NUP358 [232,327]. In 
nature, these interactions have been independently exploited at least four times during primate 
evolution in the form of TRIM5-CypA fusion proteins, two of which have been maintained in 
modern day lineages of owl monkeys and macaques [45-51,391]. SIVmac239 residue Ala86 
corresponds to Gly89 in the HIV-1 CypA binding motif, while SIVmac239 Gln88 and Gln89 are 
previously identified sites of an adaptive change permitting SIVmac to resist rhTRIM5
CypA ! 122!
restriction [61,232]. We demonstrate that both of these sites influence rhTRIM5α
TFP restriction 
(Table 2-1). Resistance mutations to both rhTRIM5
CypA and rhTRIM5α
TFP may explain why 
SIVmac239 does not utilize Nup358, which is required by other primate lentivirusess for efficient 
nuclear import and optimal target site integration [327]. 
The conserved surface patch is an extension of the CPSF6 binding site, which is 
conserved among primate lentiviruses [363].  Our data suggest that this site is targeted by the 
rhTRIM5α
TFP PRYSPRY domain (Figure 2-12). We therefore propose that the targeting of this 
site is analogous to exploitation of the CypA binding site in the 4-5loop by rhTRIM5
CypA, since 
rhTRIM5α
TFP also exploits a critical, conserved CA interface that is necessary for its interaction 
with a host co-factor that facilitates lentiviral replication.  
  Recent structural determination of the rhesusTRIM5α PRYSPRY domain shows the four 
discrete variable regions are arranged on the surface of a β-sandwich core [211,246]. Ohkura et 
al. reported that the variable regions may make independent contributions to CA recognition 
[266]. Thus, differences in targeting by the rhTRIM5α
Q and rhTRIM5α
TFP proteins may reflect 
contributions from different regions of the PRYSPRY domain. For example, the TFP insertion in 
variable region 1 (V1) may directly confer specificity for the conserved face of lentiviral CAs, 
whereas the interactions of both rhTRIM5α
TFP and rhTRIM5α
Q with the β-hairpin may involve 
contributions from one or more of the other variable loops.  ! 123!
The original insertion in V1 that gave rise to rhTRIM5
TFP in modern macaques arose 
after the Cercopithecinae-Colobinae split, but prior to divergence of the Macaca and Papio 
lineages, providing an estimate for the time of insertion between 9.8 to 11.6 million years ago 
[84]. In contrast, the TRIM5
CypA allele has only been found in Asian macaques, but not in 
Barbary macaques or any other old world primates [46-48,50,51,392], and may therefore have 
arisen less than 5-6 million years ago, after the lineage leading to Asian macaques (Macaca 
sp.) diverged from the African lineages [84]. These dates, and the observation that rhTRIM5α
TFP 
and rhTRIM5
CypA target lentiviral-specific features of CA, constitute indirect but compelling 
evidence that viruses related to modern primate lentiviruses were infecting ancestral primates 
as far back as 12 million years ago, driving selection of TRIM5 variants with enhanced capacity 
to restrict lentiviral replication. Recently, similar conclusions were independently obtained from a 
study of APOBEC3G variation in Old World monkeys [44]. Endogenous lentiviral sequences 
found in the genomes of European brown rabbits [52], Malagasey lemurs [53] and weasels 
[54,55] support the conclusion that lentiviruses were extant at this time, and structural studies 
indicate that the CA proteins of at least two of these (RELIK and pSIVgml) were very similar to 
modern lentiviruses [324].  
  The natural history of African primate lentiviruses, and the species that harbor them, 
suggests lentiviruses were a driving force for the selection and maintenance of TFP-like ! 124!
TRIM5α alleles during the last 12 million years.  Based on these observations, we propose an 
evolutionary model in which different regions of the PRYSPRY can evolve independently to 
recognize different features of retroviral CAs  (Figure 2-15).  β-hairpin recognition was 
conserved between the ancestral TRIM5α
Q allele and the evolutionary derived rhTRIM5α
TFP 
allele. Therefore, it is likely that the region encompassing the Q/TFP polymorphism in variable 
loop 1 (V1) does not contribute to β-hairpin recognition. Instead, this region may be free to make 
additional contacts with the CA. Due to its dynamic and unstructured nature, V1 may readily 
tolerate mutations and insertions (such as the 6-nucleotide insertion) affording the molecule 
enhanced evolutionary plasticity [211,246]. The SIV-HIVh6 mutant was restricted by rhTRIM5α
Q, 
implying that the rhTRIM5α
Q PRYSPRY could recognize one edge of the conserved surface 
patch (Figure 2-15A). The modern day presence of TRIM5α orthologs with the 6-nucleotide 
insertion indicate that the insertion event conferred a selective advantage (likely against primate 
lentiviruses). The simplest explanation is that the insertion allowed V1 to make additional 
contacts or possibly even extend beyond helix 6 and further into the conserved surface patch. 
We have shown that the first and last positions of the rhesus TFP polymorphism have been 
under positive selection, indicative of continued refinement of its ability to recognize the 
conserved surface patch over evolutionary time.  ! 125!
This model is likely a snapshot of a larger evolutionary scenario in which an ancestral 
PRYSPRY domain may first have acquired the ability to recognize a highly conserved retroviral 
CA element (such as the β-hairpin). On top of this intrinsic recognition ability, modularity of 
TRIM5α proteins allowed them to explore additional targets on the CA surface in response to 
pressures from specific viruses or viral families, perhaps by taking advantage of inherent 
plasticity within the variable loops (Figure 2-15B). Such a process, played out over the course of 
tens of millions of years of evolution, could help to explain both the collective breadth and 
species-specificity of modern primate TRIM5α proteins.! 126!
                     
Figure 2-15. A Proposed model for the evolution of novel TRIM5α variants. The 
rhTRIM5α
Q alleles and the rhTRIM5α
TFP alleles share the ability to recognize lentiviral β-
hairpins. The rhTRIM5α
TFP alleles evolved to recognize the conserved surface patch. We 
believe this observation underscores an inherent uncoupling between capsid recognition 
modules within the PRYSPRY domain. The β-hairpin is a conserved feature found in all 
reported retroviral capsid structures, and therefore a convenient target for host proteins that 
evolve to recognize a broad range of retroviruses. We believe β-hairpin targeting is a conserved 
feature of TRIM5α proteins and allows for the evolution of specificity of capsid recognition. (A) 
Evolution of conserved surface patch recognition. The rhTRIM5α
Q allele is capable of strongly 
recognizing the β-hairpin (dark red)
 and able to engage in a weaker contact (pink) with helix 6, 
at one edge of the conserved surface patch. Recognition of these two features is conserved 
between rhTRIM5α
Q and rhTRIM5α
TFP alleles and therefore unaffected by the Q/TFP 
polymorphism. The region of the PRYSPRY that encodes for the intrinsic β-hairpin recognition 
module is colored light blue and the module that can adapt to specific viruses is colored dark 
blue. We propose that the polymorphic region of variable loop 1 (V1) is uncoupled from intrinsic 
β-hairpin recognition (by of another region within the PRYSPRY) allowing it to tolerate mutations 
such as the 6 nucleotide insertion. In this model, the rhTRIM5α
TFP allele engages in similar 
contacts as the rhTRIM5α
Q allele, but has gained the ability to target the conserved surface 
patch (dark red). (B) The ability to recognize a conserved retroviral element, even if it allows 
very weak associations retroviral capsids, can allow for the selection of additional capsid binding 
modules within the PRYSPRY domain allowing it to adapt to specific retroviral pressures. 
Hypothetical adaptation to different retroviral targets are depicted as differently colored 
PRYSPRY domains. Together this process could lead to the breadth and specificity observed 
among TRIM5α orthologs. For simplicity this model is depicted with one PRYSPRY domain 
recognizing one capsid monomer, although the stoichiometry or orientation of TRIM5α binding 
is not know at this time.  
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Figure 2-15. A Proposed model for the evolution of novel TRIM5α variants. Continued. 
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2. E. METHODS   
Cell Lines 
Crandell-Rees Feline Kidney (CRFK) cells and Human Embryonic Kidney 293T/17 
(HEK293T/17) cells were obtained from American Type Culture Collection (Manassas, VA) and 
grown in DMEM/10% FBS. CRFK cell lines stably expressing N-terminally HA-tagged TRIM5 
orthologs were previously described [61]. Stable cell lines were maintained in DMEM/10% FBS 
supplemented with 0.5 mg/ml G418. All cultured cells were maintained at 37°C with 5% CO2.  
 
Virus Production 
All single-cycle viruses were produced in HEK293T/17 cells by cotransfection of the appropriate 
viral plasmid and pVSV-G (Clontech Laboratories, Mountain View, CA), using the GenJet 
transfection system (SignaGen; Ijamsville, MD). Culture supernatants containing the single-
cycle, GFP/EGFP expressing, VSV-G-pseudotyped virions were titered on untransfected CRFK 
cells; supernatant volumes resulting in approximately 25% GFP/ EGFP+ CRFK cells were used 
for infectivity assays on the cell lines expressing the indicated TRIM5α. Information regarding 
viral infectivity appears in Figure 2-5.  
 ! 129!
The CFP expressing HIV-1 lentiviral vector was made from 293T transfection of a 3:2:1 plasmid 
ratio of pNL-ECFP/CMV-WPREDU3 [229], pCD/NL-BH*DDD [393] and pVSV-G (Clontech 
Laboratories, Mountain View, CA)  (pNL-ECFP/CMV-WPREDU3 and pCD/NL-BH*DDD  were  
kindly provided by Dr. Jakob Reiser, Louisiana State University Health Sciences Center).  
 
Infectivity Assays 
Stably expressing TRIM5 CRFK cells were seeded at a concentration of 5x10
4 cells per well in 
12-well-plates and infected with the appropriate amount of VSV-G pseudotyped, single-cycle, 
GFP/EGFP expressing viruses. All infections were done in triplicate. After 2 days, expression of 
GFP/EGFP was analyzed by fluorescence-activated cell sorting (FACS) performed on a 
FACSCaliburTM flow cytometer (BD, Franklin Lakes, NJ), and data were analyzed using FlowJo 
software (Tree Star, Inc., Ashland, OR). Viral titers were determined using the appropriate p24 
(HIV-1) or p27 (SIVmac) antigen capture kit from Advanced Bioscience Labs (Rockville, MD).  
Information regarding viral titers appears in Figure 2-5.  
 
Protein Expression and Purification 
A codon optimized N-terminal fragment of the SIVmac239 capsid corresponding to residues 1-
144 was synthesized with a C-terminal factor Xa cleavage site and 6x-His Tag by GENEART ! 130!
(Regensburg, Germany). Using engineered XbaI and XhoI sites the N-terminal fragment was 
cloned into pET303 (Invitrogen) and expressed from BL21(DE3) E. coli cells. The SIVmac239 
capsid was purified by Ni-NTA agarose (Qiagen) followed by gel filtration chromatography on a 
Superdex 200 column (GE Healthcare). The C-terminal 6x-His tag was removed by treatment 
with factor Xa (New England Biolabs), re-purified by orthogonal Ni-NTA agarose 
chromatography and gel filtration chromatography.  
 
Crystallization 
Purified SIVmac239 capsid protein was crystallized by the hanging drop method over a 
reservoir solution containing 10 %(w/v) PEG 2000 MME, 10 mM nickel chloride and 100 mM 
Tris, pH 8.5 at 24°C. Crystals were harvested from 0.2µl drops and cryoprotected by addition of 
10-15% PEG 400 or glycerol to the reservoir solution, then flash cooled in liquid nitrogen. 
Protein concentration ranged from 10-15 mg/ml. 
 
Structure Determination and Refinement 
We recorded diffraction data at beamline 24-ID-E at the Advanced Photon Source.  Data sets 
from individual crystals were processed with HKL2000 [394]. Molecular replacement (MR) was 
carried out with PHASER [395] using the HIV-2 capsid as an initial search model. One molecule ! 131!
of SIVmac239 completes the asymmetric unit. Refinement was carried out using PHENIX 
[396,397] and all model modifications were done in COOT [398]. Initial rigid body refinement 
followed by simulated annealing and positional refinement was done. The 4-5 loop (residues 83-
97) was initially removed from the model and rebuilt into modest density. There was no clear 
density for residue proline 88 and it was omitted from the structure. The model was further 
refined by additional cycles of positional and B-factor refinement, followed by TLS. The quality 
of the data was assessed using MolProbity [399]. Data collection and refinement statistics can 
be found in Table 2-2. Coordinates and diffraction data have been submitted to the PDB, 
accession number: PDB:4HTW. 
 
Sequence Analysis 
TRIM5α sequences were identified by BLAST search of the non-redundant nucleotide 
database, aligned in Geneious Pro v.5.5.4 using the Translation Align option. The alignment 
was adjusted manually, converted back to nucleotide and the best-fit tree identified with 
MrBayes. dN/dS analysis was performed with CODEML in v4.4 of PAML [400].   
 
Plasmids and Mutagenesis  ! 132!
The SIVmac239-based retroviral vector pV1EGFP (gift from Hung Fan, University of California, 
Irvine, CA) was previously modified to contain a functional gag-pol ORF [61]. The following 
reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
pNL4-3-deltaE-EGFP (Cat# 11100) from Drs. Haili Zhang, Yan Zhou, and Robert Siliciano [401]. 
All single cycle chimeric viruses are in either the pV1EGFP-SIV or HIV-1nl4.3 pNL4-3-deltaE-
EGFP background as indicated. To facilitate the rapid production of chimeric viruses, a capsid 
and gag shuttle vector system was engineered through DNA synthesis by GENEART 
(Regensburg, Germany). Silent nucleotide changes within the capsid allowed for chimerization 
between capsids from either virus (Figure 2-16).  All chimeric capsids with the exception of 
single amino acid point mutants were produced through gene synthesis by GENEART 
(Regensburg, Germany) and were then cloned into the proper viruses using our shuttle vector 
system.  Single amino acid substitutions on the SIVmac239 surface were made using site 
directed mutagenesis.  The S100R mutant was described in a previous publication [61]. 
 
A CFP expressing HIV-1 derived lentiviral vector was created for abrogation assays. A CFP 
gene was introduced into using AgeI an XhoI sites into pNL-EGFP/CMV-WPREDU3 [229], a 
vector based on pNL-EGFP/CMV (which features the WPRE element for increased mRNA 
stability and a deleted U3 region for added safety).  ! 133!
Figure 2-16. Schematic of synthesized genes and cloning strategy used to generate 
chimeric viruses: All constructs were synthesized by GENEART (Regensburg, Germany). 
Numbering corresponds to the standard HXB2 and SIVmac239 numbering, respectively. For 
efficient exchange of capsids between viruses and chimerization within capsids silent nucleotide 
changes were made in both viruses creating identical restriction sites. Naturally occurring 
restriction sites at the ends of the shuttle vector are used for insertion into the proper parental 
virus. Amino acid differences at the N-terminus of the CA protein did not allow us to use a single 
common enzyme for this site. Instead SIVmac239 constructs use a BsrGI site while HIV-1nl4.3 
constructs use an MfeI site. Two additional shuttle vectors were made to accommodate either 
N-terminus in both SIVmac239 and HIV-1nl4.3 backbones.   ! 134!
 
Figure 2-16. Schematic of synthesized genes and cloning strategy used to generate 
chimeric viruses. Continued.  
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3. A. ABSTRACT 
TRIM5α is a host encoded protein that has evolved to block retroviral infection. TRIM5α inhibits 
replication at the reverse transcription step by directly binding to retroviral capsids and inducing 
their premature uncoating. Retroviral recognition by TRIM5α is mediated by the C-terminal 
PRYSPRY domain. Within this domain, a series of four variable loops are highly enriched for 
positively selected sites and polymorphisms, including single nucleotide and length variations. 
We observed a unique pattern of evolution in the first variable loop (V1) of Cercopithecinae 
primate TRIM5αs. At a specific position within V1, a single Gln has been maintained over 30+ 
million years of Old World primate evolution. In contrast, among the Cercopithecinae, this Gln 
has been replaced by a substitution and modified by two independent insertions. Phylogenetic 
analysis suggests modifications to the ancestral Gln began 11-16 million years ago in two 
different Cercopithecinae lineages. These modifications were then followed by further bursts of 
evolutionary refinement. To determine the selective forces that drove these adaptive changes 
we reconstructed an ancestral Cercopithecinae TRIM5α as it may have existed prior to the 
replacement of Gln. Into this Trim5α we introduced the acquired Cercopithecinae V1 
modifications. We then screened this panel of ancient and modern day V1-matched 
Cercopithecinae Trim5αs against a diverse panel of extant retroviruses. Strikingly, the 
evolutionarily acquired Cercopithecinae modifications specifically conferred the ability to restrict ! 138!
present day Cercopithecinae SIVs but did not affect the restriction of other retroviruses. Further 
characterization of Cercopithecinae TRIM5αs suggests that targeting a single site in capsid that 
sits at the junction of four positively acting lentivirus-specific cellular cofactor binding sites was 
twice acquired in two independent Cercopithecinae lineages. Taken together, our findings 
suggest these evolutionary innovations reflect the emergence of SIVs among Cercopithecinae 
primates 11-16 million years ago. For the first time our findings establish a connection between 
ancient and modern SIVs among primates. The recurrent selection we observed suggests that 
like modern SIVs, these ancient SIVs repeatedly crossed between species and caused disease. 
Therefore, the events leading to HIV infection in humans are likely the continuation of an 11-16 
million year old pattern of transmission within and between host lineages. 
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3. B. INTRODUCTION 
Within the past century, simian immunodeficiency virus (SIV) from chimpanzees have 
been transmitted to humans on at least 3 occasions, one of which resulted in the global HIV-1 
epidemic [26,28,29,43]. Multiple independent cross-species transmission events involving SIVs 
from sooty mangabeys resulted in HIV-2 in humans and SIVmac in captive macaque colonies 
[23-26,28]. These recent examples of cross-species transmission, adaptation and the 
dissemination of a virus throughout a population are a continuation of an ancient pattern. Over 
40 primate lentiviruses (HIVs and SIVs) have been identified, all from African primates [23-
25,27]. Like HIV and SIVmac, these viruses also share a history of cross-species transmissions, 
evidenced by the fact that the primate lentivirus phylogeny is incongruent with that of their hosts 
[23,26,27,29,38,56,57].  
While the clinical outcome of primate lentivirus infection varies, there is a general trend 
in which pathogenic infections are associated with a recent acquisition of a primate lentivirus. 
For example, higher mortality rates are observed among humans infected with HIV-1 or HIV-2, 
chimpanzees infected with SIVcpz, rhesus macaque species infected with SIVmac and pig-
tailed macaques infected with SIVagm [23-25,38,58,64,66]. In contrast, primates believed to be 
long-standing hosts of a particular SIV typically do not present any overt clinical symptoms of 
infection [24,25,27]. The evolutionary timescales for the process of coevolution between primate ! 140!
lentiviruses and hosts are largely unknown. While endogenous lentiviruses in rabbit, ferret and 
lemur genomes establish that lentiviruses existed 5-12 million years ago, it is not clear when the 
primate lentiviruses first appeared as a distinct lineage. The molucular dating of selective events 
in antiretroviral genes may provide compelling, yet indirect evidence of the existence of ancient 
lentiviruses [44].  
TRIM5α is a host restriction factor that can suppress the cross-species transmission of 
primate lentiviruses [61,77]. It mediates a potent post-entry pre-integration block to retroviral 
infection that is dependent upon recognition of the viral capsid [125]. TRIM proteins are named 
for their shared tripartite domain structure composed of a RING, B-box and coiled-coil domains 
[128,129]. The antiviral α isoform of TRIM5 encodes for a C-terminal PRYSPRY/B30.2 domain 
that acts as a viral recognition domain [125,208]. Among primates, the TRIM5α PRYSPRY 
domain has evolved under strong positive selection [243,251,380]. A majority of these positively 
selected sites reside within the PRYSPRY’s four variable loops (V1 to V4) [211,243,380]. These 
variable loops are thought to directly mediate contacts with retroviral capsids (CA).  
   The majority of positively selected sites in Old World primate TRIM5αs map to the first 
variable loop (V1) [211,243,380]. While the sequence of V1 varies between Old World primates, 
length variations are only found among Cercopithecinae primates [243,244,251]. Importantly, 
insertions/deletions (indels) are excluded from standard measures of positive selection. ! 141!
However, the maintenance of inserted amino acids in multiple Cercopithecinae primate species 
implies that they may have conferred selective advantages. Among Cercopithecinae primates,  
two independent insertions (a 20 amino acid and a 2 amino acid insertion) have occurred at or 
adjacent to TRIM5α position 339 in V1. Among all non-Cercopithecinae Old World primates, the 
homologous position 339 invariably encodes a Q. We refer to this site and adjacent positions as 
the V1-patch. Recently, we proposed that the 2 amino acid insertion as it is found in rhesus 
macaque TRIM5α (which replaced Q with TFP at positions 339-341) evolved to target a highly 
conserved cluster of amino acids in lentivirus capsids [380]. We therefore hypothesized that 
variation at position 339 among Cercopithecinae primates may be the result of selective 
pressure exerted by ancient primate lentiviruses. Establishing a correlation between selective 
events in the evolution of V1 in Cercopithecinae TRIM5α and specificity for modern SIVs of 
Cercopithecinae primates would provide evidence that a common ancestor of SIVs existed 11-
16 million years ago. 
Using phylogenetic techniques we reconstructed the evolutionary history of the TRIM5α 
V1 patch. We established that a Q (henceforth “V1-Q”) corresponding to position 339 in 
Cercopithecinae TRIM5αs represents the state that was present in the ancestor of all Old World 
primates 30+ million years ago [34,35]. TRIM5α V1-Q has remained unmodified in all but one 
African primate lineage, the Cercopithecinae, which includes: guenons, African green monkeys, ! 142!
baboons, mangabeys and macaques. While TRIM5α alleles with V1-Q have been preserved 
among Cercopithecinae primates, Q has also been replaced by a Q to G substitution (V1-G) 
and overwritten by a two amino acid insertion (V1+2aa). Moreover, sometime subsequent to the 
Q to G substitution, a 20 amino acid insertion occurred adjacent to the G (V1-G+20). We 
determined that selection against V1-Q began 11 and 16 million years ago in two different 
Cercopithecinae lineages [34,35]. Using a reconstructed ancestral TRIM5α, predicted to have 
existed prior to the evolution of the V1-patch modifications, we demonstrate that these 
modifications were sufficient to specifically impart the ability to restrict extant Cercopithecinae 
SIVs. We interpret our findings to mean that ancient Cercopithecinae SIVs were present in 
Cercopithecinae primates at least 11-16 million years ago. Importantly, this is the first report 
linking ancient and modern SIV lineages. We observed recurrent selection in multiple 
independent Cercopithecinae lineages. This implies that like modern primate lentiviruses, these 
ancient Cercopithecinae SIVs were crossing between species and causing disease [34,35]. 
Furthermore, TRIM5αs from two independent lineages of modern day Cercopithecinae primates 
appear to have converged upon targeting a lentivirus specific site that sits at the junction of four 
cellular cofactor binding sites [232,300,327,363,372]. Thus, it appears that Cercopithecinae 
primate TRIM5αs have independently evolved to recognize a highly conserved capsid interface 
[363,380].  ! 143!
3. C. RESULTS 
Dating selective events in the Cercopithecinae TRIM5α variable loop 1 patch 
Among reported Old World primate TRIM5α sequences, the length of variable loop 1 
(V1) is constant in all but one primate lineage, the Cercopithecinae. Among some 
Cercopithecinae primate TRIM5αs at least two independent insertion events appear to have 
occurred at or adjacent to TRIM5α position 339. Due to the length polymorphisms in this region 
we will refer to this site, centered on Cercopithecinae TRIM5α postion 339, as the V1-patch 
(Figure 3-1). To reconstruct the evolutionary events that have led to the diversification of the 
Cercopithecinae V1-patch we generated a sequence alignment and a corresponding 
phylogenetic tree of Old World primates for which TRIM5α sequences have been reported 
(Figure 3-1). To build a more robust phylogeny we additionally sequenced previously unreported 
TRIM5αs from individuals representing five additional Cercopithecinae species. These included 
four guenon species, Cercopithecus wolfi (Wolf’s Guenon n=3), Cercopithecus cephus 
(mustached guenon n=1), Cercopithecus ascanius (Schmidt’s guenon n=2), Cercopithecus 
neglectus (De Brazza's monkey n=1), and a mangabey Cercocebus torquatus (Red-Capped 
Mangabey n=1). The V1-patch features of 28 Old World primate species are indicated on the 
phylogenetic tree in Figure 3-1.  ! 144!
 
Figure 3-1. Phylogeny and TRIM5α V1 patch sequences of Old World primates. (A) 
Sequence alignment of select OWM Trim5alpha variable loop 1 sequences. The rapidly 
evolving V1 patch is indicated and novel sequences are bolded. (B) Phylogeny of select Old 
World primates and key evolutionary events in Trim5α variable loop one are indicated on the 
tree. Common species names are indicated at the branch tips. An “*” indicates full length Trim5α 
sequences reported in this manuscript. Relevant sequences in variable loop one are indicated. 
The super families, families and tribes of these primate species are indicated.   
Human      GTRY--QT--FVNF!
Colobus    GTLF--QS--LKNF!
Guenon     GTLF--GS--LTNF!
AGM        GSLF--G+20LTNF!
Mangabey   GTLFSFPS--HTNF!
Rhesus     GTLFTFPS--LTNF!
!
333          335          335            335            335            335 
342          342          342            362            344            344 
V1 Patch!
4.0 4.0
      Gorilla              Human              Bonobo               Chimpanzee              Orangutan               White-handed gibbon              Hoolock gibbon              Siamang              N. white-cheeked gibbon              Mantled guereza              Red-shanked douc                 Schmidt's guenon*             Mustached guenon*              Wolf’s Guenon*              De Brazza’s monkey*              African Green monkey              Pata’s monkey                Sooty Mangabey            Mandrill                Baboon              Galada            Assam macaque                Tibetan macaque            Rhesus macaque                Crab-eating macaque              Crested macaque               Pig-tailed macaque              Barbary macaque          
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From the phylogeny and TRIM5α sequence information we were able to infer the series 
of events that led to the present day V1 patch diversity. Examples of TRIM5αs with a Q (V1-Q) 
in the V1-patch corresponding position 339 in Cercopithecinae TRIM5αs are present in every 
Old World primate lineage (Figure 3-1). Therefore, we infer that V1-Q is the ancestral residue at 
this position, and reflects the sequence that was present in the last common ancestor of all Old 
World primates. While V1-Q has been replaced in some Cercopithecinae TRIM5αs, V1-Q is still 
found in TRIM5αs from multiple Cercopithicini and Papionini species. We conclude that V1-Q 
represents the most likely ancestral state of TRIM5α position 339 in all extant Cercopithecinae 
species. V1-Q, together with other V1-patch variants, has been preserved through long term 
balancing selection within the Cercopithecinae. Thus, V1-Q has remained unmodified for over 
30+ million years in every major Old World primate lineage except the Cercopithecinae, where it 
co-exists with other variants such as V1-G, V1-G+20aa, and V1-Q+2aa [34,35]. 
In contrast to the highly conserved V1-Q found in all Old World primate lineages, 
diversity found within the V1-patch is a unique feature of Cercopithecinae TRIM5αs (Figure 3-1). 
The Cercopithecinae include two tribes, the Cercopithicini and Papionini. Cercopithicini V1-
patch variants all share a common V1-Q to G substitution (V1-G), while Papionini V1-patch 
variants all share a two amino acid insertion (V1-Q+2AA). No evidence of either feature exists 
outside of the tribe in which it is found (Figure 3-1). We hypothesize that these present day ! 146!
variants within the V1-patch are due to the continued selection upon two tribe specific V1 
modifications. 
Two major V1-G orthologs are present among Cercopithicini TRIM5αs. The first is the 
unmodified V1-G that is found in some guenon species. The second is a modified form of V1-G 
that is found in African green monkeys and some Pata’s monkeys, in which there has been a 
duplication of sequence resulting in the insertion of 20 additional amino acids (V1-G+20aa) 
(Figure 3-1). Inter- and Intra- species differences in these 20 residues indicate that the inserted 
sequences have continued to evolve after the duplication event. The presence of G at the 
homologous position in the TRIM5α of guenons, African green monkeys and some Pata’s 
monkeys allowed us to date both evolutionary events. We infer that V1-G was present between 
8 and 16 million years ago, while the insertion event leading to G+20 likely occurred between 5 
and 14 million years ago (Figure 3-1).  
In the Papionini, there are examples of TRIM5α V-Q+2aa orthologs in every genus. This 
indicates that the insertion was at least present in the last common ancestor of all extant 
Papionini species 8-15 million years ago (Figure 3-1). Following the insertional event, this 
modified patch continued to evolve, resulting in the V1-SFP/TFP/PFP/LFP/MFP derivatives 
currently found in nature. Rapid selection has obscured the sequence of the initial insertion and 
some of its potential evolutionary intermediates. One possible evolutionary pathway is illustrated ! 147!
in figure 3-2. In short, the insertion arose from a duplication of adjacent sequence resulting in 
V1-QFQ, which became PFP followed by SFP. TRIM5α-V1-TFP could have arisen from either 
PFP or SFP. Together, the V1-SFP in baboons and mangabeys and V1-TFP in numerous 
macaque species are the only V1-2aa derivatives found in multiple species. Thus, V1-SFP and 
V1-TFP are the most commonly found V1+2aa patch features found in nature (Figure 3-1).   
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Figure 3-2. Proposed order of evolutionary steps for the evolution of the two amino acid 
insertion. A Q at position 339 was overwritten by a two amino acid insertion in an ancestor 
common to all extant Papionini species. (A) The sequences of rhesus Trim5α V1-Q (top) and 
rhesus TRIM5α V1-TFP are provided for reference. (B) The sequence of the predicted ancestral 
TRIM5α V1-Q. (C) We propose that the initial insertion event was due to the duplication of two 
codons corresponding to TRIM5α positions 338 and 339 (FQ) (underlined in black). Residues 
339-341 would then encode for QFQ (underlined in red). (D) Single nucleotide substitutions in 
codons 339 and 341 alter the sequence of 339-341 to encode for QFP or PFQ. (E) A second 
single amino acid substitution results in PFP. This variant has been found in baboon TRIM5α 
sequences. (F) Single amino acid substitutions in codon 339 result in SFP, TFP, MFP, LFP. All 
of these sequences are found among the Papionini primates. It is unclear whether TFP arose 
from PFP or SFP. Black lettering corresponds to unmodified sequences that are present in 
modern day Cercopithecinae primates. Red lettering indicates nucleotide substitutions that alter 
the above sequence. Blue lettering indicates that the corresponding sequences are found in 
nature. Green lettering indicates hypothetical intermediates.   
rhTrim5αQ!
 S   P   G   T   L   F   -   -   Q   S   L   T   N   F   N!
TCA CCA GGG ACA TTA TTT --- --- CAG TCA CTC ACG AAT TTC AAT !
 !
rhTrim5αTFP!
 S   P   G   T   L   F   T   F   P   S   L   T   N   F   N!
TCA CCA GGG ACA TTA TTT ACG TTT CCG TCA CTC ACG AAT TTC AAT !
!
!
ancestor Trim5αV1Q!
 S   P   G   T   L   F   Q   -   -   S   L   T   N   F   N!
TCA CCA GGG ACA TTA TTT CAG --- --- TCA CTC ACG AAT TTC AAT!
!
                       !
                      6-N.t. Insertion !
!
 S   P   G   T   L   F   Q   F   Q   S   L   T   N   F   N!
TCA CCA GGG ACA TTA TTT CAG TTT CAG TCA CTC ACG AAT TTC AAT!
                         !
                Q   F   P   OR    P   F   Q           !
               CAG TTT CCG       CCG TTT CAG!
                           Baboon!
!!!        P   F   P!
                        CCG TTT CCG!
     Sooty,Baboon                           Macaques         !
      S   F   P                            T   F   P!
     TCG TTT CCG                          ACG TTT CCG!
      Mandrill                          Barbary Macaque !
      L   F   P                            M   F   P!
     TTG TTT CCG                          ATG TTT CCG!
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When TRIM5α protein sequences are compared among Old World primates, diversity 
within the V1 patch is unusual. However the timing and phylogenetic relationship between V1 
patch modifications are quite remarkable. In contrast to V1-Q which has remained constant for 
30+ million years, the V1 patch was twice modified in two independent Cercopithecinae 
lineages in the space of 1.1-4 million years [34,35]. These V1 modifications then continued to 
evolve. These evolutionary signatures may signify the emergence of a significant source of 
selective pressure that was acting upon multiple independent primate lineages.   
 
The Cercopithecinae variable loop 1 patch specifically affects the restriction of modern 
day Cercopithecinae SIVs 
 We predict that the last common ancestor of all Cercopithecinae TRIM5αs had a Q at 
the position corresponding to 339. Using phylogenetic methods we reconstructed the sequence 
of this ancestral TRIM5α. A number of substitution models and methods for generating 
phylogenetic trees were used. All predictions of the last common node to all Cercopithecinae 
TRIM5αs agreed on a single sequence within the PRYSPRY domain. In the rest of the protein, 
only the residue at position 69 (in the linker between the ring and b-box domains) was 
ambiguous. This position was predicted to be either an R or a Q; an R is found among the ! 150!
modern hominoidea, colobinae and the Cercopithecinae species Macaca sylvanus (Barbary 
macaque), while all other Cercopithecinae encode for a Q at this position. 
Next, we synthesized a cDNA encoding the predicted ancestral TRIM5α of 
Cercopithecinae monkeys (ancTRIM5α
V1Q) and tested its ability to restrict a diverse panel of 
retroviruses (Figure 3-3).  We also modified ancTRIM5α
V1Q to compare the impact of each 
Cercopithecinae V1 modification on restriction in an isogenic context (i.e., in the absence of 
other evolutionary modifications).  Derivatives of ancTRIM5α
V1Q included the Cercopithicini V1 
modifications, V1-G and V1-G+20, which we refer to as ancTRIM5α
QV1G and ancTRIM5α
QV1G+20. 
The 20 inserted amino acids exactly recreate the original duplication (such that the duplicated 
sequences are still identical) and do not include the additional diversification seen in modern 
day TRIM5α orthologs. We also made ancTRIM5α
V1Q derivatives with additional V1 patch 
modifications seen/predicted to have been in Papionini species, including QFQ, PFP, SFP and 
TFP (ancTRIM5α
QV1QFQ, ancTRIM5α
QV1PFP, ancTRIM5α
QV1SFP and ancTRIM5α
QV1TFP). All of 
these HA-tagged TRIM5αs were used to generate stably expressing CRFK cell lines.  
Cell lines that stably express modern day HA-tagged Cercopithecinae TRIM5αs were 
also generated. These included TRIM5αs with the V1-G modification from Mustached guenons 
(mus), De Brazza’s monkeys (deb) and two alleles from Schmidt’s guenon (Sch1 and Sch2). 
TRIM5α V1-G+20s were cloned from vero (AgmV) and COS-1 cells (AgmC). TRIM5αs with the ! 151!
V1-SFP modification came from sooty and red-capped mangabeys (ceat-1 and Rcm 
respectively). Rhesus TRIM5α (mamu1) was the modern day V1-TFP derivative. 
Cercopithecinae TRIM5α orthologs with an unmodified V1-Q were included from rhesus 
macaque (mamu5) and Wolf’s guenon (wlf) TRIM5αs. Human TRIM5α (V1-Q) was included as 
a non-Cercopithecinae out-group.  
A diverse panel of retroviruses was assembled to assay the restrictive properties of 
these 19 TRIM5α proteins. The viruses tested included: the avian alpharetrovirus Rous sarcoma 
virus (RSV); two murine gammaretroviruses, the N-tropic and B-tropic strains of murine 
leukemia virus (MLV), the Cercopithecinae betaretrovirus Mason-Pfizer monkey virus (MPMV), 
the non-primate lentiviruses feline immunodeficiency virus (FIV) and equine infectious anemia 
virus (EIAV), and two human lentiviruses, human immunodeficiency virus -1, strain nl4.3 (HIV-
1nl4.3) and human immunodeficiency virus -2, strain Rod (HIV-2rod). Simian immunodeficiency 
viruses (SIVs) isolated from Cercopithecinae primates were also included. Infectious SIVs were 
produced from either authentic molecular clones or modified molecular clones engineered to 
express the capsids of other Cercopithecinae SIVs. These included the Cercopithicini SIVs from 
mustached guenons (SIVmus) and African green monkeys (SIVagmTan-1, SIVagmVer, and 
SIVagmGrv) and Papionini SIVs included the macaque-passaged sooty mangabey SIV ! 152!
(SIVsmE543), the rhesus macaque SIV (SIVmac239), the stump tailed macaque SIV (SIVstm) 
and an SIV from a red-capped mangabey (SIVrcm).  
The 19 TRIM5α expressing cell lines were assayed for the ability to restrict each of the 
above 16 viruses.  All TRIM5αs were functional, and each TRIM5α-expressing cell line was able 
to restrict viruses from multiple retroviral genera (Figure 3-3). With the exception of RSV, every 
virus was restricted by at least one of the TRIM5α proteins tested. Except for the SIVs, the 
retroviruses were either almost always resistant to a majority of the 19 TRIM5αs, or almost 
always sensitive to a majority of the 19 TRIM5αs (Figure 3-3). For example, N-MLV was 
sensitive to all 19 TRIM5α proteins, while RSV was resistant to all 19. Including the 
ancTRIM5α
V1Q and its derivatives, the Cercopithecinae TRIM5αs shared a capacity to restrict N-
MLV, FIV and EIAV. With the exception of wlfTRIM5α
Q, these TRIM5αs also all restricted HIV-1 
(Figure 3-3). Therefore, the capacity to restrict these viruses is an ancient and conserved 
property of all Cercopithecinae TRIM5αs. Importantly, these results demonstrate that restriction 
of these retroviruses are independent of the sequences found in the V1 patch.   
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Figure 3-3. Patterns of restriction by ancient and modern Trim5αs. The restrictive potential 
of ancestral, modified ancestral, and modern Trim5αs was measured against a panel of non-
lentiviruses and lentiviruses. A Heat map showing the level of restriction of the indicated virus 
with the corresponding Trim5α variant. Each data point is the average of at least three 
independent experiments.  
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The 8 Cercopithecinae SIVs were variably restricted by the 19 TRIM5αs (Figure 3-3). In 
contrast to the 8 non-SIV retroviruses tested, there was a strong correlation between the 
restriction of Cercopithecinae SIVs and the sequence of the V1 patch. The sufficiency of the V1 
patch to confer the ability to restrict SIVs was demonstrated by the gain of SIV restriction by the 
modified ancestral TRIM5αs (ancTRIM5α
QV1TFP, ancTRIM5α
QV1G and ancTRIM5α
QV1G+20) over 
the non-restrictive, unmodified ancestral TRIM5α (ancTRIM5α
V1Q). The patterns of resistant or 
restricted viruses for the ancestral TRIM5αs resembled those of the present day TRIM5αs with 
matched V1 patch sequences (Figure 3-3). For example, both ancient and modern 
Cercopithecinae TRIM5αs with either V1-Q or V1-SFP lacked the ability to restrict 
Cercopithecinae SIVs. In contrast, both ancTRIM5α
QV1TFP and rhTRIM5α
TFP were broadly 
restrictive against SIVs and had nearly identical patterns of restriction. Similarly, ancTRIM5α
QV1G
 
gained the ability to restrict a subset of SIVs matching those of musTRIM5α
G and sch1TRIM5
G.  
Finally, ancTRIM5α
QV1G+20 restricted a subset of SIVs that were also restricted by 
agmCTRIM5α
G+20 and agmVTRIM5α
G+20 (Figure 3-3). Specificity was further demonstrated by 
three observations: first, ancestral TRIM5αs never restricted viruses that their matched, modern 
day TRIM5α was unable to restrict; second, not every V1 modification led to SIV restriction; 
third, restriction was not observed when an SIV was tested on the TRIM5α from its natural host 
(regardless of V1 modificaiton) (Figure 3-3).   ! 155!
Convergent evolution in Papionini and Cercopithecini TRIM5αs capsid recognition 
A majority of the tested TRIM5αs restricted HIV-1nl4.3 but not SIVmac239. We 
previously generated a series of viruses with chimeric SIVmac239-HIV-1nl4.3 CAs to map the 
CA encoded determinants of restriction by rhTRIM5α
Q and rhTRIM5α
TFP [380]. We used this 
pre-existing library of CA mutants to map the determinants of restriction for 12 representative 
TRIM5αs. These included 9 TRIM5αs that restricted HIV-1nl4.3 but not SIVmac239 
(ancTRIM5α
V1Q, ancTRIM5α
QV1SFP, ancTRIM5α
QV1TFP ancTRIM5α
QV1G smTRIM5α
SFP, 
rhTRIM5α
Q, rhTRIM5α
TFP, musTRIM5α
G and sch1TRIM5α
G). We also tested ancTRIM5α
QV1G+20, 
which restricted SIVmac239 5 fold, because it was the only TRIM5α with the V1-G+20 feature 
that did not restrict both viruses in excess of 100-fold. We also included wlfTRIM5α
Q, which did 
not restrict either virus, as a control for non-specific restriction, and huTRIM5α
Q as a 
non-Cercopithecinae TRIM5α for comparisson.  
We previously demonstrated that CA surface elements (β-hairpin, 4-5 loop, helix 6 and 
6-7 loop) largely governed restriction, and that the resistant or restricted phenotype could be 
transferred between viruses by the exchange of these features [380]. To determine whether 
recognition of the CA surface was an ancient and conserved property of Cercopithecinae 
TRIM5αs, we assayed the 12 TRIM5αs for their ability to restrict HIV-1nl4.3, SIVmac239, 
SIVmac239 with the HIV-1nl4.3 CA surface (SIV-HIVsurface) and HIV-1nl4.3 with the SIVmac239 ! 156!
CA surface (HIV-SIVsurface25).  For all TRIM5αs, SIV-HIVsurface was as sensitive to restriction as 
HIV-1nl4.3. Conversely, HIV-SIVsurface25 resisted restriction, similar to SIVmac239. These results 
demonstrate that CA surface recognition is conserved between ancient and modern primate 
TRIM5αs (Figure 3-4). 
   ! 157!
                 
Figure 3-4. Capsid surface features are the major determinant of Old World monkey 
TRIM5α restriction. A subset of Trim5αs that differentially restrict HIV-1nl4.3 and SIVmac239 
were identified. We tested these Trim5αs with chimeric viruses to determine whether the major 
determinant of this phenotype was the surface of the capsid protein. Human and Wolf’s guenon 
Trim5αs which did not restrict either virus were also included. Cell lines were infected with wild 
type SIVmac239, HIV-1nl4.3, SIV with the HIV-1 surface (SIV-HIVsurface), HIV with the SIV 
surface (HIV-SIVsurface25), or with an interior chimera in which the internal alpha-helices of 
SIVmac239 were replaced with those of HIV-1 (SIV- HIVinterior). These viruses were previously 
described [380]. Fold restriction was graphed for each virus.  
   
1
10
100
1000
             Ancestor (Q)                             Human (Q)                            Rhesus (Q) 
           Ancestor-TFP                            Rhesus (TFP) 
              Ancestor-G                       Mustached Guenon (G)         Schmidt’s Guenon (G)            
           Ancestor-SFP                         Sooty Mangabey-SFP 
            Ancestor-20aa                          Wolf’s Guenon (G) 
        A                                                                                                            D                                                                                                            F                                                                                                            H                                                                                                            K 
        B                                                                                                            E                                                                                                            G                                                                                                            I                                                                                                            L                                   
        C                                                                                                                                                                                                                                                                                                                                J 
F
o
l
d
 
R
e
s
t
r
i
c
t
i
o
n
 
 
SIVmac239 
HIV-1nl4.3 
SIV-HIVsurface 
HIV-SIVsurface25 
Figure'3'
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000
1
10
100
1000! 158!
There are 25 amino acid differences between HIV-1nl4.3 and HIV-SIVsurface25. To map 
the specific sites that modulate restriction we tested a series of 25 SIVmac239 variants in which 
the amino acid at each of the 25 positions was substituted with the amino acid found at the 
corresponding position in HIV-1nl4.3 (Table 3-1) [380]. Of these viruses, 23 were infectious and 
were assayed for sensitivity to restriction by the 12 TRIM5αs (Figure 3-5). Nine of the 12 
TRIM5αs tested restricted the two viruses with mutations in the β-hairpin (SIVmac239Q3V and 
SIVmac239G6L) greater than 5 fold (Figure 3-5). A 10
th, schTRIM5α
G only restricted the 
SIVmac239G6L mutant virus greater than 5 fold. Restriction of these viruses is unlikely to be 
artifactual, as they were not restricted by wlfTRIM5α
Q.  These results support our published 
prediction that β-hairpin recognition is an ancient and conserved property of Old World primate 
TRIM5αs [380]. 
In contrast to the observations in Figures 3-3 and 3-4, we noticed that the ancestral 
TRIM5αs generally restricted fewer mutant viruses than the modern day TRIM5αs with the 
same V1 feature (Figure 3-5). This may reflect the stringency of assaying for the impact of a 
single amino acid substitution in an otherwise resistant CA. It is possible that restriction of SIVs 
or the surface swapped viruses is due to multiple determinants on the CA surface. Interestingly 
a virus with a mutation in helix 6 SIVmac239V111L, was variably restricted by the ancestral 
TRIM5αs. While ancTRIM5α
Q and ancTRIM5α
QV1G restricted this virus, ancestral TRIM5αs with ! 159!
V1 loop length alterations (V1+2aa and V1 G+20) lost the ability to restrict this virus (Figure 3-
5). This may indicate that upon CA binding, V1 is positioned in the vicinity of helix-6. 
   ! 160!
                     
Figure 3-5. Capsid targeting of select Old World monkey TRIM5αs. The Trim5αs were 
screened against a panel of SIVmac239 viruses with single amino acid substitutions on the 
capsid surface (Table 3-1). These Trim5αs are separated by tribe. Viruses restricted greater 
than 5 fold by the indicated Trim5αs are colored red. Gray squares indicate less than 5 fold 
restriction. Trim5α-Ancestor-20aa restricts SIVmac239 approximately 5-7 fold, for this TRIM5α 
only, red boxes correspond to modified viruses that were restricted greater than 18 fold and 
gray squares indicate less than 18 fold restriction.   
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HIV-1 
SIVmac 
 
SIV-V2I 
SIV-Q3V 
SIV-I5N 
SIV-G6L 
SIV-∆7Q 
SIV-N9Q 
SIV-Y10M 
SIV-Q86V 
SIV-P87H 
SIV-∆88A 
SIV-A89G 
SIV-∆91I 
SIV-Q92A 
SIV-Q93P 
SIV-L96M 
SIV-S100R 
SIV-S110T 
SIV-V111L 
SIV-D112Q 
SIV-Q116G 
SIV-Y119T 
SIV-Q122N 
      Papionini      Cercopithecini  
Fold Restriction                                        <5                                                          ≥5                                                                                      ! 161!
Table 3-1. Relationship between mutant virus numbering SIVmac239 and HIV-1nl4.3. The 
amino acid numbering of mutant viruses corresponds to the alignment in Figure 2-2A. 
Numbering of mutated residues corresponding to the SIVmac239 capsid (Accession number 
M33262) and HIV-1nl4.3 (Accession number M19921.2) are also provided.  
  
Mutant&
virus&
SIVmac239&
Residue&
HIV71nl4.3&
Residue&
V2I& V2& I2&
Q3V& Q3& 3V&
I5N& I5& N5&
G6L& G6& L6&
Δ7Q& Δ& Q7&
N9Q& N8& Q9&
Y10M& Y9& M10&
Q86V& Q85& V86&
P87H& P86& H87&
Δ88A& Δ& A88&
A89G& A87& G89&
Δ91I& Δ& I91&
Q92A& Q89& A92&
Q93P& Q90& P93&
L96M& L93& M96&
S100R& S97& R100&
S110T& S107& T110&
V111L& V108& L111&
D112Q& D109& Q112&
Q116G& Q113& G116&
Y119T& Y116& T119&
R120H& R117& H120&
R120N& R117& H120&
Q121Δ& Q118& Δ&
Q122N& Q119& N121&
N123P& N120& P122&! 162!
 
The modern TRIM5αs that restricted SIVmac239 point mutant viruses in addition to 
SIVmac239Q3V and SIVmac239G6L were the same TRIM5αs that restricted Cercopithecinae SIVs 
(Figures 3-3 and 3-5). While each TRIM5α restricted a unique subset of SIVmac239 point 
mutant viruses, it appears that Papionini (rhTRIM5α
TFP) and Cercopithecini TRIM5αs 
(musTRIM5α
G and sch2TRIM5α
G) have independently evolved to target similar or overlapping 
CA features. All three restricted SIVmac239Δ7Q, a virus with an insertion in the β-hairpin (Figure 
3-5 and 3-6A). The three TRIM5αs also shared the capacity to restrict SIVmac239P87H and 
SIVmac239D112Q. In addition, rhTRIM5α
TFP and sch2TRIM5α
G also restricted SIVmac239S100R, a 
key site of escape mutations from rhTRIM5α
TFP restriction in vivo [61]. Of note, 
ancTRIM5α
QV1G+20 also gained the ability to restrict SIVmac239Δ7Q and SIVmac239L96M (Figure 3-
5 and 3-6A).   
Positionally the mutations in viruses SIVmac239P87H, SIVmac239L96M, SIVmac239S100R, 
and SIVmac239D112Q map to the periphery of a site that is highly conserved across primate 
lentiviruses [380]. The conservation of this site may be related to its position at the junction 
between two critical CA interfaces that mediate interactions with cellular cofactors that 
specifically interact with lentiviruses. These cofactors facilitate efficient nuclear import and shield 
the reverse transcription intermediates from innate sensors (Figure 3-6B) [231-! 163!
233,300,323,327,363,372]. Taken together, the correlation between restriction of SIVs and the 
spatial arrangement of sites that modulate restriction suggests that these TRIM5αs have 
evolved to target viruses similar to present day Cercopithecinae SIVs. Furthermore, it appears 
that both Papionini and Cercopithecini TRIM5αs have independently evolved to exploit the 
same conserved site that is both structurally and functionally unique to lentiviral capsids.  ! 164!
               
Figure 3-6. Convergent evolution in capsid targeting among Old World monkey TRIM5αs. 
Both Cercopithecini and Papionini TRIM5αs have independently gained the ability to restrict 
viruses with mutations that sit at the junction of two sites that mediate interactions with cellular 
cofactors.  (A) Left a Venn diagram showing the overlap between mutations resulting in 
restriction for the ancestral Trim5α-V1Q and Cercopithecini and Papionini Trim5αs from figure 
3-5. Mutations resulting in restriction by at least two groups of Trim5αs are colored red. Right. 
Amino acid substitutions colored red mapped to the SIVmac239 capsid N-terminal domain 
structure (PDB: 4HTW). (B) Relationship between mutations modulating Trim5α sensitivity and 
cellular cofactor binding sites mapped to the HIV-1 hexamer (3GV2 and 2X2D). Notably, the 
ability to recognize mutations at SIVmac239 amino acid positions P86, L93, S97, D109 were all 
independently gained in Cercopithecini and Papionini Trim5α evolution. These sites, in addition 
to V111L, sit at the junction of the CPSF6/Nup-153 and Nup-358 CypA like domain/CypA 
binding sites. Amino acids involved in these interactions are colored according to the key. 
Structural Images created in PyMol. 
   ! 165!
                         
Figure 3-6. Convergent evolution in capsid targeting among Old World monkey TRIM5αs. 
Continued. 
      Trim5α              CypA & Nup-358              Cyp & Trim5α              CPSF6 & Nup-153             
   Hexamer Top View                    Hexamer Side View             
Q3V 
G6L 
V111L 
Papionini  
Trim5αs 
 Cercopithecini  
Trim5αs 
Δ7Q 
P87H 
L96M 
S100R 
D112Q  A89G 
Q93P 
Ancestor Trim5α        
Sites tested       
 
 >5 fold restriction 
Δ7Q 
Q3V 
G6L 
V111L 
Papionini  
Trim5αs 
 Cercopithecini  
Trim5αs 
Δ7Q 
P87H 
L96M 
S100R 
D112Q  A89G 
Q93P 
Ancestor Trim5α        
Sites tested       
 
 >5 fold restriction 
Δ7Q 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 ! 166!
3. D. DISCUSSION  
The TRIM5 gene of Old World primates has evolved under strong positive selection 
[243]. Among Old World primates, V1 in the PRYSPRY is the most rapidly evolving feature 
[243,380]. This loop not only contains a prominent cluster of positively selected sites, but 
Cercopithecinae primates also harbor lineage specific length variations [243,244]. Analytically, 
these variances in length are typically excluded from standard measures of positive selection. 
However, the maintenance and the continued evolution of these length variants across multiple 
Cercopithecinae linages argues that these modifications were strongly and repeatedly selected 
for, by retroviruses.  
We focused on a unique site of recurrent evolution among Cercopithecinae TRIM5αs 
that we refer to as the V1 patch. While this position was included in larger previously described 
V1 patches, we specifically focused on modifications that altered the sequence of 
Cercopithecinae TRIM5α position 339 or immediately adjacent residues [243,254,265]. Based 
on our present understanding of primate phylogeny and TRIM5α sequence information, we 
conservatively estimate that this patch began to diversify approximately 11-16 million years ago 
[34,35]. The diversification of this site stands in stark contrast to the Hominoidea and Colobinae 
TRIM5αs which have remained invariant for 30+ million years [34,35].  In contrast, this patch 
appears to have been twice modified in two independent Cercopithecinae lineages within a ! 167!
narrow 1.1-4 million year window. Both of these tribe specific modifications have continued to 
evolve.  
  We tested the restrictive properties of a predicted ancestral TRIM5α that represents the 
sequence of TRIM5α as it existed just prior to the diversification of the V1 patch. This TRIM5α, 
which we called ancTRIM5α
Q, was functional against a diverse panel of retroviruses, but lacked 
the ability to restrict Cercopithecinae SIVs (SIVmac239, SIVsmmE543, SIVagmTan-1, 
SIVagmGrv, SIVagmVer, SIVmus, SIVstm, SIVrcm). We introduced the Cercopithecinae V1 
patch derivatives into this TRIM5α and observed a specific gain in the ability to restrict these 
same Cercopithecinae viruses. Importantly, these gains matched those of present day TRIM5αs 
with the same V1 sequence (ex. ancTRIM5α
TFP and rhTRIM5α
TFP had very similar patterns of 
restriction) (Figure 3-3). For both ancient and modern TRIM5αs there was no correlation 
between the sequence of the V1 patch and the restriction of retroviruses other than the SIVs. In 
contrast, V1 patch sequences were strongly correlated with the ability to restrict specific 
Cercopithecinae SIVs. We did not observe a gain of restriction among an even more diverse 
panel of 8 non-Cercopithecinae SIV retroviruses. 
Among the 12 TRIM5αs tested, almost all were capable of restricting two mutant 
SIVmac239 viruses (Q3V and G6L) with substitutions in the β-hairpin (Figure 3-5 and 3-6A). 
This supports our previously proposed model in which the β-hairpin, a highly conserved ! 168!
structure in retroviral capsids, is part of a retrovirus-specific pattern widely exploited by TRIM5α 
proteins [380]. With the exception of SIVmac239V111L, SIVmac239 viruses with mutations 
outside of the β-hairpin were only restricted by those TRIM5αs that also restricted 
Cercopithecinae SIVs (Figures 3-3 and 3-5). Our data using mutant viruses suggests that both 
Papionini and Cercopithecini TRIM5αs have independently evolved to target similar regions of 
the primate lentivirus capsids (Figure 3-6A). When these positions are mapped to the structure 
of the HIV-1 hexamer, they occupy a single face of the capsid protein (Figure 3-6B). 
Substitutions affecting restriction are largely absent on the opposite CA face (Figure 3-6B). The 
positioning of these sensitizing mutations in capsid is significant. Most of these sites are found 
at the junction of two cofactor binding sites that are important for optimal lentivirus replication – 
the binding sites for CypA/Nup358 CypA-like domain and CPSF6/Nup-153 [300,327,363,372]. 
The broader implication of these observations is that primate TRIM5αs may have widely 
evolved to specifically exploit a conserved site that governs lentivirus specific interactions with 
cellular cofactors. These findings suggests that unlike at least one element of TRIM5α which 
has evolved to generally recognize retroviruses through the β-hairpin, the V1 loop evolved to 
make very specific viral interactions. Together, these observations support our previously 
proposed model for the evolution of novel TRIM5α variants among Old World primates [380].   ! 169!
Our observations strongly suggest that the rapid evolution of the TRIM5α V1 patch was 
driven by ancient retroviruses whose CAs share a common set of attributes with present day 
Cercopithecinae SIVs, distinct from any of the other retroviruses tested. The most parsimonious 
explanation for our observations is that these evolutionary innovations were selected for by 
ancient Cercopithecinae SIVs. Thus, the earliest selective events may signify the emergence of 
SIVs among the Cercopithecinae. This conclusion, for the first time, establishes continuity 
between ancient and modern SIV infection among Cercopithecinae primates. Temporally, we 
can date waves of selection in multiple independent Cercopithecinae lineages to similar periods 
of time. From these observations it is easy to envision an evolutionary scenario where ancient 
SIVs were dynamically transmitted between species resulting in pathogenic infections. This 
would mean that the repeated patterns of cross-species transmission, viral adaptation, and viral 
dissemination observed in nature today are the continuation of an ancient 11-16 million year old 
pattern. Furthermore, it implies that the propensity to cross between species may be an inherent 
property of primate lentiviruses.  
The patterns of pathogenesis associated with Cercopithecinae SIVs support our 
hypothesis that Cercopithecinae SIVs drove the evolution of the V1 patch. The only documented 
pathogenic SIV infections have arisen from the successful cross-species transmission of 
Cercopithecinae SIVs [24-29,58,59]. This includes the HIV-1/SIVcpz/SIVgor lineage which is a ! 170!
recombinant between two Cercopithecinae SIVs [29], and the SIVmac viruses which came from 
sooty mangabeys. Thus it is conceivable that the cross-species transmission of ancient SIVs 
carried the same pathogenic potential. In contrast, many modern Circopithecinae species that 
are predicted to have harbored specific SIVs for a sufficient period of time to have coevolved to 
a state of apparent apathogeneses (e.g. sooty mangabeys and African green monkeys) are also 
found in the Cercopithecinae [24,25].  
Currently, no direct evidence linking ancient SIVs to present day SIVs exists. However, 
our predictions fit within the greater context of both known and predicted (pre)history of the 
lentiviridae. Direct molecular evidence from three endogenized lentiviruses indicates that at 
least three extant lentiviral lineages existed on multiple continents 5-15 million years ago [52-
55]. Distinct Cercopithecinae SIV lineages are believed to have existed prior to the isolation of 
Bioko Island from the African continent 10,000 years ago [42]. Indirect evidence of ancient 
lentiviral infection in Old World primates has largely come from the study of patterns of selection 
in genes with known anti-lentiviral activity. While these studies have found compelling evidence 
to support the existence of ancient lentiviruses, they cannot unambiguously determine if primate 
lentiviruses were the selective force. Binding to Cyclophilin A is a ubiquitous property of lentiviral 
capsids [291,324,402]. The pro-viral interaction between CA and Cyclophilins may have been 
exploited by an ancient TRIM5-CypA fusion protein dated to approximately 30 million years ago ! 171!
[45]. Similarly, studies of APOBEC3G have identified selective events dated to 5-12 million 
years ago that disrupt the interaction with SIV Vifs [44]. However, as with cyclophilin A, other 
lentiviruses encode Vif proteins that may exploit and therefore select upon a common or 
overlapping interface. Importantly, restriction by TRIM5α is the result of a specific and 
productive interaction between TRIM5α and CA. Our conclusions are based upon assaying for 
this specific interaction, which was only observed with Cercopithecinae SIVs, giving us higher 
confidence that these evolutionary derived changes were specifically selected for by ancestors 
of these viruses. 
  Finally, we acknowledge that it has become very common in the field of indirect 
paleoviriolgy to infer ancient molecular interactions based solely on modern data; the risk is that 
alternative hypotheses including convergent or parallel evolution involving unidentified or extinct 
viruses cannot be ruled out. However, in our study we consistently observed a strong correlation 
between the independently derived V1 patch changes and the restriction of Cercopithecinae 
SIVs, and at the same time, we observed a clear lack of correlation among a diverse panel of 
other retroviruses, including other primate lentiviruses from apes. Our conclusions are also 
based upon assaying for the outcome of a very specific interaction between CAs and TRIM5αs. 
Taken together our findings strongly support the conclusion that ancient Cercopithecinae SIVs 
started driving the evolution of TRIM5α V1 approximately 11-16 million years ago, and that the ! 172!
extant versions of V1 found in nature today are the direct result of continuous adaptive 
refinement [34,35].  
 
3. E. METHODS 
Cell lines 
TRIM5α variants were isolated from: African green monkey kidney cell lines COS-1 and Vero, 
grown in DMEM/10% FBS.Skin fibroblast cell lines derived from primate species were obtained 
through Coriell Cell Repositories (Camden, NJ) and cultured according to specification. 
Cercocebus torquatus (Red-Capped Mangabey, PR00485), Cercopithecus cephus (mustached 
guenon, PR00531), Cercopithecus ascanius (Black-cheeked white-nosed monkey PR00566  
and PR00634), Cercopithecus neglectus (De Brazza's monkey, PR01144), Cercopithecus 
wolfi  (Wolf's guenon PR00486, PR00530 and PR01241). Crandell-Rees feline kidney (CRFK) 
cells and human embryonic kidney 293T/17 (HEK293T/17) cells were obtained from American 
Type Culture Collection (Manassas, VA) and grown in DMEM/10% FBS. CRFK cell lines stably 
expressing N-terminally HA-tagged TRIM5 orthologs were maintained in DMEM/10% FBS 
supplemented with 5 µg/ml Puromycin.  
 
RNA Isolation ! 173!
RNA was extracted using Trizol regaent (Ambion/life technologies). cDNA was prepared using a 
Transcriptor First Strand cDNA Synthesis Kit (Roche) using an anchored-oligo(dT)18 primer.  
TRIM5α cDNAs were amplified and N-terminally HA-tagged  using TRIM5-F-
GCGGAATTCGCCACCATGTACCCATACGACGTCCCAGACTACGCTGGCGGCGCTTCTGGA
ATCCTGCTTAATGTAAAG AND TRIM5-R-
ACCATCGATGGCTCAAGAGCTTGGTGAGCACAGAGTC primers. PCR amplicons were 
directly coloned into pLPXC (Clonetech) using EcoRI and ClaI sites. 
Plasmids  
TRIM5αs were cloned into pLPXC using EcoRI and ClaI sites. Retroviral GFP reporter viruses 
were produced from the following plasmids. HIV-1 was produced from the following reagent that 
was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3-
deltaE-EGFP (Cat# 11100) from Drs. Haili Zhang, Yan Zhou, and Robert Siliciano [401]. The 
pV1EGFP derivatives encoding the 5’ region of  SIVmac239, SIVsmE543, SIVstm/37.16 were 
previously described [403].N-tropic or B-Tropic MLVs from either pCIGN or pCIG-B and pLXIN-
EGFP (gifts of Jonathan Stoye, Medical Research Council, London, U.K.). Rous sarcoma virus 
(RSV) [404] (Addgene plasmid 13878, courtesy of Constance Cepko, Harvard Medical School, 
MA) Equine infectious anemia virus (EIAV) pEV53D and pEIAV-SIN6.1 CGFPW (Addgene 
plasmids 44168 and 44171 courtesy of John Olsen, University of North Carolina) [405,406]. ! 174!
Feline immunodeficiency virus (FIV) pFP93 and pGINSIN (gifts from Eric Poeschla, Mayo Clinic) 
[407,408]. The first 205 amino acids of the pNL43DeltaE-GFP Capsid were replaced with the 
following SIV capsids: SIVrcm (AF349680), SIVagmVerv (L40990), SIVagmGrv (M66437) and 
SIVmus-1 (AY340700). These capsids were synthesized as Strings by GeneArt/Life 
Technologies and cloned into pNL43DenvGFP using a previously described shuttle vector [380] 
HIV-1nl4.3-SIVmac239 chimeric viruses were previously described [380].  
Virus production 
All single-cycle viruses were produced in HEK293T/17 cells by cotransfection of the appropriate 
viral plasmid(s) and pVSV-G (Clontech Laboratories, Mountain View, CA), using GenJet 
(SignaGen; Ijamsville, MD). Viral supernatants were tittered on CRFK cells; supernatant 
volumes resulting in approximately 25% GFP/EGFP+ CRFK cells were used for infectivity 
assays on the cell lines expressing the indicated TRIM5α.    
Infectivity assays 
Stably expressing TRIM5 CRFK cells were seeded at a concentration of 5×10
4 cells per well in 
24-well-plates and infected with the appropriate amount of VSV-G pseudotyped, single-cycle, 
GFP/EGFP expressing viruses. After 2 days, expression of GFP/EGFP was analyzed by 
fluorescence-activated cell sorting (FACS) performed on a FACSCaliburTM flow cytometer (BD, ! 175!
Franklin Lakes, NJ), and data were analyzed using FlowJo software (Tree Star, Inc., Ashland, 
OR).  
Phylogenetic Reconstruction 
A comprehensive nucleotide alignment for 78 full-length Old World Primate TRIM5αs was 
generated. A maximum likelihood phylogenetic tree was generated using the HKY85 substation 
model [409] and 1,000 bootstrap replications. This tree was used as the input for ancestral node 
reconstruction via FASTML server (http://fastml.tau.ac.il/ ) [410-412]. The node corresponding to 
the split between Papionini and the Cercopithecini TRIM5αs was used as the ancestral 
TRIM5α. Node predictions were done in the absence of indel reconstruction. A predicted Q was 
placed position 339.  
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Chapter 4: General Discussion ! 177!
 4. A. LENTIVIRUSES ARE ANCIENT  
Evidence of ancient primate lentiviruses. In addition to primates, extant lentiviruses 
exist in feline, equine, bovine, ovine and caprine species. Each of these groups harbor 
phylogenetically distinct lentivirus lineages, with the exception of ovine and caprine lentiviruses 
which form a single lentivirus lineage. Endogenous lentivirus sequences have been found in the 
genomes of lagomorphs, mustelids and Malagasy lemurs [52-55]. These sequences indicate 
that distinct lentivirus lineages have existed for at least 8-12 million years. Among all known 
lentiviruses, both extant and endogenous, the endogenous lemur virus PSIV is most closely 
related to modern primate lentiviruses [53,324]. Based on the lemur phylogeny and molecular 
clock estimates, this virus is predicted to have colonized lemur genomes 5-8 million years ago. 
It should be noted that this estimate is for the time of endogenization and does not date the 
emergence or extinction of this viral lineage.  
The isolation of Madagascar from Africa occurred approximately 130 million years ago, 
while Prosimians likely colonized Madagascar approximately 70 million years ago [413].  It is 
unclear whether PSIV was present prior to the primate colonization of Madagascar, carried with 
the first primates to Madagascar, or introduced to the Malagasy ecosystem at a more recent 
date [53]. In the phylogeny of lentiviruses, PSIV is basal to extant primate lentiviruses. While the 
genomes of theses proviruses are degraded, this virus appears to lack many of the ! 178!
characteristic accessory genes of present day primate lentiviruses. Structurally, the capsid N-
terminal domain is similar to other capsids from lentiviruses [324]. While in some respects it is 
more similar to HIV-1 and HIV-2 than other lentivirus capsids, it also lacks some features 
commonly found in present day primate lentiviruses such as an elongated 4-5 loop [324]. The 
existence of PSIV in some lemur genomes establishes that viruses related to extant primate 
lentiviruses existed 5-8 million years ago it is unclear whether PSIV represents their 
predecessors or whether it represents a separate evolutionary branch.  
A pattern of recurrent positive selection in the APOBEC3G gene of Cercopithecidae 
primates (Old World monkeys but not apes) is consistent with the presence of an antagonizing 
Vif protein [44]. These positively selected sites are found on a common Vif interaction face of 
APOBEC3G [44,197,199,200,205,206]. Using the primate phylogeny some selective events 
have been dated to 5-12 million years ago, which is consistent with the ages of known 
endogenous lentiviruses [44,52-55].  While it is likely that a Vif protein selected for these 
adaptations, it is unclear whether the Vif protein came from viruses related to modern day 
primate lentiviruses. A Vif gene is present among all extant lentivirus lineages with the exception 
of equine lentiviruses (EIAV) [1,2,18]. While divergent, these Vifs are thought to have shared a 
common ancestor and therefore may exploit similar or overlapping interfaces on APOBEC3G. ! 179!
For example, selection by a Vif protein found in felines may alter the binding surface used by 
primate lentivirus Vif proteins.  
To date, no direct evidence exists linking ancient primate lentiviruses to the extant 
primate lentiviruses found in Africa today. Our results reveal a strong correlation between 
specific, evolutionarily derived changes in the TRIM5-V1 loop of Cercopithecinae monkeys that 
occurred between 11-16 million years ago and the restriction of modern SIVs from 
Cercopithecinae hosts. Importantly, these changes did not correlate with restriction of 
retroviruses representing any other genus, or non-Cercopithecinae lentiviruses. Rather than 
assaying for the failure of two proteins to interact (like Vif-APOBEC3) we observed specific 
gains in ability to restrict a single group of viruses, the Cercopithecinae SIVs. The most 
parsimonious explanation for these findings is that ancient Cercopithecinae SIVs were present 
in Cercopithecinae primate species at least 11-16 million years ago. Therefore, primates and 
primate lentiviruses may have been coevolving for at least this long. For selection to have 
occurred, ancient SIV infection must have been pathogenic. Together with the observation that 
selection occurred in two independent Cercopithecinae lineages, the Papionini and the 
Cercopithecini, our findings imply that like modern day SIVs, these ancient SIVs spread through 
cross-species transmission.  ! 180!
  Implications of the ancient origin of primate lentiviruses. Our observations provide 
evidence supporting the notion that SIVs have infected Cercopithecinae primates for the past 
11-16 million years. However this is a single SIV lineage among a single group of primates. At 
least three major primate lentivirus lineages exist: SIVs similar to SIVsm/SIVrcm, SIVs similar to 
SIVgsn/SIVmus/SIVmon and SIVs similar to SIVscol/SIVwrc/SIVolc [27]. Numerous 
recombinant lineages including that of SIVcpz/SIVgor/HIV-1 are also present [27,29]. It is 
therefore very likely that the last common ancestor of all primate lentiviruses is older than the 
single SIV lineage that we predict was present among Cercopithecinae SIVs 11-16 million years 
ago.  
We observed a pattern of strong and recurrent selection in a single gene, TRIM5α, in 
response to Cercopithecinae SIVs. If the relationship between primates and their SIVs is ancient 
then it is likely that other genes have also evolved to antagonize primate lentivirus infection. 
These genes may include other restriction factors, innate sensors or maybe even genes of the 
adaptive immune system. Unique Old World primate gene variants that have arisen in the past 
11-16 million years should be considered in the context of ancient primate lentivirus infection. It 
is also accepted that primates which apathogenically harbor SIVs must have coevolved with a 
particular primate lentivirus for “a long period of time” [23-27]. Our findings suggest that these ! 181!
timescales may span many millions of years. The genetic determinants of this apparent 
commensal relationship are not understood, but are of great medical interest.  
If primate lentiviruses are indeed at least 11-16 million years old, then the Lentivirus 
genus of retroviruses must be far more ancient. At these time scales molecular clock estimates 
break down and cannot provide accurate divergence dates [414]. Without evidence of 
endogenous lentiviruses we can only speculate about the true age of the Lentiviruses. It 
appears that lentiviruses are endogenized at lower frequencies than viruses from some other 
retrovirus genera. Nonetheless, considering the genetic diversity both at the sequence level as 
well as in the genome structure of known lentiviruses it is clear that this retroviral genus must be 
significantly older than the Cercopithecinae SIVs.  
 
4. B. A WORKING MODEL FOR TRIM5α BINDING  
   TRIM5α recognizes the capsid surface. In Chapter 2 we proposed an evolutionary 
model to describe how novel TRIM5α variants, like rhesus TRIM5α
TFP, could have evolved 
[380].  We believe that the breadth of TRIM5α restriction may be related to detection of the β-
hairpin. This structural feature is conserved across the capsids of the Orthoretrovirinae [328-
331,338,384]. We hypothesized that contacts with this conserved structural feature could allow 
other regions within the PRYSPRY domain to evolve additional contacts with the capsid protein. ! 182!
These contacts could be specific for certain viruses or groups of viruses. Together, this modular 
recognition could account for the observed breadth and specificity of TRIM5α mediated 
restriction. In Chapter 3 we tested this model by mapping the determinants of restriction for 
other Old World monkey TRIM5αs. These findings were consistent with our proposed 
evolutionary model [380]. Evidence from a diverse panel of 11 Old World Primate TRIM5αs, 
suggests that the capsid surface is the major determinant of resistance or sensitivity. Of these 
11 different TRIM5αs, 9 restricted two SIVmac239 viruses with single amino acid substitutions 
in the β-hairpin (Q3V and G6L), and a 10th restricted one of these viruses (G6L). Mutations 
outside the β-hairpin that resulted in restriction encircle a highly conserved patch of amino acids 
that sits at the junction of two cellular co-factor binding sites, CPSF6/Nup-153 and cyclophilin 
A/Nup-358 cyclophilin A-like domain [300,327,363,372]. Targeting of this site independently 
evolved in two primate lineages [47-51,61,257,385]. Importantly, both natural and synthetic 
TRIM5-fusion proteins that exploit either cofactor binding site are broadly restrictive against 
lentiviruses but not other retroviruses [47,48,50,51,61,257,327,370,372,385].   
Natural exploitation of cofactor binding sites. Both the structural basis and 
evolutionary forces that have selected for TRIM5Cyp proteins are clear. Structurally, the 
cyclophilin A domain binds the proline-rich 4-5 loop of lentivirus capsids [232,300,333,334,363]. 
Evolutionarily, the interaction of lentiviruses and cyclophilin A is an ancient and conserved ! 183!
property [260,291,324]. Two endogenous lentiviruses thought to have existed in an extant form 
at least 5-12 million years ago also engage cyclophilin A and can be restricted by TRIM5Cyp 
fusion proteins [52,53,324]. For modern lentiviruses the interaction with cyclophilin A in the 
cytoplasm as well as the cyclophilin A-like domain of Nup-358 are required for optimal infectivity 
and viral spread in tissue culture [232,233,323,327]. To date, no other Orthoretrovirinae capsid 
outside of the Lentiviruses has been shown to efficiently interact with cyclophilin A. Thus, the 
fusion of TRIM5 to a CypA domain leads to the generation of a broadly restrictive anti-lentivral 
factor. 
  Intelligent design of synthetic TRIM5s. Similarly, synthetic TRIM5α- fusions of 
lentivirus specific capsid interacting proteins can also generate broadly restrictive anti-lentiviral 
proteins. Like naturally occurring TRIM5Cyp proteins, these synthetic restriction factors owe 
their pan-lentivirus breadth of recognition to the conservation of capsid co-factor binding sites. 
Fusion of cellular cyclophilin A (PPIA) or the CypA-like domain of Nup-358 toTRIM5 creates 
artificial TRIM5CypA fusion proteins that bind to lentivirus capsids in a similar manner as 
naturally occurring TRIM5Cyps [327,333,334,390,415,416]. The capsid binding domain of 
CPSF6 has also been fused to the tripartite motif of TRIM5 resulting in a broadly restrictive anti-
lentivirus factor [370]. Presumably, at least part of the interaction involves the binding of the 
capsid binding peptide to a highly conserved pocket on the side of the capsid protein [363]. This ! 184!
pocket is an extension of the conserved surface patch we identified in Chapter 2. In a structure 
of the capsid protein in complex with the CPSF6 capsid binding peptide, the peptide adopts a 
conformation strikingly similar to a small molecule inhibitor, PF-3450074, that modulates capsid 
stability and virion infectivity [363,417-419]. PF-3450074 was used as the final proof that the 
FG-repeats of Nup-153 bind the same binding pocket. Fittingly, the fusion of the FG-repeats of 
Nup-153 to the tripartite motif of TRIM5α also yielded a broadly restrictive anti-lentiviral factor 
[372].  
  In regard to their interactions with lentivirus capsids, natural and synthetic TRIM5 fusion 
proteins share a number of commonalities. First, restriction, albeit broad, is limited to 
lentiviruses. Second, they all exploit highly conserved features of the lentivirus capsid protein. 
These sites are conserved because they mediate multiple interactions with cellular co-factors. 
Furthermore, mutations in both the cyclophilin A binding loop as well as the CPSF6/Nup-153 
capsid binding loop also impact virion assembly, nuclear import, and integration site biases 
[327,364,371,372,378,379]. Third, these interactions are fairly well characterized because they 
involve the interaction of a single capsid monomer and a single capsid interaction domain. 
Fourth, single amino acid substitutions are largely sufficient to disrupt restriction, without entirely 
ablating virus infectivity in tissue culture [49,327,363,367,372].  Similarly, SIVmac evolved 
resistance to rhesus TRIM5Cyp through alterations in the 4-5 loop [61].  This virus has become ! 185!
cyclophilin A and Nup-358 independent while maintaining pathogenicity 
[60,232,233,327,333,403].  
  A model for TRIM5α recognition. Aspects of the TRIM5α-capsid interaction are both 
similar to and distinct from the above factors. For example, like the above TRIM5-fusion 
proteins, the breadth of restriction by any TRIM5α ortholog is broad. However, unlike the above 
factors, this breadth encompasses retroviruses from multiple retroviral genera. For both, breadth 
of restriction is a product of a highly conserved target. While the TRIM5-fusion proteins bind a 
single capsid monomer, it is hypothesized that the binding site of TRIM5α includes binding sites 
on multiple capsid monomers in the context of the capsid lattice [208,210,213,420]. Our results 
in Chapter 2 along with the observations of many other groups support the notion that TRIM5αs 
recognize multiple features of the capsid protein (reviewed above). This observation is mirrored 
by the fact that single amino acid substitutions rarely render restricted capsids resistant to 
TRIM5α mediated restriction. This is in contrast to the TRIM5-fusion proteins that recognize a 
single target on capsid and whose recognition can be disrupted by singe amino acid 
substitutions. Our observations together with a great body of work including how these factors 
bind has led us to propose how TRIM5α recognizes retroviral capsids.  
 We believe that the Old World monkey TRIM5α PRYSPRY domain makes at least one 
contact with the β-hairpin. The β-hairpin is a conserved structural feature that is present in ! 186!
viruses from at least 5 Orthoretrovirinae genera  [328-331,338,384]. Thus, recognition of the β-
hairpin could account for the observed breadth of TRIM5α mediated-restriction that can span 
multiple retroviral genera. In the structure between TRIM21 and the IgG-Fc, the variable loops 
corresponding to TRIM5α V2 and V3 do make contacts with β-sheets and a small loop with 
some β-sheet characteristics [248].   
In the context of the hexamer the β-hairpins of the monomers form a ring around the 6-
fold axis of symmetry. Due to their proximity to one another we cannot distinguish whether 
capsid recognition is dependent upon one or more β-hairpins in a single hexametric unit. The 
distance between β-hairpins of two adjacent capsid hexamers is too great for a single 
PRYSPRY domain to engage both simultaneously; the maximum length of the PRYSPRY 
domain is approximately 45 Å while the distance between β-hairpins in adjacent hexamers is 
approximately 90 Å. However, TRIM5α binds to capsids as a dimer and this could allow for the 
PRYSPRY domain of each monomer to engage β-hairpins on adjacent hexamers [210,421].  
This model is supported by two studies in which N-MLV evolved resistance to rhesus 
and human TRIM5α [239,240]. In general, it appears that less acquired mutations were required 
to resist rhesus TRIM5α (which may have evolved to target primate lentiviruses) than human 
TRIM5α. However, in both experiments mutations in both the β-hairpin as well as the 
corresponding regions of N tropic MLV to the conserved surface patch were selected for during ! 187!
the escape from human/rhesus TRIM5α restriction [239,240]. Interestingly, while similar escape 
mutations were selected for in the β-hairpin, escape mutations were varied in the homologus 
structures to the lentivirus conserved surface patch. We interpret this overlap to mean that the 
β-hairpin is indeed the source of the observed breadth of restriction. Furthermore, this model of 
binding supports the notion that specific capsid-TRIM5α contacts can evolve in addition to the β-
hairpin.  
While the β-hairpin accounts for the observed breadth of restriction, it cannot account for 
the specificity of restriction. Specificity of the TRIM5α-capsid interaction is demonstrated in two 
ways, both suggesting that TRIM5αs target lineage specific capsid features. First, TRIM5αs 
often fail to restrict closely related viruses such as N-tropic and B-tropic MLVs. Second, some 
TRIM5αs have the ability to broadly restrict a number of viruses within a single retroviral genus. 
This is seen for rhesus TRIM5α
TFP, which in Chapters 2 and 3 restricted every primate lentivirus 
except the macaque adapted SIVmac239. Our observations from Chapter 2 allowed us to 
conclude that rhesus TRIM5α
TFP evolved to target a patch of amino acids on the capsid surface 
that are highly conserved in both composition and structure across primate lentiviruses. In 
Chapter 3 we found that both Papionini and Cercopithecini TRIM5αs have independently 
evolved to target this exact site.  ! 188!
Our results with Cercopithecinae TRIM5α proteins are consistent with the hypothesis 
that the PRYSPRY domains of TRIM5α recognize the capsid surface. We propose that capsid 
recognition involves both specific contacts with the capsid β-hairpin and with the conserved 
surface patch that sits at the junction of two cofactor binding sites. When sites modulating 
TRIM5α sensitivity are mapped onto an HIV 1 capsid hexamer they form a pinwheel pattern that 
radiates from a central ring formed by the β-hairpins (Figure 4-1A). Cofactor binding sites 
closely match this pattern (Figure 4-1A). Importantly, the pinwheel analogy is used to 
emphasize that the arrangement of both sites modulating interactions with cellular cofactors and 
those that modulate sensitivity to TRIM5α radiate from a central β-hairpin ring with the same 
handedness. When this pattern is placed in the context of known structures (capsid lattice, 
PRYSPRY domains, the B-box and coiled-coil) a potential model for TRIM5α becomes 
apparent.  
Structures of the TRIM5α B-box and coiled-coil form an antiparallel dimer [421,422]. This 
observation is supported by electron microscopy studies [210,422].  When two rhesus TRIM5α 
PRYSPRY domain structures are docked into the structure of the B-box and coiled-coil (through 
a shared helix) the two PRYSPRY domains are found within close proximity [422], and the two 
PRYSPRY domains are antiparallel relative to each other.  In this model, the distance between 
PRYSPRY domains is too small to bridge β-hairpins of adjacent hexamers. However, if the B-! 189!
box + coiled-coil structure is placed across the 2-fold axis of symmetry of a single capsid 
hexamer, the PRYSPRY domains overlap with the β-hairpins of adjacent capsid monomers 
(Figure 4-1B). In this model, the antiparallel arrangement of the PRYSPRY domains matches 
the handedness of the sites that modulate TRIM5α sensitivity (Figure 4-1B). Based on the 
relative sizes of the primary components, a PRYSPRY domain can sit centered on the β-hairpin 
of one capsid monomer and the first variable loop (V1) can fill the volume of the gap between 
that monomer an adjacent capsid monomer (Figure 4-1B). This arrangement places V1 near the 
conserved surface patch that sits at the junction between the cellular cofactor binding sites of 
the second capsid monomer. Due to the handedness of the mutations that modulate TRIM5α 
sensitivity, the antiparallel arrangement of the PRYSPRY domains allows the second PRYSPRY 
domain to make the same contacts on the opposite side of the capsid hexamer.  
   ! 190!
 
Figure 4-1. Model for TRIM5α Binding. A. A single capsid hexamer (gray)in the context of a 
capsid lattice (pink and green). Top (left) and side (right) views are shown. In the side view two 
capsid hexamers have been removed to view the gray hexamer. Sites that modulate 
interactions with capsid binding proteins are colored according to the key below. B. A model 
TRIM5α Binding based on structures of the B-Box and coiled-coil dimer (gold and orange) and 
two PRYSPRY domains dark (dark purple and magenta).  PDB 3GV2, 2X2D, 3J3Y, 4TN3, 
2LM3. Images generated in PyMOL. 
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The conserved surface patch sits at the junction between the cyclophilin A/Nup358 
cyclophilin A-like domain and the CPSF6/Nup-153 binding sites [300,327,333,334,363,372]. 
Selective pressure to preserve interactions with these cofactors likely explains the conservation 
of this region. Considering that mutations outside of the cyclophilin A binding loop modulate 
TRIM5α sensitivity we do not believe that the PRYSPRY domain binds to capsid by directly 
engaging the 4-5 loop in a manner reminiscent of cyclophilin A. However we have noted 
similarities between the V1 loop of Cercopithecinae TRIM5αs and factors that bind to the 
CPSF6/Nup-153 binding site. Convergent structures among the interaction partners of this 
binding pocket have been previously observed [363]. In complex with capsid, the capsid binding 
peptide of CPSF6 adopts a conformation very similar that of the small molecule inhibitor PF-
3450074 [363,417]. A phenylalanine at position 321 in CPSF6 makes extensive contacts with 
the hydrophobic interior of the CPSF6 binding pocket (Figure 4-2A). Similarly a phenyl group of 
PF-3450074 occupies the same position when in bound to the HIV-1 capsid. In the capsid-
bound CPSF6 peptide the side chain for L315 makes very similar hydrophobic contacts within 
HIV-1 α-helix 4 as a second phenyl group of PF-3450074. The acetyl group of PF-3450074 
mimics the peptide oxygen of CPSF6-Q319. In both instances these oxygens form a hydrogen 
bond with HIV-1 capsid residue K70.  ! 192!
The V1 loop of rhesus macaque TRIM5α is predicted to be highly dynamic and the 
reported structure was solved by NMR in the absence of capsid [211]. Even in the absence of 
its capsid ligand this loop adopts a conformation similar to that of the CPSF6 capsid binding 
peptide and PF-3450074 [211,363,417] (Figure 4-2A). The structures of all three capsid 
interacting factors can be aligned (Figure 4-2B). In this proposed model of rhesus TRIM5α 
binding F338 can be aligned to CPSF6 F321 and the phenyl group of PF-3450074. Notably, this 
phenylalanine is absolutely conserved across Old World monkey TRIM5αs. The R-groups of 
rhesus TRIM5α L337 and the methyl group of A333 form a hydrophobic surface similar to that of 
the 2-methyl-indol group of PF-3450074. The peptide oxygen of L337 is also positioned similarly 
to the acetyl group of PF-3450074 and the peptide oxygen of CPSF6 Q319 (Figure 4-2B). 
Among Old World monkey TRIM5αs L337 is also highly conserved. Therefore, it is possible that 
upon capsid binding V1 can adopt a conformation that can mimic these capsid binding factors.   
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Figure 4-2. Similarities between capsid interaction proteins and rhesus TRIM5α. (A) 
Structural similarities between variable loop one (V1) of rhesus TRIM5α, the CPSF6 capsid 
binding peptide and PF-3450074 (PDB: 2LM3, 4B4N, 2XDE). Key amino acids and functional 
groups are labeled. An “*” denotes an oxygen that is predicted to make contacts with the HIV-1 
capsid. (B) A pairwise structural alignment of the structures in A. Left. Rhesus TRIM5α V1 and 
the CPSF6 capsid binding peptide. Middle. Rhesus TRIM5α V1 and PF-3450074. Right. The 
CPSF6 capsid binding peptide and PF-3450074. (C) Sequence similarity between rhesus 
TRIM5α V1 and residues 1423-1440  Nup-153. Multiple primate TRIM5α V1 sequences aligned 
to Nup-153. Asterisks indicate sites of identity or similarity, “.” indicate identity and “-” denote 
gaps.  Structural Images created in PyMol. 
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The FG-repeats of Nup-153 are also predicted to bind to this same site [372]. Its 
interaction can be outcompeted by PF-3450074 in vitro. We have also noticed that the amino 
acid sequence of rhesus TRIM5α V1 and other old world monkey TRIM5αs are similar to a 
stretch of amino acids in Nup-153. Rhesus TRIM5α residues 335-351 can be aligned to Nup-
153 residues 1423-1440 (Figure 4-2C). These residues are found in the segment of Nup-153 
that appears to mediate its interaction with HIV-1 [372]. Interestingly, the stretch of amino acids 
in TRIM5α that resembles Nup-153 has been duplicated in the G+20 insertion found in African 
green monkeys and Pata’s monkeys [243,244].  
Our assignment of V1 to this cofactor binding site is highly speculative. However, the 
commonalities between V1 and known interactors of this binding pocket are striking. These 
observations fit with our mutagenic data from Chapters 2 and 3. From our observations, V1 is 
clearly involved in making primate lentivirus specific capsid contacts. This proposed model of 
binding matches observations from NMR titration experiments between the N-terminal domain 
of the HIV-1 capsid and the rhesus PRYSPRY domain [211,212]. The addition of capsid causes 
chemical perturbations in amino acids in V1 [211]. Conversely, the addition of the rhesus 
PRYSPRY domain to HIV-1 capsid N-terminal domains causes chemical shifts on the capsid 
surface around the conserved patch [212]. Perhaps a structure of V1 in complex with capsid will 
one day support our speculations.  ! 195!
4. C. OTHER CAPSID TARGETING RESTRICTION FACTORS 
FV1 and MX2. The exact qualities of capsid that permitted the evolution of a factor such 
as TRIM5α have also facilitated the evolution of other capsid targeting anti-retroviral factors. 
Many of the evolutionary constraints acting upon primate lentiviruses are also likely present for 
capsids of other members of the orthoretroviridae. Despite the absence of well characterized 
capsid binding cellular cofactors, the dynamic exchange of inter- and intra- capsid interactions 
during assembly surely imparts a number of constraints. The sum of these constraints has 
resulted in a viral capsid protein that has been largely intolerant of mutation [273,376-379]. 
While the capsid sequences of members of each Orthoretrovirinae genus are divergent, their 
capsids are structurally conserved [324,328-331,338]. This conservation extends to the 
hexamers that make up all but 12 of the higher ordered building blocks of capsid [330,373,375]. 
A growing body of evidence, including the results presented here, supports the notion that the 
pattern created by the higher ordered arrangement of the capsid lattice is a highly conserved 
and uniquely retroviral pattern. The stability of this structure over deep evolutionary time has 
been exploited by other anti-retroviral factors. 
The cross-strain transmission of the gammaretroviruses (Friend murine leukemia virus) 
between laboratory strains of mice identified a number of restriction factors, before the 
discovery of the first primate lentivirus, HIV-1 [423-429]. One particular block, FV1 (named for ! 196!
its restriction of Friend murine leukemia virus) [428-431], acts in a way reminiscent of TRIM5α. 
A more accurate statement is that TRIM5α acts in a manner reminiscent of FV1. It should be 
noted that the FV1 block was identified and characterized before the presence of TRIM5α was 
fully appreciated. The characterization of the FV block laid much of the conceptual framework 
that would later be applied to define the LV1 block and identification of TRIM5α.  
Through genetics it was determined that FV1 was a heritable, dominant acting, intrinsic 
property of cells from resistant mice [428-431]. The block was shown to be saturable and 
dependent on the sequence of the viral capsid [432-437]. Importantly, the block was dependent 
upon the higher ordered arrangement of capsid in the context of the capsid core [438,439]. FV1 
acts at a post-entry and pre-integration step that is distinct from that of TRIM5α [226,440-442]. 
The concept that different inbred mouse strains harbored distinct alleles with unique anti-
gammaretrovirus specificities preceded many of the properties later discovered for TRIM5 
[428,429,443]. Interestingly, FV1 is not a TRIM protein but rather a coopted remnant of an 
endogenous retrovirus gag gene [444].   
Despite the fact that FV1 bears no genetic similarity to TRIM5, both appear to engage 
capsids in a similar manner. Mutations in MLVs affecting both TRIM5 and FV1 sensitivity map to 
the capsid surface, which is nicely illustrated by Ohkura and collogues in 2011 [239,240]. While 
the dimensions are different from TRIM5α, FV1 forms a regular lattice on MLV capsid tubes ! 197!
[319,445]. Furthermore, both TRIM5α and FV1 form dimers that are largely alpha helical and 
antiparallel [421,422]. While FV1 was once thought to only act on gammaretroviruses, it has 
recently been demonstrated that some variants can restrict supmaretroviruses and lentiviruses 
[446]. Thus, like TRIM5α, FV1 orthologs have the capacity to broadly restrict retroviruses.  
In addition to FV1, the recently characterized anti-lentiviral protein MX2 is believed to 
target lentiviral capsids [447-450]. Mutations throughout the capsid protein can modulate 
sensitivity to MX2 [447-450]. Notably some mutations are in positions that may not be 
accessible for a factor as large as MX2 to bind in the context of the fullerene cone of TRIM5α 
[320,449,451]. MX2 is also predicted to adopt a long alpha helical structure, perhaps similar to 
FV1 and TRIM5α [421,422,448,451]. While immunoprecipitation experiments hint that 
monomeric capsid protein can interact with exogenously expressed MX2 [448], it will be 
interesting to see how MX2 mediated restriction compares to FV1 and TRIM5α. 
Thus it appears that the evolutionary stability of the capsid structure has been widely 
exploited by antiretroviral factors. As evidenced by the overwhelming number of endogenized 
retroviruses in the genomes of eukaryotes and the number of characterized extant retroviruses, 
it is clear that the Retroviridae has been a successful viral genus [452-454]. The evolutionary 
history of the Retroviridae and eukaryotes may extend in excess of 400 million years [238]. ! 198!
Considering the evolutionary stability of orthoretrovirinae capsids, it would not be surprising to 
this author if additional capsid dependent blocks to retrovirus infection are identified.  
 
4.D. TRIM5α: THE BIG PICTURE   
Integrated immunity. It is important to note that host restriction factors are not insular 
acting proteins as they were discussed above. Rather, they contribute to a multilayered 
organismal defense system. At least two restriction factors, TRIM5α and BST2, have the 
capacity to signal through the same cascades as innate sensors [272,455,456]. This is likely 
due to the specificity of the processes they target: retroviral capsids and viral budding. Signaling 
through these pathways not only upregulates the expression of other restriction factors and 
other antiviral factors in the infected cell but also in adjacent cells due to autocrine and 
paracrine signaling of the interferon pathway. 
  TRIM5α and BST2 may also modulate the adaptive immune response. Aside from the 
requirement of certain cytokines for the maturation of the immune response, these factors may 
influence the T-cell and B-cell responses. BST2 entrapment of virions on the cell surface can 
theoretically expose viral antigens to B-cells [122,123]. In macaques vaccinated with 
SIVmac239ΔNef, which is unable to counteract rhesus BST2, there are higher titers of 
antibodies that mediate antibody-dependent cell-mediated cytotoxicity [177]. The higher ! 199!
antibody-dependent cell-mediated cytotoxicity titers correlate with protection from SIV infection 
in vivo. Similarly, modified HIV-1 viruses lacking the ability to antagonize BST2 have increased 
levels of antibody-dependent cell-mediated cytotoxicity in vitro [178].  
We and others have demonstrated that single amino acid substitutions in an otherwise 
TRIM5α resistant capsid are sufficient to lead to viral restriction (reviewed above). Therefore, a 
TRIM5α that does not restrict a virus may still place a “cap” upon capsid diversity in vivo. In 
instances where regions with the potential to be recognized by TRIM5α overlap with cytolytic T 
lymphocyte epitopes, escape mutations may be limited or come at the cost of sensitizing a 
resistant capsid to TRIM5α mediated restriction. Known cytotoxic T lymphocyte epitopes 
overlap the conserved capsid surface patch and β-hairpin in both humans and rhesus 
macaques [457-467]. Indeed, some escape mutations in cytotoxic T lymphocyte epitopes lead 
to increased human TRIM5α sensitivity [468-470]. Natural killer cells can select for viral 
peptides that bind to inhibitory KIRs when presented on MHC to prevent natural killer cell 
mediated killing. Specific KIRs in humans can select for changes in the β-hairpin [471]. 
Understanding the impact of a TRIM5α mediated “cap” on capsid diversity may be critical for the 
development of vaccines against primate lentiviruses.  
Human TRIM5α. At times it is tempting to place our observations in the context of 
humans and human viruses, however homo sapiens are indeed primates whose evolutionary ! 200!
history is hardly unique among the other approximately 500 primate species [37]. At times 
human TRIM5α is discussed as being inferior to some primate TRIM5αs primarily because it 
cannot restrict HIV-1 and a handful of common SIV molecular clones. Human TRIM5α has 
clearly evolved with purpose [243]. Thus, while HIV-1 has evaded human TRIM5α mediated 
restriction we will never know of the pandemics it has prevented. Human TRIM5α is capable of 
restricting isolates of HIV-2 [288,348,472-475]. Specific mutations in the HIV-2 capsid are 
associated with lower viral loads in vivo [288]. These viruses are more sensitive to human 
TRIM5α than capsids associated with high viral loads in vivo [288]. Furthermore, while human 
TRIM5α does not restrict most HIV-1 isolates, its presence likely places a “cap” on viral 
diversity. While HIV-1 is usually weakly restricted by human TRIM5α in overexpression 
experiments our observations as well as others support the notion that very few amino acid 
substitutions would be required for HIV-1 to become restricted. Thus, human TRIM5α may play 
an important role in vivo.  
Human TRIM5α, like that of non-Cercopithecinae TRIM5αs, has V1-Q in the rapidly 
evolving patch of amino acids (Chapter 3). However, in contrast to other TRIM5αs with this 
feature, human TRIM5α has the capacity to restrict Cercopithecinae SIVs. Human TRIM5α 
restricted SIVs from both sooty and red-capped mangabeys. Thus, human TRIM5α is more 
restrictive than TRIM5αs from wolf’s guenon, sooty mangabey, red-capped mangabey, rhesus ! 201!
TRIM5α
Q  (Chapter 3). Importantly, the activity of human TRIM5α cannot be discounted when 
studying human retrovirus infection.  
Heterozygous advantage. Along similar lines we cannot impose observations made 
from studying a single primate species upon all primates. In contrast to many primate species 
there appears to be less allelic diversity among human restriction factor genes. In contrast to 
humans, during Cercopithecinae primate evolution multiple TRIM5α variants were maintained 
through long term balancing selection (Chapter 3 and [251]). Within a single species, rhesus 
macaques, there are three TRIM5 allelic classes that differ in their capsid binding specificities 
[46,47,51,61,251,257,380]. These allelic classes can be further subdivided into a number of 
distinct alleles [251].  A moderate to high frequency of distinct TRIM5α alleles are also found in 
other macaque species, sooty mangabeys, and likely Schmidt’s guenons (Chapter 3 and [46-
48,51,243,251,257,476-479]). It is important to note that large genotyping surveys for other 
primate species have not been conducted. However, from these observations there appears to 
be recurrent selection to maintain multiple TRIM5α alleles. Our findings in Chapters 2 and 3 
indicate that rhesus macaque and Schmidt’s guenon TRIM5αs restrict different subsets of 
viruses or mutants thereof. Similar findings have been observed for sooty mangabey TRIM5α 
alleles [251].  ! 202!
The high frequency of TRIM5α alleles in captive rhesus macaques influenced the 
emergence of SIVmac [60,403]. This virus has clearly made multiple adaptations to evade at 
least two rhesus TRIM5 variants. This may have come at the expense of interacting with the 
Nup-358 cyclophilin A-like domain [61,327]. TRIM5α genotype influences viral loads of animals 
inoculated with SIVsmm viruses [60,61,385]. Heterozygous advantage for TRIM5 has been 
demonstrated in vivo [61]. The strongest reduction of viral loads in SIVsmm infected rhesus 
macaques is found in animals with two different restrictive alleles, rhTRIM5α
TFP an rhTRIM5
CypA 
[60,61,385]. Furthermore, experimental infections recreating the initial SIVsmm-rhesus 
macaque transmission that gave rise to SIVmac indicate that some animals with restrictive 
alleles can suppress viral loads below the limit of detection [61,480]. These observations 
together with the selection to maintain multiple TRIM5α alleles suggests allelism among 
restriction factors may influence cross-species transmission events or the emergence of new 
viruses in nature. Thus, as we embark upon conservation efforts for endangered primate 
species, efforts to persevere allelic diversity of restriction factors should be considered.  
   ! 203!
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